

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number

WO 2013/052677 A1

(43) International Publication Date  
11 April 2013 (11.04.2013)

(51) International Patent Classification:  
C07H 21/02 (2006.01) C12N 15/11 (2006.01)

(21) International Application Number:  
PCT/US2012/058770

(22) International Filing Date:  
4 October 2012 (04.10.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/543,700 5 October 2011 (05.10.2011) US  
61/599,238 15 February 2012 (15.02.2012) US

(71) Applicant: PROTIVA BIOTHERAPEUTICS INC.  
[CA/CA]; 100 - 8900 Glenlyon Parkway, Burnaby, British Columbia V5J 5J8 (CA).

(72) Inventors: MACLACHLAN, Ian; 13331 Sylvester Road, Mission, British Columbia V2V 0B1 (CA). LEE, Amy C.H.; 3315 Beaverbrook Drive, Burnaby, British Columbia V3J 7Y2 (CA).

(74) Agents: LAHERTY, Carol D. et al.; Cooley LLP, 777 - 6th Street, NW, Suite 1100, Washington, District of Columbia 20001 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR SILENCING ALDEHYDE DEHYDROGENASE

(57) Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating alcoholism in humans).

# COMPOSITIONS AND METHODS FOR SILENCING ALDEHYDE DEHYDROGENASE

## CROSS-REFERENCE TO RELATED APPLICATIONS

5 [0001] This application claims benefit under 35 U.S.C. §119(e) of U.S. provisional patent application no. 61/599,238 filed on February 15, 2012 and U.S. provisional patent application no. 61/543,700 filed on October 5, 2011, the contents of which are incorporated herein by reference in their entireties.

## STATEMENT REGARDING SEQUENCE LISTING

10 [0002] The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is TEKM\_074\_02WO\_ST25.txt. The text file is 12 KB, was created on October 4, 2012, and is being submitted electronically via EFS-Web.

## 15 BACKGROUND OF THE INVENTION

[0003] Alcoholism is the addiction to or dependency upon drinking excessive amounts of alcoholic beverages such as beer, wine and distilled spirits. Alcoholism is sometimes also referred to as alcohol abuse or alcohol dependence.

20 [0004] The biological mechanisms underpinning alcoholism are uncertain, however risk factors include stress, mental health problems, and genetic predisposition. Long-term alcohol abuse produces physiological changes in the brain that result in alcohol withdrawal syndrome upon discontinuation of alcohol consumption. Alcohol damages almost every organ in the body, and the alcoholic risks suffering medical and psychiatric disorders.

25 [0005] Treatment of alcoholism is problematic and typically includes alcohol detoxification to withdraw the alcoholic person from drinking alcohol. Neurologically active drugs, such as benzodiazepines, may be used to manage alcohol withdrawal symptoms. Post-medical care, such as psychological therapy, is usually required to maintain alcoholic abstention.

[0006] Disulfiram is a drug that causes an acute sensitivity to ingested alcohol (ethanol), and is sometimes used in the treatment of chronic alcoholism. Alcohol is broken down in the liver by the

enzyme alcohol dehydrogenase to acetaldehyde, which is then converted by the enzyme acetaldehyde dehydrogenase to acetic acid. Disulfiram blocks the enzyme acetaldehyde dehydrogenase. Thus, disulfiram can cause the concentration of acetaldehyde in the blood of a human being who has consumed alcohol to be substantially higher (e.g., 5 to 10 times higher) than that found in the blood of a person who consumed the same amount of alcohol in the absence of disulfiram. Acetaldehyde is one of the major causes of the symptoms of a "hangover", and so consumption of disulfiram produces severe negative reaction to alcohol. Symptoms include flushing of the skin, accelerated heart rate, shortness of breath, nausea, vomiting, throbbing headache, visual disturbance, mental confusion, postural fainting, and circulatory collapse.

10 [0007] Disulfiram has clinical limitations, however, due to poor compliance by patients, and a range of side-effects, such as drowsiness, headache and, less often, neurotoxicity. Disulfiram is usually administered daily in order to be effective, and so it is easy for a patient to discontinue use of the drug.

15 [0008] Thus, there is a continuing need for compositions and methods for suppressing, reducing and/or eliminating the activity of the acetaldehyde dehydrogenase that is involved in metabolising alcohol in a mammal, particularly a human being. Such compositions and methods can be used, for example, in the treatment of alcoholism. In particular, there is a need for compositions and methods that suppress, reduce and/or eliminate the activity of acetaldehyde dehydrogenase for a period of time (e.g., weeks or months) that is significantly longer than the effective period of disulfiram, thereby 20 making it difficult for a human subject to discontinue alcohol aversion therapy after consuming such a relatively long lasting inhibitor of ALDH. There is also a particular need for compositions and methods that suppress, reduce and/or eliminate the activity of acetaldehyde dehydrogenase and that have fewer, or less severe, side effects than disulfiram.

#### BRIEF SUMMARY OF THE INVENTION

25 [0009] As described more fully herein, acetaldehyde dehydrogenase is a member of the broader class of aldehyde dehydrogenase (ALDH) enzymes. A member of the ALDH family that is believed to be primarily responsible for converting acetaldehyde to acetic acid in the human liver is the aldehyde dehydrogenase 2 (ALDH2) enzyme, although other isoforms of ALDH, such as ALDH1, are also implicated in the metabolism of alcohol in humans. It is an object of the present invention to 30 provide compositions and methods for inhibiting the expression of one or more genes encoding one or more ALDH enzymes, in particular the ALDH2 enzyme. Inhibition is through the mechanism of RNA interference. The compositions and methods of the present invention are thus useful, for example, for treating alcoholism in a human being by inhibiting, or blocking, the conversion of acetaldehyde to acetic acid, thereby increasing the amount of acetaldehyde in the body of a human

who consumes alcohol, and consequently intensifying the adverse effects associated with the presence of acetaldehyde in the body (e.g., headache and nausea).

**[0010]** Thus, the present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating alcoholism).

**[0011]** More particularly, the invention provides compositions comprising unmodified and chemically modified interfering RNA (e.g., siRNA) molecules which inhibit or silence ALDH gene expression. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) and formulations thereof comprising one or more (e.g., a cocktail) of the interfering RNA (e.g., siRNA) described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Examples of interfering RNA molecules include, but are not limited to, double-stranded RNA (dsRNA) such as siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, pre-miRNA, and combinations thereof.

**[0012]** In one aspect, the present invention provides an interfering RNA that targets ALDH gene expression, wherein the interfering RNA comprises a sense strand and a complementary antisense strand, and wherein the interfering RNA comprises a double-stranded region of about 15 to about 60 nucleotides in length. In certain embodiments, the present invention provides compositions comprising a combination (e.g., a cocktail) of at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, or more interfering RNA molecules that target the same and/or different regions of the ALDH genome. The interfering RNA of the invention are capable of inhibiting or silencing ALDH gene expression *in vitro* and *in vivo*.

**[0013]** Non-limiting examples of ALDH2 transcript sequences that can be used, for example, in the design of siRNA molecules that inhibit ALDH2 gene expression are set forth in Genbank ([www.ncbi.nlm.nih.gov/genbank](http://www.ncbi.nlm.nih.gov/genbank)) as Accession Nos. NM\_000690.3 (Gene ID 217, isoform 1) and NM 001204889.1 (Gene ID 217, isoform 2).

**[0014]** Non-limiting examples of ALDH1 transcript sequences that can be used, for example, in the design of siRNA molecules that inhibit ALDH1 gene expression are set forth in Genbank ([www.ncbi.nlm.nih.gov/genbank](http://www.ncbi.nlm.nih.gov/genbank)) as Accession Nos. NM\_000689.4 (ALDH1A1, Gene ID 216), and NM\_000692.4 (ALDH1B1, Gene ID 219).

**[0015]** In another aspect, the present invention provides an interfering RNA that targets aldehyde dehydrogenase (ALDH) gene expression, wherein the interfering RNA comprises a sense

strand and a complementary antisense strand, and wherein the interfering RNA comprises a double-stranded region of about 15 to about 60 nucleotides in length. In certain embodiments, the present invention provides compositions comprising a combination (e.g., a cocktail) of at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, or more interfering RNA molecules that target the same and/or different regions of 5 the ALDH gene. The interfering RNA of the invention are capable of inhibiting or completely silencing ALDH gene expression *in vitro* and *in vivo*.

[0016] Each of the interfering RNA sequences present in the compositions of the invention may independently comprise at least one, two, three, four, five, six, seven, eight, nine, ten, or more modified nucleotides such as 2'OMe nucleotides, e.g., in the sense and/or antisense strand of the 10 double-stranded region. Preferably, uridine and/or guanosine nucleotides are modified with 2'OMe nucleotides. In particular embodiments, each of the interfering RNA sequences present in the compositions of the invention comprises at least one 2'OMe-uridine nucleotide and at least one 2'OMe-guanosine nucleotide in the sense and/or antisense strands.

[0017] Examples of double-stranded siRNA molecules that are useful in the practice of 15 the present invention for inhibiting ALDH2 gene expression include the double-stranded siRNA molecules (numbered 1 through 6) having the chemically modified sense and antisense strand sequences set forth in Table A of Example 4 herein. The double-stranded siRNA molecules set forth in Table A of Example 4 are chemically modified by the presence of a 2'-*O*-methyl moiety on the ribonucleotide units identified with the letter "m". The 20 present invention also includes double-stranded siRNA molecules having the sense and antisense sequences set forth in Table A of Example 4, wherein the sense and antisense strands are not chemically modified. The present invention also includes isolated, single-stranded, nucleic acid molecules having any one of the sense strand sequences (chemically modified or not chemically modified) set forth in Table A of Example 4. The present 25 invention also includes isolated, single-stranded, nucleic acid molecules having any one of the antisense strand sequences (chemically modified or not chemically modified) set forth in Table A of Example 4.

[0018] The present invention also provides a pharmaceutical composition comprising one or a cocktail of interfering RNA (e.g., siRNA) molecules that target ALDH gene expression, and a 30 pharmaceutically acceptable carrier.

[0019] In another aspect, the present invention provides a nucleic acid-lipid particle that targets ALDH gene expression. The nucleic acid-lipid particle typically comprises one or more unmodified and/or modified interfering RNA that silence ALDH gene expression, a cationic lipid, and a non-

cationic lipid. In certain instances, the nucleic acid-lipid particle further comprises a conjugated lipid that inhibits aggregation of particles. In preferred embodiments, the nucleic acid-lipid particle comprises one or more unmodified and/or modified interfering RNA that silence ALDH gene expression, a cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of particles.

[0020] In other embodiments, the interfering RNA molecules of the invention are fully encapsulated in the nucleic acid-lipid particle (e.g., SNALP). With respect to formulations comprising a cocktail of interfering RNA, the different types of interfering RNA molecules may be co-encapsulated in the same nucleic acid-lipid particle, or each type of interfering RNA species present in the cocktail may be encapsulated in its own particle.

[0021] The present invention also provides pharmaceutical compositions comprising a nucleic acid-lipid particle and a pharmaceutically acceptable carrier.

[0022] The nucleic acid-lipid particles of the invention are useful for the prophylactic or therapeutic delivery of interfering RNA (e.g., dsRNA) molecules that silence the expression of one or more ALDH genes (e.g., ALDH2 gene). In some embodiments, one or more of the interfering RNA molecules described herein are formulated into nucleic acid-lipid particles, and the particles are administered to a mammal (e.g., a human) requiring such treatment. In certain instances, a therapeutically effective amount of the nucleic acid-lipid particle can be administered to the mammal, e.g., for preventing or treating alcoholism in a human being). The nucleic acid-lipid particles of the invention are particularly useful for targeting liver cells in humans which is the site of most ALDH2 gene expression. Administration of the nucleic acid-lipid particle can be by any route known in the art, such as, e.g., oral, intranasal, intravenous, intraperitoneal, intramuscular, intra-articular, intralesional, intratracheal, subcutaneous, or intradermal. In particular embodiments, the nucleic acid-lipid particle is administered systemically, e.g., via enteral or parenteral routes of administration.

[0023] In some embodiments, downregulation of ALDH gene expression is determined by detecting ALDH RNA or protein levels in a biological sample from a mammal after nucleic acid-lipid particle administration. In other embodiments, downregulation of ALDH gene expression is determined by detecting ALDH mRNA or protein levels in a biological sample from a mammal after nucleic acid-lipid particle administration. In certain embodiments, downregulation of ALDH or ALDH gene expression is detected by monitoring symptoms associated with alcohol withdrawal in a mammal after particle administration.

[0024] In another embodiment, the present invention provides methods for introducing an interfering RNA that silences ALDH gene expression into a cell, the method comprising the step of contacting the cell with a nucleic acid-lipid particle of the present invention.

[0025] In another embodiment, the present invention provides methods for silencing ALDH gene expression in a mammal (e.g., a human) in need thereof, wherein the methods each include the step of administering to the mammal a nucleic acid-lipid particle of the present invention.

[0026] In another aspect, the present invention provides methods for treating and/or ameliorating one or more symptoms associated with alcoholism in a human, wherein the methods each include the step of administering to the human a therapeutically effective amount of a nucleic acid-lipid particle of the present invention.

[0027] In another aspect, the present invention provides methods for inhibiting the expression of ALDH in a mammal in need thereof (e.g., a human suffering from alcoholism), wherein the methods each include the step of administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle of the present invention.

[0028] In a further aspect, the present invention provides methods for preventing and/or treating alcoholism in a human, wherein the methods each include the step of administering to the human a therapeutically effective amount of a nucleic acid-lipid particle of the present invention.

[0029] Other objects, features, and advantages of the present invention will be apparent to one of skill in the art from the following detailed description and figures.

## 20 DETAILED DESCRIPTION OF THE INVENTION

### I. Introduction

[0030] The interfering RNA (e.g., siRNA) drug therapy described herein advantageously provides significant new compositions and methods for treating alcoholism in human beings. Embodiments of the present invention can be administered, for example, once per day, once per week, or once every several weeks (e.g., once every two, three, four, five or six weeks). It is more difficult for an alcoholic person to discontinue alcohol aversion therapy after consuming a composition of the present invention that is effective to inhibit ALDH for a period of several days or weeks.

[0031] Furthermore, the lipid particles described herein (e.g., SNALP) enable the effective delivery of a nucleic acid drug such as an interfering RNA into target tissues and cells within the body. The presence of the lipid particle confers protection from nuclease degradation in the

bloodstream, allows preferential accumulation in target tissue and provides a means of drug entry into the cellular cytoplasm where the siRNAs can perform their intended function of RNA interference.

## II. Definitions

[0032] As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

[0033] The term “aldehyde dehydrogenase” (abbreviated as ALDH) means an enzyme that catalyzes the oxidation (dehydrogenation) of an aldehyde (e.g., acetaldehyde) to a carboxylic acid (e.g., acetic acid). A family of structurally and functionally related aldehyde dehydrogenases exists in mammals, and includes aldehyde dehydrogenase 2 (ALDH2) that is a mitochondrially localized enzyme that is believed to be mainly responsible for the conversion of acetaldehyde to acetic acid in human beings.

[0034] The term “interfering RNA” or “RNAi” or “interfering RNA sequence” as used herein includes single-stranded RNA (e.g., mature miRNA, ssRNAi oligonucleotides, ssDNAi oligonucleotides) or double-stranded RNA (*i.e.*, duplex RNA such as siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, or pre-miRNA) that is capable of reducing or inhibiting the expression of a target gene or sequence (e.g., by mediating the degradation or inhibiting the translation of mRNAs which are complementary to the interfering RNA sequence) when the interfering RNA is in the same cell as the target gene or sequence. Interfering RNA thus refers to the single-stranded RNA that is complementary to a target mRNA sequence or to the double-stranded RNA formed by two complementary strands or by a single, self-complementary strand. Interfering RNA may have substantial or complete identity to the target gene or sequence, or may comprise a region of mismatch (*i.e.*, a mismatch motif). The sequence of the interfering RNA can correspond to the full-length target gene, or a subsequence thereof. Preferably, the interfering RNA molecules are chemically synthesized.

[0035] Interfering RNA includes “small-interfering RNA” or “siRNA,” *e.g.*, interfering RNA of about 15-60, 15-50, or 15-40 (duplex) nucleotides in length, more typically about 15-30, 15-25, or 19-25 (duplex) nucleotides in length, and is preferably about 20-24, 21-22, or 21-23 (duplex) nucleotides in length (*e.g.*, each complementary sequence of the double-stranded siRNA is 15-60, 15-50, 15-40, 15-30, 15-25, or 19-25 nucleotides in length, preferably about 20-24, 21-22, or 21-23 nucleotides in length, and the double-stranded siRNA is about 15-60, 15-50, 15-40, 15-30, 15-25, or 19-25 base pairs in length, preferably about 18-22, 19-20, or 19-21 base pairs in length). siRNA duplexes may comprise 3’ overhangs of about 1 to about 4 nucleotides or about 2 to about 3 nucleotides and 5’ phosphate termini. Examples of siRNA include, without limitation, a double-stranded polynucleotide

molecule assembled from two separate stranded molecules, wherein one strand is the sense strand and the other is the complementary antisense strand; a double-stranded polynucleotide molecule assembled from a single stranded molecule, where the sense and antisense regions are linked by a nucleic acid-based or non-nucleic acid-based linker; a double-stranded polynucleotide molecule with 5 a hairpin secondary structure having self-complementary sense and antisense regions; and a circular single-stranded polynucleotide molecule with two or more loop structures and a stem having self-complementary sense and antisense regions, where the circular polynucleotide can be processed *in vivo* or *in vitro* to generate an active double-stranded siRNA molecule.

[0036] Preferably, siRNA are chemically synthesized. siRNA can also be generated by 10 cleavage of longer dsRNA (e.g., dsRNA greater than about 25 nucleotides in length) with the *E. coli* RNase III or Dicer. These enzymes process the dsRNA into biologically active siRNA (see, e.g., Yang *et al.*, *Proc. Natl. Acad. Sci. USA*, 99:9942-9947 (2002); Calegari *et al.*, *Proc. Natl. Acad. Sci. USA*, 99:14236 (2002); Byrom *et al.*, *Ambion TechNotes*, 10(1):4-6 (2003); Kawasaki *et al.*, *Nucleic Acids Res.*, 31:981-987 (2003); Knight *et al.*, *Science*, 293:2269-2271 (2001); and Robertson *et al.*, *J. Biol. Chem.*, 243:82 (1968)). Preferably, dsRNA are at least 50 nucleotides to about 100, 200, 300, 15 400, or 500 nucleotides in length. A dsRNA may be as long as 1000, 1500, 2000, 5000 nucleotides in length, or longer. The dsRNA can encode for an entire gene transcript or a partial gene transcript. In certain instances, siRNA may be encoded by a plasmid (e.g., transcribed as sequences that automatically fold into duplexes with hairpin loops).

[0037] As used herein, the term “mismatch motif” or “mismatch region” refers to a portion of an 20 interfering RNA (e.g., siRNA) sequence that does not have 100 % complementarity to its target sequence. An interfering RNA may have at least one, two, three, four, five, six, or more mismatch regions. The mismatch regions may be contiguous or may be separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more nucleotides. The mismatch motifs or regions may comprise a single nucleotide or 25 may comprise two, three, four, five, or more nucleotides.

[0038] The phrase “inhibiting expression of a target gene” refers to the ability of an interfering 30 RNA (e.g., siRNA) of the invention to silence, reduce, or inhibit expression of a target gene (e.g., ALDH gene). To examine the extent of gene silencing, a test sample (e.g., a biological sample from an organism of interest expressing the target gene or a sample of cells in culture expressing the target gene) is contacted with an interfering RNA (e.g., siRNA) that silences, reduces, or inhibits expression of the target gene. Expression of the target gene in the test sample is compared to expression of the target gene in a control sample (e.g., a biological sample from an organism of interest expressing the target gene or a sample of cells in culture expressing the target gene) that is not contacted with the interfering RNA (e.g., siRNA). Control samples (e.g., samples expressing the target gene) may be 35 assigned a value of 100%. In particular embodiments, silencing, inhibition, or reduction of expression

of a target gene is achieved when the value of the test sample relative to the control sample is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 10%, 5%, or 0%. Suitable assays include, without limitation, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, *e.g.*, dot blots, Northern blots, *in situ* hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.

5 [0039] An “effective amount” or “therapeutically effective amount” of a therapeutic nucleic acid such as an interfering RNA is an amount sufficient to produce the desired effect, *e.g.*, an inhibition of expression of a target sequence in comparison to the normal expression level detected in the absence of an interfering RNA. In particular embodiments, inhibition of expression of a target gene or target sequence is achieved when the value obtained with an interfering RNA relative to the control is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%. Suitable assays for measuring the expression of a target gene or target sequence include, but are not limited to, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, *e.g.*, dot blots, Northern blots, *in situ* hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.

10 [0040] By “decrease,” “decreasing,” “reduce,” or “reducing” of an immune response by an interfering RNA is intended to mean a detectable decrease of an immune response to a given interfering RNA (*e.g.*, a modified interfering RNA). The amount of decrease of an immune response by a modified interfering RNA may be determined relative to the level of an immune response in the presence of an unmodified interfering RNA. A detectable decrease can be about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or more lower than the immune response detected in the presence of the unmodified interfering RNA. A decrease in the immune response to interfering RNA is typically measured by a decrease in cytokine 15 production (*e.g.*, IFN $\gamma$ , IFN $\alpha$ , TNF $\alpha$ , IL-6, or IL-12) by a responder cell *in vitro* or a decrease in cytokine production in the sera of a mammalian subject after administration of the interfering RNA.

20 [0041] As used herein, the term “responder cell” refers to a cell, preferably a mammalian cell, that produces a detectable immune response when contacted with an immunostimulatory interfering RNA such as an unmodified siRNA. Exemplary responder cells include, *e.g.*, dendritic cells, macrophages, peripheral blood mononuclear cells (PBMCs), splenocytes, and the like. Detectable 25 immune responses include, *e.g.*, production of cytokines or growth factors such as TNF- $\alpha$ , IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, TGF, and combinations thereof. Detectable immune responses also include, *e.g.*, induction of interferon-induced protein with tetratricopeptide repeats 1 (*IFIT1*) mRNA.

**[0042]** “Substantial identity” refers to a sequence that hybridizes to a reference sequence under stringent conditions, or to a sequence that has a specified percent identity over a specified region of a reference sequence.

**[0043]** The phrase “stringent hybridization conditions” refers to conditions under which a nucleic acid will hybridize to its target sequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Probes*, “Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength pH. The  $T_m$  is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at  $T_m$ , 50% of the probes are occupied at equilibrium). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization.

**[0044]** Exemplary stringent hybridization conditions can be as follows: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C-95°C for 30 sec. to 2 min., an annealing phase lasting 30 sec. to 2 min., and an extension phase of about 72°C for 1 to 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis *et al.*, *PCR Protocols, A Guide to Methods and Applications*, Academic Press, Inc. N.Y. (1990).

**[0045]** Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary “moderately stringent hybridization conditions” include a

hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in 5 numerous references, *e.g.*, Current Protocols in Molecular Biology, Ausubel *et al.*, eds.

[0046] The terms “substantially identical” or “substantial identity,” in the context of two or more nucleic acids, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides that are the same (*i.e.*, at least about 60%, preferably at least about 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity over a specified region), when compared and 10 aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. This definition, when the context indicates, also refers analogously to the complement of a sequence. Preferably, the substantial identity exists over a region that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 nucleotides in length.

15 [0047] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the 20 percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

[0048] A “comparison window,” as used herein, includes reference to a segment of any one of a 25 number of contiguous positions selected from the group consisting of from about 5 to about 60, usually about 10 to about 45, more usually about 15 to about 30, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith and Waterman, *Adv. Appl. Math.*, 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.*, 48:443 (1970), by the search for similarity 30 method of Pearson and Lipman, *Proc. Natl. Acad. Sci. USA*, 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESALDHIT, FASTA, and ALDHASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (*see, e.g.*, *Current Protocols in Molecular Biology*, Ausubel *et al.*, eds. (1995 supplement)).

[0049] Non-limiting examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nuc. Acids Res.*, 25:3389-3402 (1977) and Altschul *et al.*, *J. Mol. Biol.*, 215:403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with the parameters described herein, to

5 determine percent sequence identity for the nucleic acids of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). Another example is a global alignment algorithm for determining percent sequence identiy such as the Needleman-Wunsch algorithm for aligning protein or nucleotide (e.g., RNA) sequences.

10 [0050] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, *Proc. Natl. Acad. Sci. USA*, 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the 15 smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

[0051] The term “nucleic acid” as used herein refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in either single- or double-stranded form and includes DNA and RNA. DNA may be in the form of, e.g., antisense molecules, plasmid DNA, pre-condensed 20 DNA, a PCR product, vectors (P1, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric sequences, chromosomal DNA, or derivatives and combinations of these groups. RNA may be in the form of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), mRNA, tRNA, rRNA, tRNA, viral RNA (vRNA), and combinations thereof. Nucleic acids include nucleic acids containing 25 known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2'-O-methyl ribonucleotides, and peptide-nucleic acids (PNAs). Unless specifically limited, the term encompasses nucleic acids 30 containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the 35 third position of one or more selected (or all) codons is substituted with mixed-base and/or

deoxyinosine residues (Batzer *et al.*, *Nucleic Acid Res.*, 19:5081 (1991); Ohtsuka *et al.*, *J. Biol. Chem.*, 260:2605-2608 (1985); Rossolini *et al.*, *Mol. Cell. Probes*, 8:91-98 (1994)). “Nucleotides” contain a sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups. “Bases” include purines and pyrimidines, which further include natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, and synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications which place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkylhalides.

5 [0052] The term “gene” refers to a nucleic acid (*e.g.*, DNA or RNA) sequence that comprises 10 partial length or entire length coding sequences necessary for the production of a polypeptide or precursor polypeptide.

10 [0053] “Gene product,” as used herein, refers to a product of a gene such as an RNA transcript or a polypeptide.

15 [0054] The term “lipid” refers to a group of organic compounds that include, but are not limited to, esters of fatty acids and are characterized by being insoluble in water, but soluble in many organic solvents. They are usually divided into at least three classes: (1) “simple lipids,” which include fats and oils as well as waxes; (2) “compound lipids,” which include phospholipids and glycolipids; and (3) “derived lipids” such as steroids.

20 [0055] The term “lipid particle” includes a lipid formulation that can be used to deliver a therapeutic nucleic acid (*e.g.*, interfering RNA) to a target site of interest (*e.g.*, cell, tissue, organ, and the like). In preferred embodiments, the lipid particle of the invention is a nucleic acid-lipid particle, which is typically formed from a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that prevents aggregation of the particle. In other preferred embodiments, the therapeutic nucleic acid (*e.g.*, interfering RNA) may be encapsulated in the lipid portion of the particle, thereby protecting it 25 from enzymatic degradation.

30 [0056] As used herein, the term “SNALP” refers to a stable nucleic acid-lipid particle. A SNALP represents a particle made from lipids (*e.g.*, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that prevents aggregation of the particle), wherein the nucleic acid (*e.g.*, interfering RNA) is fully encapsulated within the lipid. In certain instances, SNALP are extremely useful for systemic applications, as they can exhibit extended circulation lifetimes following intravenous (i.v.) injection, they can accumulate at distal sites (*e.g.*, sites physically separated from the administration site), and they can mediate silencing of target gene expression at these distal sites. The nucleic acid may be complexed with a condensing agent and encapsulated within a SNALP as set

forth in PCT Publication No. WO 00/03683, the disclosure of which is herein incorporated by reference in its entirety for all purposes.

[0057] The lipid particles of the invention (*e.g.*, SNALP) typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm, and are substantially non-toxic. In addition, nucleic acids, when present in the lipid particles of the present invention, are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, *e.g.*, U.S. Patent Publication Nos. 20040142025 and 20070042031, the disclosures of which are herein incorporated by reference in their entirety for all purposes.

[0058] As used herein, “lipid encapsulated” can refer to a lipid particle that provides a therapeutic nucleic acid such as an interfering RNA (*e.g.*, siRNA), with full encapsulation, partial encapsulation, or both. In a preferred embodiment, the nucleic acid (*e.g.*, interfering RNA) is fully encapsulated in the lipid particle (*e.g.*, to form a SNALP or other nucleic acid-lipid particle).

[0059] The term “lipid conjugate” refers to a conjugated lipid that inhibits aggregation of lipid particles. Such lipid conjugates include, but are not limited to, PEG-lipid conjugates such as, *e.g.*, PEG coupled to dialkylxyloxypropyls (*e.g.*, PEG-DAA conjugates), PEG coupled to diacylglycerols (*e.g.*, PEG-DAG conjugates), PEG coupled to cholesterol, PEG coupled to phosphatidylethanolamines, and PEG conjugated to ceramides (*see, e.g.*, U.S. Patent No. 5,885,613), cationic PEG lipids, polyoxazoline (POZ)-lipid conjugates (*e.g.*, POZ-DAA conjugates; *see, e.g.*, U.S. Provisional Application No. 61/294,828, filed January 13, 2010, and U.S. Provisional Application No. 61/295, 140, filed January 14, 2010), polyamide oligomers (*e.g.*, ATTA-lipid conjugates), and mixtures thereof. Additional examples of POZ-lipid conjugates are described in PCT Publication No. WO 2010/006282. PEG or POZ can be conjugated directly to the lipid or may be linked to the lipid via a linker moiety. Any linker moiety suitable for coupling the PEG or the POZ to a lipid can be used including, *e.g.*, non-ester containing linker moieties and ester-containing linker moieties. In certain preferred embodiments, non-ester containing linker moieties, such as amides or carbamates, are used. The disclosures of each of the above patent documents are herein incorporated by reference in their entirety for all purposes.

[0060] The term “amphipathic lipid” refers, in part, to any suitable material wherein the hydrophobic portion of the lipid material orients into a hydrophobic phase, while the hydrophilic portion orients toward the aqueous phase. Hydrophilic characteristics derive from the presence of polar or charged groups such as carbohydrates, phosphate, carboxylic, sulfato, amino, sulfhydryl, 5 nitro, hydroxyl, and other like groups. Hydrophobicity can be conferred by the inclusion of apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Examples of amphipathic compounds include, but are not limited to, phospholipids, aminolipids, and sphingolipids.

10 [0061] Representative examples of phospholipids include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, 15 distearoylphosphatidylcholine, and dilinoleoylphosphatidylcholine. Other compounds lacking in phosphorus, such as sphingolipid, glycosphingolipid families, diacylglycerols, and  $\beta$ -acyloxyacids, are also within the group designated as amphipathic lipids. Additionally, the amphipathic lipids described above can be mixed with other lipids including triglycerides and sterols.

20 [0062] The term “neutral lipid” refers to any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at a selected pH. At physiological pH, such lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerols.

[0063] The term “non-cationic lipid” refers to any amphipathic lipid as well as any other neutral lipid or anionic lipid.

25 [0064] The term “anionic lipid” refers to any lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerols, cardiolipins, diacylphosphatidylserines, diacylphosphatidic acids, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutarylphosphatidylethanolamines, lysylphosphatidylglycerols, palmitoyloleyolphosphatidylglycerol (POPG), and other anionic modifying groups joined to neutral lipids.

30 [0065] The term “hydrophobic lipid” refers to compounds having apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups optionally substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Suitable

examples include, but are not limited to, diacylglycerol, dialkylglycerol, N-N-dialkylamino, 1,2-diacyloxy-3-aminopropane, and 1,2-dialkyl-3-aminopropane.

**[0066]** The terms “cationic lipid” and “amino lipid” are used interchangeably herein to include those lipids and salts thereof having one, two, three, or more fatty acid or fatty alkyl chains and a pH-titratable amino head group (e.g., an alkylamino or dialkylamino head group). The cationic lipid is typically protonated (i.e., positively charged) at a pH below the  $pK_a$  of the cationic lipid and is substantially neutral at a pH above the  $pK_a$ . The cationic lipids of the invention may also be termed titratable cationic lipids. In some embodiments, the cationic lipids comprise: a protonatable tertiary amine (e.g., pH-titratable) head group;  $C_{18}$  alkyl chains, wherein each alkyl chain independently has 0 to 3 (e.g., 0, 1, 2, or 3) double bonds; and ether, ester, or ketal linkages between the head group and alkyl chains. Such cationic lipids include, but are not limited to, DSDMA, DODMA, DLinDMA, DLenDMA,  $\gamma$ -DLenDMA, DLin-K-DMA, DLin-K-C2-DMA (also known as DLin-C2K-DMA, XTC2, and C2K), DLin-K-C3-DMA, DLin-K-C4-DMA, DLen-C2K-DMA,  $\gamma$ -DLen-C2K-DMA, DLin-M-C2-DMA (also known as MC2), and DLin-M-C3-DMA (also known as MC3).

**[0067]** The term “salts” includes any anionic and cationic complex, such as the complex formed between a cationic lipid and one or more anions. Non-limiting examples of anions include inorganic and organic anions, e.g., hydride, fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfite, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylate, fumarate, maleate, itaconate, glycolate, gluconate, malate, mandelate, tiglate, ascorbate, salicylate, polymethacrylate, perchlorate, chlorate, chlorite, hypochlorite, bromate, hypobromite, iodate, an alkylsulfonate, an arylsulfonate, arsenate, arsenite, chromate, dichromate, cyanide, cyanate, thiocyanate, hydroxide, peroxide, permanganate, and mixtures thereof. In particular embodiments, the salts of the cationic lipids disclosed herein are crystalline salts.

**[0068]** The term “alkyl” includes a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms. Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, *n*-propyl, *n*-butyl, *n*-pentyl, *n*-hexyl, and the like, while saturated branched alkyls include, without limitation, isopropyl, *sec*-butyl, isobutyl, *tert*-butyl, isopentyl, and the like. Representative saturated cyclic alkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, while unsaturated cyclic alkyls include, without limitation, cyclopentenyl, cyclohexenyl, and the like.

**[0069]** The term “alkenyl” includes an alkyl, as defined above, containing at least one double bond between adjacent carbon atoms. Alkenyls include both *cis* and *trans* isomers. Representative

straight chain and branched alkenyls include, but are not limited to, ethylenyl, propylenyl, 1-but enyl, 2-but enyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-but enyl, 2-methyl-2-but enyl, 2,3-dimethyl-2-but enyl, and the like.

[0070] The term “alkynyl” includes any alkyl or alkenyl, as defined above, which additionally contains at least one triple bond between adjacent carbons. Representative straight chain and branched alkynyls include, without limitation, acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, and the like.

[0071] The term “acyl” includes any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below. The following are non-limiting examples of acyl groups: -C(=O)alkyl, -C(=O)alkenyl, and -C(=O)alkynyl.

[0072] The term “heterocycle” includes a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring. The heterocycle may be attached via any heteroatom or carbon atom. Heterocycles include, but are not limited to, heteroaryls as defined below, as well as morpholinyl, pyrrolidinyl, pyrrolidinyl, piperidinyl, piperizynyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.

[0073] The terms “optionally substituted alkyl”, “optionally substituted alkenyl”, “optionally substituted alkynyl”, “optionally substituted acyl”, and “optionally substituted heterocycle” mean that, when substituted, at least one hydrogen atom is replaced with a substituent. In the case of an oxo substituent (=O), two hydrogen atoms are replaced. In this regard, substituents include, but are not limited to, oxo, halogen, heterocycle, -CN, -OR<sup>x</sup>, -NR<sup>x</sup>R<sup>y</sup>, -NR<sup>x</sup>C(=O)R<sup>y</sup>, -NR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, -C(=O)R<sup>x</sup>, -C(=O)OR<sup>x</sup>, -C(=O)NR<sup>x</sup>R<sup>y</sup>, -SO<sub>n</sub>R<sup>x</sup>, and -SO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, R<sup>x</sup> and R<sup>y</sup> are the same or different and are independently hydrogen, alkyl, or heterocycle, and each of the alkyl and heterocycle substituents may be further substituted with one or more of oxo, halogen, -OH, -CN, alkyl, -OR<sup>x</sup>, heterocycle, -NR<sup>x</sup>R<sup>y</sup>, -NR<sup>x</sup>C(=O)R<sup>y</sup>, -NR<sup>x</sup>SO<sub>2</sub>R<sup>y</sup>, -C(=O)R<sup>x</sup>, -C(=O)OR<sup>x</sup>, -C(=O)NR<sup>x</sup>R<sup>y</sup>, -SO<sub>n</sub>R<sup>x</sup>, and -SO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>. The term “optionally substituted,” when used before a list of substituents, means that each of the substituents in the list may be optionally substituted as described herein.

[0074] The term “halogen” includes fluoro, chloro, bromo, and iodo.

[0075] The term “fusogenic” refers to the ability of a lipid particle, such as a SNALP, to fuse with the membranes of a cell. The membranes can be either the plasma membrane or membranes surrounding organelles, *e.g.*, endosome, nucleus, *etc.*

5 [0076] As used herein, the term “aqueous solution” refers to a composition comprising in whole, or in part, water.

[0077] As used herein, the term “organic lipid solution” refers to a composition comprising in whole, or in part, an organic solvent having a lipid.

10 [0078] “Distal site,” as used herein, refers to a physically separated site, which is not limited to an adjacent capillary bed, but includes sites broadly distributed throughout an organism.

[0079] “Serum-stable” in relation to nucleic acid-lipid particles such as SNALP means that the particle is not significantly degraded after exposure to a serum or nuclease assay that would significantly degrade free DNA or RNA. Suitable assays include, for example, a standard serum assay, a DNase assay, or an RNase assay.

15 [0080] “Systemic delivery,” as used herein, refers to delivery of lipid particles that leads to a broad biodistribution of an active agent such as an interfering RNA (*e.g.*, siRNA) within an organism. Some techniques of administration can lead to the systemic delivery of certain agents, but not others. Systemic delivery means that a useful, preferably therapeutic, amount of an agent is exposed to most parts of the body. To obtain broad biodistribution generally requires a blood lifetime such that the 20 agent is not rapidly degraded or cleared (such as by first pass organs (liver, lung, *etc.*) or by rapid, nonspecific cell binding) before reaching a disease site distal to the site of administration. Systemic delivery of lipid particles can be by any means known in the art including, for example, intravenous, subcutaneous, and intraperitoneal. In a preferred embodiment, systemic delivery of lipid particles is by intravenous delivery.

25 [0081] “Local delivery,” as used herein, refers to delivery of an active agent such as an interfering RNA (*e.g.*, siRNA) directly to a target site within an organism. For example, an agent can be locally delivered by direct injection into a disease site, other target site, or a target organ such as the liver, heart, pancreas, kidney, and the like.

[0082] The term “mammal” refers to any mammalian species such as a human, mouse, rat, dog, 30 cat, hamster, guinea pig, rabbit, livestock, and the like.

[0083] The term “reticuloendothelial system” or “RES” refers to the part of the immune system that contains reticuloendothelial cells, including the phagocytic cells located in reticular connective tissue such as monocytes and macrophages. These cells typically accumulate in lymph nodes and the spleen. The Kupffer cells of the liver and tissue histiocytes are also part of the RES. The RES is 5 divided into primary and secondary lymphoid organs. Primary (“central”) lymphoid organs are the sites where the cells of the RES are produced. The cells of the RES are produced in the bone marrow. The thymus is also included as it is the required site for T cell maturation. Secondary (“peripheral”) lymphoid organs are the sites where the cells of the RES function. This includes the lymph nodes, tonsils, spleen, and “MALT” (mucosa-associated lymphoid tissue). MALT is further divided into 10 “GALT” (gut-associated lymphoid tissue) and “BALT” (bronchus-associated lymphoid tissue). The Kupffer cells of the liver act as part of this system, but are not organized into a tissue; rather, they are dispersed throughout the liver sinusoids. The microglia of the central nervous system (CNS) can be considered a part of the RES. They are scavenger cells that proliferate in response to CNS injury.

### III. Description of the Embodiments

[0084] The present invention provides therapeutic nucleic acids such as interfering RNA (*e.g.*, dsRNA such as siRNA) that target the expression of ALDH genes, in particular ALDH2 gene, lipid particles comprising one or more (*e.g.*, a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (*e.g.*, for the treatment of alcoholism in humans).

[0085] In one aspect, the present invention provides interfering RNA molecules that target ALDH gene expression. Non-limiting examples of interfering RNA molecules include double-stranded RNA capable of mediating RNAi such as siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, pre-miRNA, and mixtures thereof. In certain instances, the present invention provides compositions comprising a combination (*e.g.*, a cocktail, pool, or mixture) of interfering RNAs that target different 25 regions of the ALDH gene. In certain instances, the interfering RNA (*e.g.*, siRNA) molecules of the invention are capable of silencing ALDH gene expression, inactivating ALDH, and/or inhibiting the replication of ALDH *in vitro* or *in vivo*.

[0086] In particular embodiments, the present invention provides an interfering RNA (*e.g.*, siRNA) that silences ALDH gene expression, wherein the interfering RNA comprises a sense strand 30 and a complementary antisense strand, and wherein the interfering RNA comprises a double-stranded region of about 15 to about 60 nucleotides in length (*e.g.*, about 15-60, 15-30, 15-25, 19-30, 19-25, 20-60, 20-55, 20-50, 20-45, 20-40, 20-35, 20-30, 20-25, 21-30, 21-29, 22-30, 22-29, 22-28, 23-30, 23-28, 24-30, 24-28, 25-60, 25-55, 25-50, 25-45, 25-40, 25-35, or 25-30 nucleotides in length, or about

15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nucleotides in length).

**[0087]** In certain embodiments, the interfering RNA (e.g., siRNA) of the present invention may comprise at least one, two, three, four, five, six, seven, eight, nine, ten, or more modified nucleotides such as 2'OMe nucleotides, e.g., in the sense and/or antisense strand of the double-stranded region of the interfering RNA. Preferably, uridine and/or guanosine nucleotides in the interfering RNA are modified with 2'OMe nucleotides. In certain instances, the interfering RNA contains 2'OMe nucleotides in both the sense and antisense strands and comprises at least one 2'OMe-uridine nucleotide and at least one 2'OMe-guanosine nucleotide in the double-stranded region. In some embodiments, the sense and/or antisense strand of the interfering RNA may further comprise modified (e.g., 2'OMe-modified) adenosine and/or modified (e.g., 2'OMe-modified) cytosine nucleotides, e.g., in the double-stranded region of the interfering RNA.

**[0088]** In particular embodiments, the interfering RNA (e.g., siRNA) molecules of the present invention comprise a 3' overhang of 1, 2, 3, or 4 nucleotides in one or both strands. In certain instances, the interfering RNA may contain at least one blunt end. In particular embodiments, the 3' overhangs in one or both strands of the interfering RNA may each independently comprise 1, 2, 3, or 4 modified and/or unmodified deoxythymidine ("t" or "dT") nucleotides, 1, 2, 3, or 4 modified (e.g., 2'OMe) and/or unmodified uridine ("U") ribonucleotides, or 1, 2, 3, or 4 modified (e.g., 2'OMe) and/or unmodified ribonucleotides or deoxyribonucleotides having complementarity to the target sequence or the complementary strand thereof.

**[0089]** The present invention also provides a pharmaceutical composition comprising one or more (e.g., a cocktail) of the interfering RNAs described herein and a pharmaceutically acceptable carrier.

**[0090]** In another aspect, the present invention provides a nucleic acid-lipid particle (e.g., SNALP) that targets ALDH gene expression. The nucleic acid-lipid particles (e.g., SNALP) typically comprise one or more (e.g., a cocktail) of the interfering RNAs described herein, a cationic lipid, and a non-cationic lipid. In certain instances, the nucleic acid-lipid particles (e.g., SNALP) further comprise a conjugated lipid that inhibits aggregation of particles. Preferably, the nucleic acid-lipid particles (e.g., SNALP) comprise one or more (e.g., a cocktail) of the interfering RNAs described herein, a cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of particles.

**[0091]** In some embodiments, the interfering RNAs (e.g., siRNAs) of the present invention are fully encapsulated in the nucleic acid-lipid particle (e.g., SNALP). With respect to formulations

comprising an interfering RNA cocktail, the different types of interfering RNA species present in the cocktail (e.g., interfering RNA compounds with different sequences) may be co-encapsulated in the same particle, or each type of interfering RNA species present in the cocktail may be encapsulated in a separate particle. The interfering RNA cocktail may be formulated in the particles described herein

5 using a mixture of two or more individual interfering RNAs (each having a unique sequence) at identical, similar, or different concentrations or molar ratios. In one embodiment, a cocktail of interfering RNAs (corresponding to a plurality of interfering RNAs with different sequences) is formulated using identical, similar, or different concentrations or molar ratios of each interfering RNA species, and the different types of interfering RNAs are co-encapsulated in the same particle. In

10 another embodiment, each type of interfering RNA species present in the cocktail is encapsulated in different particles at identical, similar, or different interfering RNA concentrations or molar ratios, and the particles thus formed (each containing a different interfering RNA payload) are administered separately (e.g., at different times in accordance with a therapeutic regimen), or are combined and administered together as a single unit dose (e.g., with a pharmaceutically acceptable carrier). The

15 particles described herein are serum-stable, are resistant to nuclease degradation, and are substantially non-toxic to mammals such as humans.

**[0092]** The cationic lipid in the nucleic acid-lipid particles of the invention (e.g., SNALP) may comprise, e.g., one or more cationic lipids of Formula I-III described herein or any other cationic lipid species. In one particular embodiment, the cationic lipid is selected from the group consisting of 1,2-

20 dilinoleyl-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinoleyl-N,N-dimethylaminopropane (DLenDMA), 1,2-di- $\gamma$ -linolenyloxy-N,N-dimethylaminopropane ( $\gamma$ -DLenDMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-K-C2-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), dilinoleylmethyl-3-dimethylaminopropionate (DLin-M-C2-DMA), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-M-C3-DMA), salts thereof, and mixtures thereof.

25

**[0093]** The non-cationic lipid in the nucleic acid-lipid particles of the present invention (e.g., SNALP) may comprise, e.g., one or more anionic lipids and/or neutral lipids. In some embodiments, the non-cationic lipid comprises one of the following neutral lipid components: (1) a mixture of a phospholipid and cholesterol or a derivative thereof; (2) cholesterol or a derivative thereof; or (3) a

30 phospholipid. In certain preferred embodiments, the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof. In a particularly preferred embodiment, the non-cationic lipid is a mixture of DPPC and cholesterol.

**[0094]** The lipid conjugate in the nucleic acid-lipid particles of the invention (e.g., SNALP) inhibits aggregation of particles and may comprise, e.g., one or more of the lipid conjugates described herein. In one particular embodiment, the lipid conjugate comprises a PEG-lipid conjugate.

Examples of PEG-lipid conjugates include, but are not limited to, PEG-DAG conjugates, PEG-DAA conjugates, and mixtures thereof. In certain embodiments, the PEG-DAA conjugate in the lipid particle may comprise a PEG-didecyloxypropyl (C<sub>10</sub>) conjugate, a PEG-dilauryloxypropyl (C<sub>12</sub>) conjugate, a PEG-dimyristyloxypropyl (C<sub>14</sub>) conjugate, a PEG-dipalmityloxypropyl (C<sub>16</sub>) conjugate, a 5 PEG-distearyloxypropyl (C<sub>18</sub>) conjugate, or mixtures thereof. In another embodiment, the lipid conjugate comprises a POZ-lipid conjugate such as a POZ-DAA conjugate.

**[0095]** In some embodiments, the present invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more (e.g., a cocktail) interfering RNA molecules that target ALDH gene expression; (b) one or more cationic lipids or salts thereof comprising from about 50 mol % to 10 about 85 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.

**[0096]** In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or 15 more (e.g., a cocktail) interfering RNA molecules that target ALDH gene expression; (b) a cationic lipid or a salt thereof comprising from about 52 mol % to about 62 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 36 mol % to about 47 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle.

20 This embodiment of nucleic acid-lipid particle is generally referred to herein as the “1:57” formulation. In one particular embodiment, the 1:57 formulation is a four-component system comprising about 1.4 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 57.1 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 7.1 mol % DPPC (or DSPC), and about 34.3 mol % cholesterol (or derivative thereof).

25 **[0097]** In another aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) interfering RNA molecules that target ALDH gene expression; (b) a cationic lipid or a salt thereof comprising from about 56.5 mol % to about 66.5 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 31.5 mol % to about 42.5 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 30 mol % to about 2 mol % of the total lipid present in the particle. This embodiment of nucleic acid-lipid particle is generally referred to herein as the “1:62” formulation. In one particular embodiment, the 1:62 formulation is a three-component system which is phospholipid-free and comprises about 1.5 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 61.5 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, and about 36.9 mol % cholesterol (or derivative thereof).

**[0098]** Additional embodiments related to the 1:57 and 1:62 formulations are described in PCT Publication No. WO 09/127060 and published US patent application publication number US 2011/0071208 A1, the disclosures of which are herein incorporated by reference in their entirety for all purposes.

5 **[0099]** In other embodiments, the present invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more (e.g., a cocktail) interfering RNA molecules that target ALDH gene expression; (b) one or more cationic lipids or salts thereof comprising from about 2 mol % to about 50 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 5 mol % to about 90 mol % of the total lipid present in the particle; and (d) 10 one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 20 mol % of the total lipid present in the particle.

15 **[00100]** In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) interfering RNA molecules that target ALDH gene expression; (b) a cationic lipid or a salt thereof comprising from about 30 mol % to about 50 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 47 mol % to about 69 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 3 mol % of the total lipid present in the particle. This embodiment of nucleic acid-lipid particle is generally referred to herein as the “2:40” formulation. In one particular embodiment, the 2:40 formulation is a four-component system which 20 comprises about 2 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 40 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 10 mol % DPPC (or DSPC), and about 48 mol % cholesterol (or derivative thereof).

25 **[00101]** In further embodiments, the present invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more (e.g., a cocktail) interfering RNA molecules that target ALDH gene expression; (b) one or more cationic lipids or salts thereof comprising from about 50 mol % to about 65 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 25 mol % to about 45 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.

30 **[00102]** In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) interfering RNA molecules that target ALDH gene expression; (b) a cationic lipid or a salt thereof comprising from about 50 mol % to about 60 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 35 mol % to about 45 mol % of the total lipid present in the particle; and (d) a PEG-lipid

conjugate comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle. This embodiment of nucleic acid-lipid particle is generally referred to herein as the “7:54” formulation. In certain instances, the non-cationic lipid mixture in the 7:54 formulation comprises: (i) a phospholipid of from about 5 mol % to about 10 mol % of the total lipid present in the particle; and (ii) cholesterol or a derivative thereof of from about 25 mol % to about 35 mol % of the total lipid present in the particle. In one particular embodiment, the 7:54 formulation is a four-component system which comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 54 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 7 mol % DPPC (or DSPC), and about 32 mol % cholesterol (or derivative thereof).

10 [00103] In another aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) interfering RNA molecules that target ALDH gene expression; (b) a cationic lipid or a salt thereof comprising from about 55 mol % to about 65 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 30 mol % to about 40 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle. This embodiment of nucleic acid-lipid particle is generally referred to herein as the “7:58” formulation. In one particular embodiment, the 7:58 formulation is a three-component system which is phospholipid-free and comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 58 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, and about 35 mol % cholesterol (or derivative thereof).

15 [00104] Additional embodiments related to the 7:54 and 7:58 formulations are described in published US patent application publication number US 2011/0076335 A1, the disclosure of which is herein incorporated by reference in its entirety for all purposes.

[00105] The present invention also provides pharmaceutical compositions comprising a nucleic acid-lipid particle such as a SNALP and a pharmaceutically acceptable carrier.

20 [00106] The nucleic acid-lipid particles of the present invention (e.g., SNALP) are useful for the therapeutic delivery of interfering RNAs (e.g., siRNAs) that silence the expression of one or more ALDH genes. In some embodiments, a cocktail of interfering RNAs that target different regions (e.g., overlapping and/or non-overlapping sequences) of an ALDH gene is formulated into the same or different nucleic acid-lipid particles, and the particles are administered to a mammal (e.g., a human) 25 requiring such treatment. In certain instances, a therapeutically effective amount of the nucleic acid-lipid particles can be administered to the mammal, e.g., for treating alcoholism in a human.

[00107] In certain embodiments, the present invention provides a method for introducing one or more interfering RNA (e.g., siRNA) molecules described herein into a cell by contacting the cell with

a nucleic acid-lipid particle described herein (e.g., a SNALP formulation). In one particular embodiment, the cell is a reticuloendothelial cell (e.g., monocyte or macrophage), fibroblast cell, endothelial cell, or platelet cell.

[00108] In some embodiments, the nucleic acid-lipid particles described herein (e.g., SNALP) are 5 administered by one of the following routes of administration: oral, intranasal, intravenous, intraperitoneal, intramuscular, intra-articular, intralesional, intratracheal, subcutaneous, and intradermal. In particular embodiments, the nucleic acid-lipid particles are administered systemically, e.g., via enteral or parenteral routes of administration.

[00109] In particular embodiments, the nucleic acid-lipid particles of the invention (e.g., SNALP) 10 can preferentially deliver a payload such as an interfering RNA (e.g., dsRNA) to the liver as compared to other tissues, e.g., for the treatment of acute or chronic alcoholism.

[00110] In certain aspects, the present invention provides methods for silencing ALDH gene expression in a mammal (e.g., human) in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP 15 formulation) comprising one or more interfering RNAs (e.g., siRNAs) described herein (e.g., siRNAs targeting one or more ALDH genes). In some embodiments, administration of nucleic acid-lipid particles comprising one or more ALDH interfering RNAs reduces ALDH RNA levels by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or 20 any range therein) relative to ALDH RNA levels detected in the absence of the interfering RNA (e.g., buffer control or irrelevant non-ALDH targeting interfering RNA control). In other embodiments, administration of nucleic acid-lipid particles comprising one or more ALDH-targeting interfering RNAs reduces ALDH RNA levels for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 days or 25 more (or any range therein) relative to a negative control such as, e.g., a buffer control or an irrelevant non-ALDH targeting interfering RNA control.

[00111] In other aspects, the present invention provides methods for silencing ALDH gene expression in a mammal (e.g., human) in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP 30 formulation) comprising one or more interfering RNAs (e.g., siRNAs) described herein (e.g., siRNAs targeting one or more regions of the ALDH gene). In some embodiments, administration of nucleic acid-lipid particles comprising one or more ALDH interfering RNAs reduces ALDH mRNA levels by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%

(or any range therein) relative to ALDH mRNA levels detected in the absence of the interfering RNA (e.g., buffer control or irrelevant non-ALDH targeting interfering RNA control). In other embodiments, administration of nucleic acid-lipid particles comprising one or more ALDH-targeting interfering RNAs reduces ALDH mRNA levels for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 5 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 days or more (or any range therein) relative to a negative control such as, e.g., a buffer control or an irrelevant non-ALDH targeting interfering RNA control.

10 [00112] In other aspects, the present invention provides methods for treating, preventing, reducing the risk or likelihood of developing (e.g., reducing the susceptibility to), delaying the onset of, and/or ameliorating one or more symptoms associated with alcoholism in a mammal (e.g., human) in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP formulation) comprising one or more interfering RNA molecules (e.g., siRNAs) described herein that target ALDH gene expression.

15 [00113] In further aspects, the present invention provides a method for inactivating ALDH in a mammal (e.g., human) in need thereof (e.g., a human suffering from alcoholism), the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP formulation) comprising one or more interfering RNAs (e.g., siRNAs) described herein that target ALDH gene expression. In some embodiments, administration of nucleic acid-lipid particles comprising one or more ALDH-targeting interfering RNAs lowers, reduces, or 20 decreases ALDH enzyme levels by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range therein) relative to the ALDH enzyme levels detected in the absence of the interfering RNA (e.g., buffer control or irrelevant non-ALDH targeting interfering RNA control).

25 [00114] By way of example, ALDH2 mRNA can be measured using a branched DNA assay (QuantiGene®; Affymetrix). The branched DNA assay is a sandwich nucleic acid hybridization method that uses bDNA molecules to amplify signal from captured target RNA. Again by way of example, ALDH enzymatic activity can be measured spectrophotometrically by adding NAD and a substrate (e.g., acetaldehyde) to a protein sample and measuring the formation of NADH at 340 nm 30 (see, e.g., Sheppard, Albersheim & McClearn, J. Biol. Chem. 1970 245(11):2876; Arolfo *et al* Alcoholism: Clinical and Experimental Research 2009 33(11):1935; Garver *et al*, Alcohol & Alcoholism 2000 35(5):435)).

#### IV. Therapeutic Nucleic Acids

[00115] The term “nucleic acid” includes any oligonucleotide or polynucleotide, with fragments containing up to 60 nucleotides generally termed oligonucleotides, and longer fragments termed polynucleotides. In particular embodiments, oligonucleotides of the invention are from about 15 to 5 about 60 nucleotides in length. In some embodiments, nucleic acid is associated with a carrier system such as the lipid particles described herein. In certain embodiments, the nucleic acid is fully encapsulated in the lipid particle. Nucleic acid may be administered alone in the lipid particles of the invention, or in combination (*e.g.*, co-administered) with lipid particles comprising peptides, polypeptides, or small molecules such as conventional drugs.

10 [00116] In the context of this invention, the terms “polynucleotide” and “oligonucleotide” refer to a polymer or oligomer of nucleotide or nucleoside monomers consisting of naturally-occurring bases, sugars and intersugar (backbone) linkages. The terms “polynucleotide” and “oligonucleotide” also include polymers or oligomers comprising non-naturally occurring monomers, or portions thereof, which function similarly. Such modified or substituted oligonucleotides are often preferred over 15 native forms because of properties such as, for example, enhanced cellular uptake, reduced immunogenicity, and increased stability in the presence of nucleases.

20 [00117] Oligonucleotides are generally classified as deoxyribooligonucleotides or ribooligonucleotides. A deoxyribooligonucleotide consists of a 5-carbon sugar called deoxyribose joined covalently to phosphate at the 5' and 3' carbons of this sugar to form an alternating, unbranched polymer. A ribooligonucleotide consists of a similar repeating structure where the 5-carbon sugar is ribose.

25 [00118] The nucleic acid can be single-stranded DNA or RNA, or double-stranded DNA or RNA, or DNA-RNA hybrids. In preferred embodiments, the nucleic acid is double-stranded RNA. Examples of double-stranded RNA are described herein and include, *e.g.*, siRNA and other RNAi agents such as Dicer-substrate dsRNA, shRNA, aiRNA, and pre-miRNA. In other embodiments, the nucleic acid is single-stranded. Single-stranded nucleic acids include, *e.g.*, antisense oligonucleotides, ribozymes, mature miRNA, and triplex-forming oligonucleotides.

30 [00119] Nucleic acids of the invention may be of various lengths, generally dependent upon the particular form of nucleic acid. For example, in particular embodiments, plasmids or genes may be from about 1,000 to about 100,000 nucleotide residues in length. In particular embodiments, oligonucleotides may range from about 10 to about 100 nucleotides in length. In various related embodiments, oligonucleotides, both single-stranded, double-stranded, and triple-stranded, may range in length from about 10 to about 60 nucleotides, from about 15 to about 60 nucleotides, from about 20

to about 50 nucleotides, from about 15 to about 30 nucleotides, or from about 20 to about 30 nucleotides in length.

[00120] In particular embodiments, an oligonucleotide (or a strand thereof) of the invention specifically hybridizes to or is complementary to a target polynucleotide sequence. The terms 5 “specifically hybridizable” and “complementary” as used herein indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the oligonucleotide. It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. In preferred embodiments, an oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target sequence 10 interferes with the normal function of the target sequence to cause a loss of utility or expression therefrom, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired, *i.e.*, under physiological conditions in the case of *in vivo* assays or therapeutic treatment, or, in the case of 15 *in vitro* assays, under conditions in which the assays are conducted. Thus, the oligonucleotide may include 1, 2, 3, or more base substitutions as compared to the region of a gene or mRNA sequence that it is targeting or to which it specifically hybridizes.

#### A. siRNA

[00121] The unmodified and modified siRNA molecules of the invention are capable of silencing ALDH gene expression. Each strand of the siRNA duplex is typically about 15 to about 60 20 nucleotides in length, preferably about 15 to about 30 nucleotides in length. In certain embodiments, the siRNA comprises at least one modified nucleotide. The modified siRNA is generally less immunostimulatory than a corresponding unmodified siRNA sequence and retains RNAi activity 25 against the target gene of interest. In some embodiments, the modified siRNA contains at least one 2'OMe purine or pyrimidine nucleotide such as a 2'OMe-guanosine, 2'OMe-uridine, 2'OMe-adenosine, and/or 2'OMe-cytosine nucleotide. The modified nucleotides can be present in one strand (*i.e.*, sense or antisense) or both strands of the siRNA. In some preferred embodiments, one or more 30 of the uridine and/or guanosine nucleotides are modified (*e.g.*, 2'OMe-modified) in one strand (*i.e.*, sense or antisense) or both strands of the siRNA. In these embodiments, the modified siRNA can further comprise one or more modified (*e.g.*, 2'OMe-modified) adenosine and/or modified (*e.g.*, 2'OMe-modified) cytosine nucleotides. In other preferred embodiments, only uridine and/or 35 guanosine nucleotides are modified (*e.g.*, 2'OMe-modified) in one strand (*i.e.*, sense or antisense) or both strands of the siRNA. The siRNA sequences may have overhangs (*e.g.*, 3' or 5' overhangs as described in Elbashir *et al.*, *Genes Dev.*, 15:188 (2001) or Nykänen *et al.*, *Cell*, 107:309 (2001)), or may lack overhangs (*i.e.*, have blunt ends).

[00122] In particular embodiments, the selective incorporation of modified nucleotides such as 2'OMe uridine and/or guanosine nucleotides into the double-stranded region of either or both strands of the siRNA reduces or completely abrogates the immune response to that siRNA molecule. In certain instances, the immunostimulatory properties of specific siRNA sequences and their ability to silence gene expression can be balanced or optimized by the introduction of minimal and selective 2'OMe modifications within the double-stranded region of the siRNA duplex. This can be achieved at therapeutically viable siRNA doses without cytokine induction, toxicity, and off-target effects associated with the use of unmodified siRNA.

[00123] The modified siRNA generally comprises from about 1% to about 100% (e.g., about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%) modified nucleotides in the double-stranded region of the siRNA duplex. In certain embodiments, one, two, three, four, five, six, seven, eight, nine, ten, or more of the nucleotides in the double-stranded region of the siRNA comprise modified nucleotides. In certain other embodiments, some or all of the modified nucleotides in the double-stranded region of the siRNA are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more nucleotides apart from each other. In one preferred embodiment, none of the modified nucleotides in the double-stranded region of the siRNA are adjacent to each other (e.g., there is a gap of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 unmodified nucleotides between each modified nucleotide).

[00124] In some embodiments, less than about 50% (e.g., less than about 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, 40%, 39%, 38%, 37%, or 36%, preferably less than about 35%, 34%, 33%, 32%, 31%, or 30%) of the nucleotides in the double-stranded region of the siRNA comprise modified (e.g., 2'OMe) nucleotides. In one aspect of these embodiments, less than about 50% of the uridine and/or guanosine nucleotides in the double-stranded region of one or both strands of the siRNA are selectively (e.g., only) modified. In another aspect of these embodiments, less than about 50% of the nucleotides in the double-stranded region of the siRNA comprise 2'OMe nucleotides, wherein the siRNA comprises 2'OMe nucleotides in both strands of the siRNA, wherein the siRNA comprises at least one 2'OMe-guanosine nucleotide and at least one 2'OMe-uridine nucleotide, and wherein 2'OMe-guanosine nucleotides and 2'OMe-uridine nucleotides are the only 2'OMe nucleotides present in the double-stranded region. In yet another aspect of these embodiments, less than about 50% of the nucleotides in the double-stranded region of the siRNA comprise 2'OMe nucleotides, wherein the siRNA comprises 2'OMe nucleotides in both strands of the modified siRNA, wherein the siRNA comprises 2'OMe nucleotides selected from the group consisting of 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, 2'OMe-adenosine nucleotides, and mixtures thereof, and wherein the siRNA does not comprise 2'OMe-cytosine nucleotides in the double-

stranded region. In a further aspect of these embodiments, less than about 50% of the nucleotides in the double-stranded region of the siRNA comprise 2'OMe nucleotides, wherein the siRNA comprises 2'OMe nucleotides in both strands of the siRNA, wherein the siRNA comprises at least one 2'OMe-guanosine nucleotide and at least one 2'OMe-uridine nucleotide, and wherein the siRNA does not 5 comprise 2'OMe-cytosine nucleotides in the double-stranded region. In another aspect of these embodiments, less than about 50% of the nucleotides in the double-stranded region of the siRNA comprise 2'OMe nucleotides, wherein the siRNA comprises 2'OMe nucleotides in both strands of the modified siRNA, wherein the siRNA comprises 2'OMe nucleotides selected from the group 10 consisting of 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, 2'OMe-adenosine nucleotides, and mixtures thereof, and wherein the 2'OMe nucleotides in the double-stranded region are not adjacent to each other.

**[00125]** In other embodiments, from about 1% to about 50% (e.g., from about 5%-50%, 10%-50%, 15%-50%, 20%-50%, 25%-50%, 30%-50%, 35%-50%, 40%-50%, 45%-50%, 5%-45%, 10%-45%, 15%-45%, 20%-45%, 25%-45%, 30%-45%, 35%-45%, 40%-45%, 5%-40%, 10%-40%, 15%-40%, 20%-40%, 25%-40%, 25%-39%, 25%-38%, 25%-37%, 25%-36%, 26%-39%, 26%-38%, 26%-37%, 26%-36%, 27%-39%, 27%-38%, 27%-37%, 27%-36%, 28%-39%, 28%-38%, 28%-37%, 28%-36%, 29%-39%, 29%-38%, 29%-37%, 29%-36%, 30%-40%, 30%-39%, 30%-38%, 30%-37%, 30%-36%, 31%-39%, 31%-38%, 31%-37%, 31%-36%, 32%-39%, 32%-38%, 32%-37%, 32%-36%, 33%-39%, 33%-38%, 33%-37%, 33%-36%, 34%-39%, 34%-38%, 34%-37%, 34%-36%, 35%-40%, 5%-35%, 10%-35%, 15%-35%, 20%-35%, 21%-35%, 22%-35%, 23%-35%, 24%-35%, 25%-35%, 26%-35%, 27%-35%, 28%-35%, 29%-35%, 30%-35%, 31%-35%, 32%-35%, 33%-35%, 34%-35%, 30%-34%, 31%-34%, 32%-34%, 33%-34%, 30%-33%, 31%-33%, 32%-33%, 30%-32%, 31%-32%, 25%-34%, 25%-33%, 25%-32%, 25%-31%, 26%-34%, 26%-33%, 26%-32%, 26%-31%, 27%-34%, 27%-33%, 27%-32%, 27%-31%, 28%-34%, 28%-33%, 28%-32%, 28%-31%, 29%-34%, 29%-33%, 29%-32%, 29%-31%, 5%-30%, 10%-30%, 15%-30%, 20%-34%, 20%-33%, 20%-32%, 20%-31%, 20%-30%, 21%-30%, 22%-30%, 23%-30%, 24%-30%, 25%-30%, 25%-29%, 25%-28%, 25%-27%, 25%-26%, 26%-30%, 26%-29%, 26%-28%, 26%-27%, 27%-30%, 27%-29%, 27%-28%, 28%-30%, 28%-29%, 29%-30%, 5%-25%, 10%-25%, 15%-25%, 20%-29%, 20%-28%, 20%-27%, 20%-26%, 20%-25%, 5%-20%, 10%-20%, 15%-20%, 5%-15%, 10%-15%, or 5%-10%) of the nucleotides in the double-stranded region of the siRNA comprise modified nucleotides. In one aspect of these embodiments, from about 1% to about 50% of the uridine and/or guanosine nucleotides in the double-stranded region of one or both strands of the siRNA are selectively (e.g., only) modified. In another aspect of these embodiments, from about 1% to about 50% of the nucleotides in the double-stranded region of the siRNA comprise 2'OMe nucleotides, wherein the siRNA comprises 2'OMe nucleotides in both strands of the siRNA, wherein the siRNA comprises at least one 2'OMe-guanosine nucleotide and at least one 2'OMe-uridine nucleotide, and wherein 2'OMe-guanosine nucleotides and 2'OMe-

uridine nucleotides are the only 2'OMe nucleotides present in the double-stranded region. In yet another aspect of these embodiments, from about 1% to about 50% of the nucleotides in the double-stranded region of the siRNA comprise 2'OMe nucleotides, wherein the siRNA comprises 2'OMe nucleotides in both strands of the modified siRNA, wherein the siRNA comprises 2'OMe nucleotides 5 selected from the group consisting of 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, 2'OMe-adenosine nucleotides, and mixtures thereof, and wherein the siRNA does not comprise 2'OMe-cytosine nucleotides in the double-stranded region. In a further aspect of these embodiments, from about 1% to about 50% of the nucleotides in the double-stranded region of the siRNA comprise 10 2'OMe nucleotides, wherein the siRNA comprises 2'OMe nucleotides in both strands of the siRNA, wherein the siRNA comprises at least one 2'OMe-guanosine nucleotide and at least one 2'OMe-uridine nucleotide, and wherein the siRNA does not comprise 2'OMe-cytosine nucleotides in the double-stranded region. In another aspect of these embodiments, from about 1% to about 50% of the 15 nucleotides in the double-stranded region of the siRNA comprise 2'OMe nucleotides, wherein the siRNA comprises 2'OMe nucleotides in both strands of the modified siRNA, wherein the siRNA comprises 2'OMe nucleotides selected from the group consisting of 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, 2'OMe-adenosine nucleotides, and mixtures thereof, and wherein the 2'OMe nucleotides in the double-stranded region are not adjacent to each other.

[00126] Additional ranges, percentages, and patterns of modifications that may be introduced into siRNA are described in U.S. Patent Publication No. 20070135372, the disclosure of which is herein 20 incorporated by reference in its entirety for all purposes.

### 1. Selection of siRNA Sequences

[00127] Suitable siRNA sequences can be identified using any means known in the art. Typically, the methods described in Elbashir *et al.*, *Nature*, 411:494-498 (2001) and Elbashir *et al.*, *EMBO J.*, 20:6877-6888 (2001) are combined with rational design rules set forth in Reynolds *et al.*, 25 *Nature Biotech.*, 22(3):326-330 (2004).

[00128] As a non-limiting example, the nucleotide sequence 3' of the AUG start codon of a transcript from the target gene of interest may be scanned for dinucleotide sequences (*e.g.*, AA, NA, CC, GG, or UU, wherein N = C, G, or U) (*see, e.g.*, Elbashir *et al.*, *EMBO J.*, 20:6877-6888 (2001)). The nucleotides immediately 3' to the dinucleotide sequences are identified as potential siRNA 30 sequences (*i.e.*, a target sequence or a sense strand sequence). Typically, the 19, 21, 23, 25, 27, 29, 31, 33, 35, or more nucleotides immediately 3' to the dinucleotide sequences are identified as potential siRNA sequences. In some embodiments, the dinucleotide sequence is an AA or NA sequence and the 19 nucleotides immediately 3' to the AA or NA dinucleotide are identified as potential siRNA sequences. siRNA sequences are usually spaced at different positions along the

length of the target gene. To further enhance silencing efficiency of the siRNA sequences, potential siRNA sequences may be analyzed to identify sites that do not contain regions of homology to other coding sequences, *e.g.*, in the target cell or organism. For example, a suitable siRNA sequence of about 21 base pairs typically will not have more than 16-17 contiguous base pairs of homology to 5 coding sequences in the target cell or organism. If the siRNA sequences are to be expressed from an RNA Pol III promoter, siRNA sequences lacking more than 4 contiguous A's or T's are selected.

[00129] Once a potential siRNA sequence has been identified, a complementary sequence (*i.e.*, an antisense strand sequence) can be designed. A potential siRNA sequence can also be analyzed using a variety of criteria known in the art. For example, to enhance their silencing efficiency, the 10 siRNA sequences may be analyzed by a rational design algorithm to identify sequences that have one or more of the following features: (1) G/C content of about 25% to about 60% G/C; (2) at least 3 A/Us at positions 15-19 of the sense strand; (3) no internal repeats; (4) an A at position 19 of the sense strand; (5) an A at position 3 of the sense strand; (6) a U at position 10 of the sense strand; (7) no G/C at position 19 of the sense strand; and (8) no G at position 13 of the sense strand. siRNA 15 design tools that incorporate algorithms that assign suitable values of each of these features and are useful for selection of siRNA can be found at, *e.g.*, <http://ihome.ust.hk/~bokcmho/siRNA/siRNA.html>. One of skill in the art will appreciate that sequences with one or more of the foregoing characteristics may be selected for further analysis and testing as potential siRNA sequences.

20 [00130] Additionally, potential siRNA sequences with one or more of the following criteria can often be eliminated as siRNA: (1) sequences comprising a stretch of 4 or more of the same base in a row; (2) sequences comprising homopolymers of Gs (*i.e.*, to reduce possible non-specific effects due to structural characteristics of these polymers; (3) sequences comprising triple base motifs (*e.g.*, GGG, CCC, AAA, or TTT); (4) sequences comprising stretches of 7 or more G/Cs in a row; and (5) 25 sequences comprising direct repeats of 4 or more bases within the candidates resulting in internal fold-back structures. However, one of skill in the art will appreciate that sequences with one or more of the foregoing characteristics may still be selected for further analysis and testing as potential siRNA sequences.

[00131] In some embodiments, potential siRNA sequences may be further analyzed based on 30 siRNA duplex asymmetry as described in, *e.g.*, Khvorova *et al.*, *Cell*, 115:209-216 (2003); and Schwarz *et al.*, *Cell*, 115:199-208 (2003). In other embodiments, potential siRNA sequences may be further analyzed based on secondary structure at the target site as described in, *e.g.*, Luo *et al.*, *Biophys. Res. Commun.*, 318:303-310 (2004). For example, secondary structure at the target site can be modeled using the Mfold algorithm (available at [http://mfold.burnet.edu.au/rna\\_form](http://mfold.burnet.edu.au/rna_form)) to select

siRNA sequences which favor accessibility at the target site where less secondary structure in the form of base-pairing and stem-loops is present.

[00132] Once a potential siRNA sequence has been identified, the sequence can be analyzed for the presence of any immunostimulatory properties, *e.g.*, using an *in vitro* cytokine assay or an *in vivo* animal model. Motifs in the sense and/or antisense strand of the siRNA sequence such as GU-rich motifs (*e.g.*, 5'-GU-3', 5'-UGU-3', 5'-GUGU-3', 5'-UGUGU-3', *etc.*) can also provide an indication of whether the sequence may be immunostimulatory. Once an siRNA molecule is found to be immunostimulatory, it can then be modified to decrease its immunostimulatory properties as described herein. As a non-limiting example, an siRNA sequence can be contacted with a mammalian responder cell under conditions such that the cell produces a detectable immune response to determine whether the siRNA is an immunostimulatory or a non-immunostimulatory siRNA. The mammalian responder cell may be from a naïve mammal (*i.e.*, a mammal that has not previously been in contact with the gene product of the siRNA sequence). The mammalian responder cell may be, *e.g.*, a peripheral blood mononuclear cell (PBMC), a macrophage, and the like. The detectable immune response may comprise production of a cytokine or growth factor such as, *e.g.*, TNF- $\alpha$ , IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IL-6, IL-12, or a combination thereof. An siRNA molecule identified as being immunostimulatory can then be modified to decrease its immunostimulatory properties by replacing at least one of the nucleotides on the sense and/or antisense strand with modified nucleotides. For example, less than about 30% (*e.g.*, less than about 30%, 25%, 20%, 15%, 10%, or 5%) of the nucleotides in the double-stranded region of the siRNA duplex can be replaced with modified nucleotides such as 2'OMe nucleotides. The modified siRNA can then be contacted with a mammalian responder cell as described above to confirm that its immunostimulatory properties have been reduced or abrogated.

[00133] Suitable *in vitro* assays for detecting an immune response include, but are not limited to, the double monoclonal antibody sandwich immunoassay technique of David *et al.* (U.S. Patent No. 4,376,110); monoclonal-polyclonal antibody sandwich assays (Wide *et al.*, in Kirkham and Hunter, eds., *Radioimmunoassay Methods*, E. and S. Livingstone, Edinburgh (1970)); the “Western blot” method of Gordon *et al.* (U.S. Patent No. 4,452,901); immunoprecipitation of labeled ligand (Brown *et al.*, *J. Biol. Chem.*, 255:4980-4983 (1980)); enzyme-linked immunosorbent assays (ELISA) as described, for example, by Raines *et al.*, *J. Biol. Chem.*, 257:5154-5160 (1982); immunocytochemical techniques, including the use of fluorochromes (Brooks *et al.*, *Clin. Exp. Immunol.*, 39:477 (1980)); and neutralization of activity (Bowen-Pope *et al.*, *Proc. Natl. Acad. Sci. USA*, 81:2396-2400 (1984)). In addition to the immunoassays described above, a number of other immunoassays are available, including those described in U.S. Patent Nos. 3,817,827; 3,850,752; 3,901,654; 3,935,074; 3,984,533;

3,996,345; 4,034,074; and 4,098,876. The disclosures of these references are herein incorporated by reference in their entirety for all purposes.

[00134] A non-limiting example of an *in vivo* model for detecting an immune response includes an *in vivo* mouse cytokine induction assay as described in, *e.g.*, Judge *et al.*, *Mol. Ther.*, 13:494-505 (2006). In certain embodiments, the assay that can be performed as follows: (1) siRNA can be administered by standard intravenous injection in the lateral tail vein; (2) blood can be collected by cardiac puncture about 6 hours after administration and processed as plasma for cytokine analysis; and (3) cytokines can be quantified using sandwich ELISA kits according to the manufacturer's instructions (*e.g.*, mouse and human IFN- $\alpha$  (PBL Biomedical; Piscataway, NJ); human IL-6 and TNF- $\alpha$  (eBioscience; San Diego, CA); and mouse IL-6, TNF- $\alpha$ , and IFN- $\gamma$  (BD Biosciences; San Diego, CA)).

[00135] Monoclonal antibodies that specifically bind cytokines and growth factors are commercially available from multiple sources and can be generated using methods known in the art (*see, e.g.*, Kohler *et al.*, *Nature*, 256: 495-497 (1975) and Harlow and Lane, *ANTIBODIES, A LABORATORY MANUAL*, Cold Spring Harbor Publication, New York (1999)). Generation of monoclonal antibodies has been previously described and can be accomplished by any means known in the art (Buhring *et al.*, in *Hybridoma*, Vol. 10, No. 1, pp. 77-78 (1991)). In some methods, the monoclonal antibody is labeled (*e.g.*, with any composition detectable by spectroscopic, photochemical, biochemical, electrical, optical, or chemical means) to facilitate detection.

20                   2.        Generating siRNA Molecules

[00136] siRNA can be provided in several forms including, *e.g.*, as one or more isolated small-interfering RNA (siRNA) duplexes, as longer double-stranded RNA (dsRNA), or as siRNA or dsRNA transcribed from a transcriptional cassette in a DNA plasmid. In some embodiments, siRNA may be produced enzymatically or by partial/total organic synthesis, and modified ribonucleotides can be introduced by *in vitro* enzymatic or organic synthesis. In certain instances, each strand is prepared chemically. Methods of synthesizing RNA molecules are known in the art, *e.g.*, the chemical synthesis methods as described in Verma and Eckstein (1998) or as described herein.

[00137] An RNA population can be used to provide long precursor RNAs, or long precursor RNAs that have substantial or complete identity to a selected target sequence can be used to make the siRNA. The RNAs can be isolated from cells or tissue, synthesized, and/or cloned according to methods well known to those of skill in the art. The RNA can be a mixed population (obtained from cells or tissue, transcribed from cDNA, subtracted, selected, *etc.*), or can represent a single target sequence. RNA can be naturally occurring (*e.g.*, isolated from tissue or cell samples), synthesized *in*

*vitro* (e.g., using T7 or SP6 polymerase and PCR products or a cloned cDNA), or chemically synthesized.

5 [00138] To form a long dsRNA, for synthetic RNAs, the complement is also transcribed *in vitro* and hybridized to form a dsRNA. If a naturally occurring RNA population is used, the RNA complements are also provided (e.g., to form dsRNA for digestion by *E. coli* RNase III or Dicer), *e.g.*, by transcribing cDNAs corresponding to the RNA population, or by using RNA polymerases. The precursor RNAs are then hybridized to form double stranded RNAs for digestion. The dsRNAs can be directly administered to a subject or can be digested *in vitro* prior to administration.

10 [00139] Methods for isolating RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR are well known in the art (see, *e.g.*, Gubler and Hoffman, *Gene*, 25:263-269 (1983); Sambrook *et al.*, *supra*; Ausubel *et al.*, *supra*), as are PCR methods (see, U.S. Patent Nos. 4,683,195 and 4,683,202; *PCR Protocols: A Guide to Methods and Applications* (Innis *et al.*, eds, 1990)). Expression libraries are also well known to those of skill in the art. Additional basic texts disclosing the general methods of use in this invention include Sambrook 15 *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994). The disclosures of these references are herein incorporated by reference in their entirety for all purposes.

20 [00140] Preferably, siRNA are chemically synthesized. The oligonucleotides that comprise the siRNA molecules of the invention can be synthesized using any of a variety of techniques known in the art, such as those described in Usman *et al.*, *J. Am. Chem. Soc.*, 109:7845 (1987); Scaringe *et al.*, *Nucl. Acids Res.*, 18:5433 (1990); Wincott *et al.*, *Nucl. Acids Res.*, 23:2677-2684 (1995); and Wincott 25 *et al.*, *Methods Mol. Bio.*, 74:59 (1997). The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end and phosphoramidites at the 3'-end. As a non-limiting example, small scale syntheses can be conducted on an Applied Biosystems synthesizer using a 0.2  $\mu$ mol scale protocol. Alternatively, syntheses at the 0.2  $\mu$ mol scale can be performed on a 96-well plate synthesizer from Protogene (Palo Alto, CA). However, a larger or smaller scale of synthesis is also within the scope of this invention. Suitable 30 reagents for oligonucleotide synthesis, methods for RNA deprotection, and methods for RNA purification are known to those of skill in the art.

[00141] siRNA molecules can also be synthesized via a tandem synthesis technique, wherein both strands are synthesized as a single continuous oligonucleotide fragment or strand separated by a cleavable linker that is subsequently cleaved to provide separate fragments or strands that hybridize to form the siRNA duplex. The linker can be a polynucleotide linker or a non-nucleotide linker. The

tandem synthesis of siRNA can be readily adapted to both multiwell/multiplate synthesis plaALDHorms as well as large scale synthesis plaALDHorms employing batch reactors, synthesis columns, and the like. Alternatively, siRNA molecules can be assembled from two distinct oligonucleotides, wherein one oligonucleotide comprises the sense strand and the other comprises the 5 antisense strand of the siRNA. For example, each strand can be synthesized separately and joined together by hybridization or ligation following synthesis and/or deprotection. In certain other instances, siRNA molecules can be synthesized as a single continuous oligonucleotide fragment, where the self-complementary sense and antisense regions hybridize to form an siRNA duplex having hairpin secondary structure.

10

### 3. Modifying siRNA Sequences

[00142] In certain aspects, siRNA molecules comprise a duplex having two strands and at least one modified nucleotide in the double-stranded region, wherein each strand is about 15 to about 60 nucleotides in length. Advantageously, the modified siRNA is less immunostimulatory than a corresponding unmodified siRNA sequence, but retains the capability of silencing the expression of a 15 target sequence. In preferred embodiments, the degree of chemical modifications introduced into the siRNA molecule strikes a balance between reduction or abrogation of the immunostimulatory properties of the siRNA and retention of RNAi activity. As a non-limiting example, an siRNA molecule that targets a gene of interest can be minimally modified (e.g., less than about 30%, 25%, 20%, 15%, 10%, or 5% modified) at selective uridine and/or guanosine nucleotides within the siRNA 20 duplex to eliminate the immune response generated by the siRNA while retaining its capability to silence target gene expression.

[00143] Examples of modified nucleotides suitable for use in the invention include, but are not limited to, ribonucleotides having a 2'-O-methyl (2'OMe), 2'-deoxy-2'-fluoro (2'F), 2'-deoxy, 5-C-methyl, 2'-O-(2-methoxyethyl) (MOE), 4'-thio, 2'-amino, or 2'-C-allyl group. Modified nucleotides 25 having a Northern conformation such as those described in, e.g., Saenger, *Principles of Nucleic Acid Structure*, Springer-Verlag Ed. (1984), are also suitable for use in siRNA molecules. Such modified nucleotides include, without limitation, locked nucleic acid (LNA) nucleotides (e.g., 2'-O, 4'-C-methylene-(D-ribofuranosyl) nucleotides), 2'-O-(2-methoxyethyl) (MOE) nucleotides, 2'-methyl-thio-ethyl nucleotides, 2'-deoxy-2'-fluoro (2'F) nucleotides, 2'-deoxy-2'-chloro (2'Cl) nucleotides, 30 and 2'-azido nucleotides. In certain instances, the siRNA molecules described herein include one or more G-clamp nucleotides. A G-clamp nucleotide refers to a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine nucleotide within a duplex (see, e.g., Lin *et al.*, *J. Am. Chem. Soc.*, 120:8531-8532 (1998)). In addition, nucleotides having a nucleotide base analog such as, for example, C-35 phenyl, C-naphthyl, other aromatic derivatives, inosine, azole carboxamides, and nitroazole

derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole (*see, e.g.*, Loakes, *Nucl. Acids Res.*, 29:2437-2447 (2001)) can be incorporated into siRNA molecules.

**[00144]** In certain embodiments, siRNA molecules may further comprise one or more chemical modifications such as terminal cap moieties, phosphate backbone modifications, and the like.

5 Examples of terminal cap moieties include, without limitation, inverted deoxy abasic residues, glyceryl modifications, 4',5'-methylene nucleotides, 1-( $\beta$ -D-erythrofuranosyl) nucleotides, 4'-thio nucleotides, carbocyclic nucleotides, 1,5-anhydrohexitol nucleotides, L-nucleotides,  $\alpha$ -nucleotides, modified base nucleotides, *threo*-pentofuranosyl nucleotides, acyclic 3',4'-seco nucleotides, acyclic 3,4-dihydroxybutyl nucleotides, acyclic 3,5-dihydroxypentyl nucleotides, 3'-3'-inverted nucleotide 10 moieties, 3'-3'-inverted abasic moieties, 3'-2'-inverted nucleotide moieties, 3'-2'-inverted abasic moieties, 5'-5'-inverted nucleotide moieties, 5'-5'-inverted abasic moieties, 3'-5'-inverted deoxy abasic moieties, 5'-amino-alkyl phosphate, 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate, 6-aminohexyl phosphate, 1,2-aminododecyl phosphate, hydroxypropyl phosphate, 1,4-butanediol phosphate, 3'-phosphoramidate, 5'-phosphoramidate, hexylphosphate, aminohexyl 15 phosphate, 3'-phosphate, 5'-amino, 3'-phosphorothioate, 5'-phosphorothioate, phosphorodithioate, and bridging or non-bridging methylphosphonate or 5'-mercapto moieties (*see, e.g.*, U.S. Patent No. 5,998,203; Beaucage *et al.*, *Tetrahedron* 49:1925 (1993)). Non-limiting examples of phosphate backbone modifications (*i.e.*, resulting in modified internucleotide linkages) include phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amide, 20 carbamate, carboxymethyl, acetamide, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and alkylsilyl substitutions (*see, e.g.*, Hunziker *et al.*, *Nucleic Acid Analogues: Synthesis and Properties*, in *Modern Synthetic Methods*, VCH, 331-417 (1995); Mesmaeker *et al.*, *Novel Backbone Replacements for Oligonucleotides*, in *Carbohydrate Modifications in Antisense Research*, ACS, 24-39 (1994)). Such chemical modifications can occur at the 5'-end and/or 3'-end of 25 the sense strand, antisense strand, or both strands of the siRNA. The disclosures of these references are herein incorporated by reference in their entirety for all purposes.

**[00145]** In some embodiments, the sense and/or antisense strand of the siRNA molecule can further comprise a 3'-terminal overhang having about 1 to about 4 (*e.g.*, 1, 2, 3, or 4) 2'-deoxy ribonucleotides, modified (*e.g.*, 2'OMe) and/or unmodified uridine ribonucleotides, and/or any other 30 combination of modified (*e.g.*, 2'OMe) and unmodified nucleotides.

**[00146]** Additional examples of modified nucleotides and types of chemical modifications that can be introduced into siRNA molecules are described, *e.g.*, in UK Patent No. GB 2,397,818 B and U.S. Patent Publication Nos. 20040192626, 20050282188, and 20070135372, the disclosures of which are herein incorporated by reference in their entirety for all purposes.

[00147] The siRNA molecules described herein can optionally comprise one or more non-nucleotides in one or both strands of the siRNA. As used herein, the term “non-nucleotide” refers to any group or compound that can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base such as adenosine, guanine, cytosine, uracil, or thymine and therefore lacks a base at the 1'-position.

[00148] In other embodiments, chemical modification of the siRNA comprises attaching a conjugate to the siRNA molecule. The conjugate can be attached at the 5' and/or 3'-end of the sense and/or antisense strand of the siRNA via a covalent attachment such as, *e.g.*, a biodegradable linker. The conjugate can also be attached to the siRNA, *e.g.*, through a carbamate group or other linking group (*see, e.g.*, U.S. Patent Publication Nos. 20050074771, 20050043219, and 20050158727). In certain instances, the conjugate is a molecule that facilitates the delivery of the siRNA into a cell. Examples of conjugate molecules suitable for attachment to siRNA include, without limitation, 15 steroids such as cholesterol, glycols such as polyethylene glycol (PEG), human serum albumin (HSA), fatty acids, carotenoids, terpenes, bile acids, folates (*e.g.*, folic acid, folate analogs and derivatives thereof), sugars (*e.g.*, galactose, galactosamine, N-acetyl galactosamine, glucose, mannose, fructose, fucose, *etc.*), phospholipids, peptides, ligands for cellular receptors capable of mediating cellular uptake, and combinations thereof (*see, e.g.*, U.S. Patent Publication Nos. 20030130186, 20040110296, and 20040249178; U.S. Patent No. 6,753,423). Other examples include the lipophilic moiety, vitamin, polymer, peptide, protein, nucleic acid, small molecule, oligosaccharide, carbohydrate cluster, intercalator, minor groove binder, cleaving agent, and cross-linking agent conjugate molecules described in U.S. Patent Publication Nos. 20050119470 and 20050107325. Yet other examples include the 2'-O-alkyl amine, 2'-O-alkoxyalkyl amine, polyamine, 25 C5-cationic modified pyrimidine, cationic peptide, guanidinium group, amidinium group, cationic amino acid conjugate molecules described in U.S. Patent Publication No. 20050153337. Additional examples include the hydrophobic group, membrane active compound, cell penetrating compound, cell targeting signal, interaction modifier, and steric stabilizer conjugate molecules described in U.S. Patent Publication No. 20040167090. Further examples include the conjugate molecules described in 30 U.S. Patent Publication No. 20050239739. The type of conjugate used and the extent of conjugation to the siRNA molecule can be evaluated for improved pharmacokinetic profiles, bioavailability, and/or stability of the siRNA while retaining RNAi activity. As such, one skilled in the art can screen siRNA molecules having various conjugates attached thereto to identify ones having improved properties and full RNAi activity using any of a variety of well-known *in vitro* cell culture or *in vivo* 35 animal models. The disclosures of the above-described patent documents are herein incorporated by reference in their entirety for all purposes.

#### 4. Exemplary siRNA Embodiments

**[00149]** In some embodiments, each strand of the siRNA molecule comprises from about 15 to about 60 nucleotides in length (e.g., about 15-60, 15-50, 15-40, 15-30, 15-25, or 19-25 nucleotides in length, or 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length). In one particular 5 embodiment, the siRNA is chemically synthesized. The siRNA molecules of the invention are capable of silencing the expression of a target sequence *in vitro* and/or *in vivo*.

**[00150]** In other embodiments, the siRNA comprises at least one modified nucleotide. In certain embodiments, the siRNA comprises one, two, three, four, five, six, seven, eight, nine, ten, or more modified nucleotides in the double-stranded region. In particular embodiments, less than about 50% 10 (e.g., less than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%) of the nucleotides in the double-stranded region of the siRNA comprise modified nucleotides. In preferred embodiments, from about 1% to about 50% (e.g., from about 5%-50%, 10%-50%, 15%-50%, 20%-50%, 25%-50%, 30%-50%, 35%-50%, 40%-50%, 45%-50%, 5%-45%, 10%-45%, 15%-45%, 20%-45%, 25%-45%, 30%-45%, 35%-45%, 40%-45%, 5%-40%, 10%-40%, 15%-40%, 20%-40%, 25%-40%, 30%-40%, 15 35%-40%, 5%-35%, 10%-35%, 15%-35%, 20%-35%, 25%-35%, 30%-35%, 5%-30%, 10%-30%, 15%-30%, 20%-30%, 25%-30%, 5%-25%, 10%-25%, 15%-25%, 20%-25%, 5%-20%, 10%-20%, 15%-20%, 5%-15%, 10%-15%, or 5%-10%) of the nucleotides in the double-stranded region of the siRNA comprise modified nucleotides.

**[00151]** In further embodiments, the siRNA comprises modified nucleotides including, but not 20 limited to, 2'-O-methyl (2'OMe) nucleotides, 2'-deoxy-2'-fluoro (2'F) nucleotides, 2'-deoxy nucleotides, 2'-O-(2-methoxyethyl) (MOE) nucleotides, locked nucleic acid (LNA) nucleotides, and mixtures thereof. In preferred embodiments, the siRNA comprises 2'OMe nucleotides (e.g., 2'OMe purine and/or pyrimidine nucleotides) such as, e.g., 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, 2'OMe-adenosine nucleotides, 2'OMe-cytosine nucleotides, or mixtures thereof. In one 25 particular embodiment, the siRNA comprises at least one 2'OMe-guanosine nucleotide, 2'OMe-uridine nucleotide, or mixtures thereof. In certain instances, the siRNA does not comprise 2'OMe-cytosine nucleotides. In other embodiments, the siRNA comprises a hairpin loop structure.

**[00152]** In certain embodiments, the siRNA comprises modified nucleotides in one strand (*i.e.*, sense or antisense) or both strands of the double-stranded region of the siRNA molecule. Preferably, 30 uridine and/or guanosine nucleotides are modified at selective positions in the double-stranded region of the siRNA duplex. With regard to uridine nucleotide modifications, at least one, two, three, four, five, six, or more of the uridine nucleotides in the sense and/or antisense strand can be a modified uridine nucleotide such as a 2'OMe-uridine nucleotide. In some embodiments, every uridine nucleotide in the sense and/or antisense strand is a 2'OMe-uridine nucleotide. With regard to

guanosine nucleotide modifications, at least one, two, three, four, five, six, or more of the guanosine nucleotides in the sense and/or antisense strand can be a modified guanosine nucleotide such as a 2'OMe-guanosine nucleotide. In some embodiments, every guanosine nucleotide in the sense and/or antisense strand is a 2'OMe-guanosine nucleotide.

5 [00153] In certain embodiments, at least one, two, three, four, five, six, seven, or more 5'-GU-3' motifs in an siRNA sequence may be modified, *e.g.*, by introducing mismatches to eliminate the 5'-GU-3' motifs and/or by introducing modified nucleotides such as 2'OMe nucleotides. The 5'-GU-3' motif can be in the sense strand, the antisense strand, or both strands of the siRNA sequence. The 5'-GU-3' motifs may be adjacent to each other or, alternatively, they may be separated by 1, 2, 3, 4, 5, 6,  
10 7, 8, 9, 10, 11, 12, or more nucleotides.

15 [00154] In some embodiments, a modified siRNA molecule is less immunostimulatory than a corresponding unmodified siRNA sequence. In such embodiments, the modified siRNA molecule with reduced immunostimulatory properties advantageously retains RNAi activity against the target sequence. In another embodiment, the immunostimulatory properties of the modified siRNA molecule and its ability to silence target gene expression can be balanced or optimized by the introduction of minimal and selective 2'OMe modifications within the siRNA sequence such as, *e.g.*, within the double-stranded region of the siRNA duplex. In certain instances, the modified siRNA is at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% less  
20 immunostimulatory than the corresponding unmodified siRNA. It will be readily apparent to those of skill in the art that the immunostimulatory properties of the modified siRNA molecule and the corresponding unmodified siRNA molecule can be determined by, for example, measuring INF- $\alpha$  and/or IL-6 levels from about two to about twelve hours after systemic administration in a mammal or transfection of a mammalian responder cell using an appropriate lipid-based delivery system (such as  
25 the SNALP delivery system disclosed herein).

30 [00155] In other embodiments, a modified siRNA molecule has an IC<sub>50</sub> (*i.e.*, half-maximal inhibitory concentration) less than or equal to ten-fold that of the corresponding unmodified siRNA (*i.e.*, the modified siRNA has an IC<sub>50</sub> that is less than or equal to ten-times the IC<sub>50</sub> of the corresponding unmodified siRNA). In other embodiments, the modified siRNA has an IC<sub>50</sub> less than or equal to three-fold that of the corresponding unmodified siRNA sequence. In yet other embodiments, the modified siRNA has an IC<sub>50</sub> less than or equal to two-fold that of the corresponding unmodified siRNA. It will be readily apparent to those of skill in the art that a dose-response curve can be generated and the IC<sub>50</sub> values for the modified siRNA and the corresponding unmodified siRNA can be readily determined using methods known to those of skill in the art.

[00156] In another embodiment, an unmodified or modified siRNA molecule is capable of silencing at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the expression of the target sequence 5 relative to a negative control (e.g., buffer only, an siRNA sequence that targets a different gene, a scrambled siRNA sequence, etc.).

[00157] In yet another embodiment, a modified siRNA molecule is capable of silencing at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 10 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the expression of the target sequence relative to the corresponding unmodified siRNA sequence.

[00158] In some embodiments, the siRNA molecule does not comprise phosphate backbone modifications, e.g., in the sense and/or antisense strand of the double-stranded region. In other embodiments, the siRNA comprises one, two, three, four, or more phosphate backbone modifications, 15 e.g., in the sense and/or antisense strand of the double-stranded region. In preferred embodiments, the siRNA does not comprise phosphate backbone modifications.

[00159] In further embodiments, the siRNA does not comprise 2'-deoxy nucleotides, e.g., in the sense and/or antisense strand of the double-stranded region. In yet further embodiments, the siRNA comprises one, two, three, four, or more 2'-deoxy nucleotides, e.g., in the sense and/or antisense 20 strand of the double-stranded region. In preferred embodiments, the siRNA does not comprise 2'-deoxy nucleotides.

[00160] In certain instances, the nucleotide at the 3'-end of the double-stranded region in the sense and/or antisense strand is not a modified nucleotide. In certain other instances, the nucleotides near the 3'-end (e.g., within one, two, three, or four nucleotides of the 3'-end) of the double-stranded 25 region in the sense and/or antisense strand are not modified nucleotides.

[00161] The siRNA molecules described herein may have 3' overhangs of one, two, three, four, or more nucleotides on one or both sides of the double-stranded region, or may lack overhangs (i.e., have blunt ends) on one or both sides of the double-stranded region. In certain embodiments, the 3' overhang on the sense and/or antisense strand independently comprises one, two, three, four, or more 30 modified nucleotides such as 2'OMe nucleotides and/or any other modified nucleotide described herein or known in the art.

[00162] In particular embodiments, siRNAs targeting ALDH RNA or ALDH mRNA are administered using a carrier system such as a nucleic acid-lipid particle. In a preferred embodiment,

the nucleic acid-lipid particle comprises: (a) one or more siRNA molecules targeting ALDH; (b) a cationic lipid (e.g., DLinDMA, DLenDMA, DLin-K-C2-DMA, and/or  $\gamma$ -DLenDMA); and (c) a non-cationic lipid (e.g., DPPC, DSPC, DSPE, and/or cholesterol). In certain instances, the nucleic acid-lipid particle may further comprise a conjugated lipid that prevents aggregation of particles (e.g., 5 PEG-DAA and/or POZ-DAA).

[00163] In addition to its utility in silencing the expression of any of the above-described ALDH genes for therapeutic purposes, the siRNA described herein are also useful in research and development applications as well as diagnostic, prophylactic, prognostic, clinical, and other healthcare applications. As a non-limiting example, the siRNA can be used in target validation studies directed 10 at testing whether a specific member of the ALDH gene family has the potential to be a therapeutic target.

#### B. Dicer-Substrate dsRNA

[00164] As used herein, the term “Dicer-substrate dsRNA” or “precursor RNAi molecule” is intended to include any precursor molecule that is processed *in vivo* by Dicer to produce an active 15 siRNA which is incorporated into the RISC complex for RNA interference of a target gene.

[00165] In one embodiment, the Dicer-substrate dsRNA has a length sufficient such that it is processed by Dicer to produce an siRNA. According to this embodiment, the Dicer-substrate dsRNA comprises (i) a first oligonucleotide sequence (also termed the sense strand) that is between about 25 and about 60 nucleotides in length (e.g., about 25-60, 25-55, 25-50, 25-45, 25-40, 25-35, or 25-30 20 nucleotides in length), preferably between about 25 and about 30 nucleotides in length (e.g., 25, 26, 27, 28, 29, or 30 nucleotides in length), and (ii) a second oligonucleotide sequence (also termed the antisense strand) that anneals to the first sequence under biological conditions, such as the conditions found in the cytoplasm of a cell. The second oligonucleotide sequence may be between about 25 and about 60 nucleotides in length (e.g., about 25-60, 25-55, 25-50, 25-45, 25-40, 25-35, or 25-30 25 nucleotides in length), and is preferably between about 25 and about 30 nucleotides in length (e.g., 25, 26, 27, 28, 29, or 30 nucleotides in length). In addition, a region of one of the sequences, particularly of the antisense strand, of the Dicer-substrate dsRNA has a sequence length of at least about 19 nucleotides, for example, from about 19 to about 60 nucleotides (e.g., about 19-60, 19-55, 19-50, 19-45, 19-40, 19-35, 19-30, or 19-25 nucleotides), preferably from about 19 to about 23 nucleotides (e.g., 30 19, 20, 21, 22, or 23 nucleotides) that are sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger an RNAi response.


[00166] In a second embodiment, the Dicer-substrate dsRNA has several properties which enhance its processing by Dicer. According to this embodiment, the dsRNA has a length sufficient

such that it is processed by Dicer to produce an siRNA and has at least one of the following properties: (i) the dsRNA is asymmetric, *e.g.*, has a 3'-overhang on the antisense strand; and/or (ii) the dsRNA has a modified 3'-end on the sense strand to direct orientation of Dicer binding and processing of the dsRNA to an active siRNA. According to this latter embodiment, the sense strand 5 comprises from about 22 to about 28 nucleotides and the antisense strand comprises from about 24 to about 30 nucleotides.

**[00167]** In one embodiment, the Dicer-substrate dsRNA has an overhang on the 3'-end of the antisense strand. In another embodiment, the sense strand is modified for Dicer binding and processing by suitable modifiers located at the 3'-end of the sense strand. Suitable modifiers include 10 nucleotides such as deoxyribonucleotides, acyclonucleotides, and the like, and sterically hindered molecules such as fluorescent molecules and the like. When nucleotide modifiers are used, they replace ribonucleotides in the dsRNA such that the length of the dsRNA does not change. In another embodiment, the Dicer-substrate dsRNA has an overhang on the 3'-end of the antisense strand and the sense strand is modified for Dicer processing. In another embodiment, the 5'-end of the sense strand 15 has a phosphate. In another embodiment, the 5'-end of the antisense strand has a phosphate. In another embodiment, the antisense strand or the sense strand or both strands have one or more 2'-O-methyl (2'OMe) modified nucleotides. In another embodiment, the antisense strand contains 2'OMe modified nucleotides. In another embodiment, the antisense stand contains a 3'-overhang that is comprised of 2'OMe modified nucleotides. The antisense strand could also include additional 2'OMe 20 modified nucleotides. The sense and antisense strands anneal under biological conditions, such as the conditions found in the cytoplasm of a cell. In addition, a region of one of the sequences, particularly of the antisense strand, of the Dicer-substrate dsRNA has a sequence length of at least about 19 nucleotides, wherein these nucleotides are in the 21-nucleotide region adjacent to the 3'-end of the antisense strand and are sufficiently complementary to a nucleotide sequence of the RNA produced 25 from the target gene. Further, in accordance with this embodiment, the Dicer-substrate dsRNA may also have one or more of the following additional properties: (a) the antisense strand has a right shift from the typical 21-mer (*i.e.*, the antisense strand includes nucleotides on the right side of the molecule when compared to the typical 21-mer); (b) the strands may not be completely complementary, *i.e.*, the strands may contain simple mismatch pairings; and (c) base modifications 30 such as locked nucleic acid(s) may be included in the 5'-end of the sense strand.

**[00168]** In a third embodiment, the sense strand comprises from about 25 to about 28 nucleotides (*e.g.*, 25, 26, 27, or 28 nucleotides), wherein the 2 nucleotides on the 3'-end of the sense strand are deoxyribonucleotides. The sense strand contains a phosphate at the 5'-end. The antisense strand comprises from about 26 to about 30 nucleotides (*e.g.*, 26, 27, 28, 29, or 30 nucleotides) and contains 35 a 3'-overhang of 1-4 nucleotides. The nucleotides comprising the 3'-overhang are modified with

2'OMe modified ribonucleotides. The antisense strand contains alternating 2'OMe modified nucleotides beginning at the first monomer of the antisense strand adjacent to the 3'-overhang, and extending 15-19 nucleotides from the first monomer adjacent to the 3'-overhang. For example, for a 27-nucleotide antisense strand and counting the first base at the 5'-end of the antisense strand as 5 position number 1, 2'OMe modifications would be placed at bases 9, 11, 13, 15, 17, 19, 21, 23, 25, 26, and 27. In one embodiment, the Dicer-substrate dsRNA has the following structure:



wherein "X" = RNA, "p" = a phosphate group, "X" = 2'OMe RNA, "Y" is an overhang domain 10 comprised of 1, 2, 3, or 4 RNA monomers that are optionally 2'OMe RNA monomers, and "D" = DNA. The top strand is the sense strand, and the bottom strand is the antisense strand.

**[00169]** In a fourth embodiment, the Dicer-substrate dsRNA has several properties which enhance its processing by Dicer. According to this embodiment, the dsRNA has a length sufficient such that it is processed by Dicer to produce an siRNA and at least one of the following properties: 15 (i) the dsRNA is asymmetric, *e.g.*, has a 3'-overhang on the sense strand; and (ii) the dsRNA has a modified 3'-end on the antisense strand to direct orientation of Dicer binding and processing of the dsRNA to an active siRNA. According to this embodiment, the sense strand comprises from about 24 to about 30 nucleotides (*e.g.*, 24, 25, 26, 27, 28, 29, or 30 nucleotides) and the antisense strand comprises from about 22 to about 28 nucleotides (*e.g.*, 22, 23, 24, 25, 26, 27, or 28 nucleotides). In 20 one embodiment, the Dicer-substrate dsRNA has an overhang on the 3'-end of the sense strand. In another embodiment, the antisense strand is modified for Dicer binding and processing by suitable modifiers located at the 3'-end of the antisense strand. Suitable modifiers include nucleotides such as deoxyribonucleotides, acyclonucleotides, and the like, and sterically hindered molecules such as fluorescent molecules and the like. When nucleotide modifiers are used, they replace ribonucleotides 25 in the dsRNA such that the length of the dsRNA does not change. In another embodiment, the dsRNA has an overhang on the 3'-end of the sense strand and the antisense strand is modified for Dicer processing. In one embodiment, the antisense strand has a 5'-phosphate. The sense and antisense strands anneal under biological conditions, such as the conditions found in the cytoplasm of a cell. In addition, a region of one of the sequences, particularly of the antisense strand, of the dsRNA 30 has a sequence length of at least 19 nucleotides, wherein these nucleotides are adjacent to the 3'-end of antisense strand and are sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene. Further, in accordance with this embodiment, the Dicer-substrate dsRNA may also have one or more of the following additional properties: (a) the antisense strand has a left shift from the typical 21-mer (*i.e.*, the antisense strand includes nucleotides on the left side of the molecule

when compared to the typical 21-mer); and (b) the strands may not be completely complementary, *i.e.*, the strands may contain simple mismatch pairings.

**[00170]** In a preferred embodiment, the Dicer-substrate dsRNA has an asymmetric structure, with the sense strand having a 25-base pair length, and the antisense strand having a 27-base pair length 5 with a 2 base 3'-overhang. In certain instances, this dsRNA having an asymmetric structure further contains 2 deoxynucleotides at the 3'-end of the sense strand in place of two of the ribonucleotides. In certain other instances, this dsRNA having an asymmetric structure further contains 2'OMe modifications at positions 9, 11, 13, 15, 17, 19, 21, 23, and 25 of the antisense strand (wherein the first base at the 5'-end of the antisense strand is position 1). In certain additional instances, this 10 dsRNA having an asymmetric structure further contains a 3'-overhang on the antisense strand comprising 1, 2, 3, or 4 2'OMe nucleotides (*e.g.*, a 3'-overhang of 2'OMe nucleotides at positions 26 and 27 on the antisense strand).

**[00171]** In another embodiment, Dicer-substrate dsRNAs may be designed by first selecting an antisense strand siRNA sequence having a length of at least 19 nucleotides. In some instances, the 15 antisense siRNA is modified to include about 5 to about 11 ribonucleotides on the 5'-end to provide a length of about 24 to about 30 nucleotides. When the antisense strand has a length of 21 nucleotides, 3-9, preferably 4-7, or more preferably 6 nucleotides may be added on the 5'-end. Although the added ribonucleotides may be complementary to the target gene sequence, full complementarity between the target sequence and the antisense siRNA is not required. That is, the resultant antisense 20 siRNA is sufficiently complementary with the target sequence. A sense strand is then produced that has about 22 to about 28 nucleotides. The sense strand is substantially complementary with the antisense strand to anneal to the antisense strand under biological conditions. In one embodiment, the sense strand is synthesized to contain a modified 3'-end to direct Dicer processing of the antisense strand. In another embodiment, the antisense strand of the dsRNA has a 3'-overhang. In a further 25 embodiment, the sense strand is synthesized to contain a modified 3'-end for Dicer binding and processing and the antisense strand of the dsRNA has a 3'-overhang.

**[00172]** In a related embodiment, the antisense siRNA may be modified to include about 1 to about 9 ribonucleotides on the 5'-end to provide a length of about 22 to about 28 nucleotides. When the antisense strand has a length of 21 nucleotides, 1-7, preferably 2-5, or more preferably 4 30 ribonucleotides may be added on the 3'-end. The added ribonucleotides may have any sequence. Although the added ribonucleotides may be complementary to the target gene sequence, full complementarity between the target sequence and the antisense siRNA is not required. That is, the resultant antisense siRNA is sufficiently complementary with the target sequence. A sense strand is then produced that has about 24 to about 30 nucleotides. The sense strand is substantially 35 complementary with the antisense strand to anneal to the antisense strand under biological conditions.

In one embodiment, the antisense strand is synthesized to contain a modified 3'-end to direct Dicer processing. In another embodiment, the sense strand of the dsRNA has a 3'-overhang. In a further embodiment, the antisense strand is synthesized to contain a modified 3'-end for Dicer binding and processing and the sense strand of the dsRNA has a 3'-overhang.

5 [00173] Suitable Dicer-substrate dsRNA sequences can be identified, synthesized, and modified using any means known in the art for designing, synthesizing, and modifying siRNA sequences. In certain embodiments, Dicer-substrate dsRNAs of the invention may silence ALDH gene expression. In particular embodiments, Dicer-substrate dsRNAs targeting ALDH mRNA are administered using a carrier system such as a nucleic acid-lipid particle. In a preferred embodiment, the nucleic acid-lipid  
10 particle comprises: (a) one or more Dicer-substrate dsRNA molecules targeting ALDH gene expression; (b) a cationic lipid (e.g., DLinDMA, DLenDMA, DLin-K-C2-DMA, and/or  $\gamma$ -DLenDMA); and (c) a non-cationic lipid (e.g., DPPC, DSPC, DSPE, and/or cholesterol). In certain instances, the nucleic acid-lipid particle may further comprise a conjugated lipid that prevents aggregation of particles (e.g., PEG-DAA and/or POZ-DAA).

15 [00174] Additional embodiments related to the Dicer-substrate dsRNAs of the invention, as well as methods of designing and synthesizing such dsRNAs, are described in U.S. Patent Publication Nos. 20050244858, 20050277610, and 20070265220, 2011/0071208, the disclosures of which are herein incorporated by reference in their entirety for all purposes.

### C. shRNA

20 [00175] A “small hairpin RNA” or “short hairpin RNA” or “shRNA” includes a short RNA sequence that makes a tight hairpin turn that can be used to silence gene expression via RNA interference. The shRNAs of the invention may be chemically synthesized or transcribed from a transcriptional cassette in a DNA plasmid. The shRNA hairpin structure is cleaved by the cellular machinery into siRNA, which is then bound to the RNA-induced silencing complex (RISC).

25 [00176] The shRNAs of the invention are typically about 15-60, 15-50, or 15-40 (duplex) nucleotides in length, more typically about 15-30, 15-25, or 19-25 (duplex) nucleotides in length, and are preferably about 20-24, 21-22, or 21-23 (duplex) nucleotides in length (e.g., each complementary sequence of the double-stranded shRNA is 15-60, 15-50, 15-40, 15-30, 15-25, or 19-25 nucleotides in length, preferably about 20-24, 21-22, or 21-23 nucleotides in length, and the double-stranded shRNA  
30 is about 15-60, 15-50, 15-40, 15-30, 15-25, or 19-25 base pairs in length, preferably about 18-22, 19-20, or 19-21 base pairs in length). shRNA duplexes may comprise 3' overhangs of about 1 to about 4 nucleotides or about 2 to about 3 nucleotides on the antisense strand and/or 5'-phosphate termini on the sense strand. In some embodiments, the shRNA comprises a sense strand and/or antisense strand

sequence of from about 15 to about 60 nucleotides in length (e.g., about 15-60, 15-55, 15-50, 15-45, 15-40, 15-35, 15-30, or 15-25 nucleotides in length), preferably from about 19 to about 40 nucleotides in length (e.g., about 19-40, 19-35, 19-30, or 19-25 nucleotides in length), more preferably from about 19 to about 23 nucleotides in length (e.g., 19, 20, 21, 22, or 23 nucleotides in length).

5 [00177] Non-limiting examples of shRNA include a double-stranded polynucleotide molecule assembled from a single-stranded molecule, where the sense and antisense regions are linked by a nucleic acid-based or non-nucleic acid-based linker; and a double-stranded polynucleotide molecule with a hairpin secondary structure having self-complementary sense and antisense regions. In preferred embodiments, the sense and antisense strands of the shRNA are linked by a loop structure  
10 comprising from about 1 to about 25 nucleotides, from about 2 to about 20 nucleotides, from about 4 to about 15 nucleotides, from about 5 to about 12 nucleotides, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more nucleotides.

15 [00178] Suitable shRNA sequences can be identified, synthesized, and modified using any means known in the art for designing, synthesizing, and modifying siRNA sequences. In certain embodiments, shRNAs of the invention may silence ALDH gene expression. In particular embodiments, shRNAs targeting ALDH mRNA are administered using a carrier system such as a nucleic acid-lipid particle. In a preferred embodiment, the nucleic acid-lipid particle comprises: (a) one or more shRNA molecules targeting ALDH gene expression; (b) a cationic lipid (e.g., DLinDMA, DLenDMA, DLin-K-C2-DMA, and/or  $\gamma$ -DLenDMA); and (c) a non-cationic lipid (e.g., DPPC, 20 DSPC, DSPE, and/or cholesterol). In certain instances, the nucleic acid-lipid particle may further comprise a conjugated lipid that prevents aggregation of particles (e.g., PEG-DAA and/or POZ-DAA).

25 [00179] Additional embodiments related to the shRNAs of the invention, as well as methods of designing and synthesizing such shRNAs, are described in U.S. patent application publication number 2011/0071208, the disclosure of which is herein incorporated by reference in its entirety for all purposes.

#### D. aiRNA

30 [00180] Like siRNA, asymmetrical interfering RNA (aiRNA) can recruit the RNA-induced silencing complex (RISC) and lead to effective silencing of a variety of genes in mammalian cells by mediating sequence-specific cleavage of the target sequence between nucleotide 10 and 11 relative to the 5' end of the antisense strand (Sun *et al.*, *Nat. Biotech.*, 26:1379-1382 (2008)). Typically, an aiRNA molecule comprises a short RNA duplex having a sense strand and an antisense strand, wherein the duplex contains overhangs at the 3' and 5' ends of the antisense strand. The aiRNA is

generally asymmetric because the sense strand is shorter on both ends when compared to the complementary antisense strand. In some aspects, aiRNA molecules may be designed, synthesized, and annealed under conditions similar to those used for siRNA molecules. As a non-limiting example, aiRNA sequences may be selected and generated using the methods described above for 5 selecting siRNA sequences.

**[00181]** In another embodiment, aiRNA duplexes of various lengths (e.g., about 10-25, 12-20, 12-19, 12-18, 13-17, or 14-17 base pairs, more typically 12, 13, 14, 15, 16, 17, 18, 19, or 20 base pairs) may be designed with overhangs at the 3' and 5' ends of the antisense strand to target an mRNA of interest. In certain instances, the sense strand of the aiRNA molecule is about 10-25, 12-10 20, 12-19, 12-18, 13-17, or 14-17 nucleotides in length, more typically 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length. In certain other instances, the antisense strand of the aiRNA molecule is about 15-60, 15-50, or 15-40 nucleotides in length, more typically about 15-30, 15-25, or 19-25 nucleotides in length, and is preferably about 20-24, 21-22, or 21-23 nucleotides in length.

**[00182]** In some embodiments, the 5' antisense overhang contains one, two, three, four, or more 15 nontargeting nucleotides (e.g., "AA", "UU", "dTdT", *etc.*). In other embodiments, the 3' antisense overhang contains one, two, three, four, or more nontargeting nucleotides (e.g., "AA", "UU", "dTdT", *etc.*). In certain aspects, the aiRNA molecules described herein may comprise one or more modified nucleotides, *e.g.*, in the double-stranded (duplex) region and/or in the antisense overhangs. As a non-limiting example, aiRNA sequences may comprise one or more of the modified nucleotides described 20 above for siRNA sequences. In a preferred embodiment, the aiRNA molecule comprises 2'OMe nucleotides such as, for example, 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, or mixtures thereof.

**[00183]** In certain embodiments, aiRNA molecules may comprise an antisense strand which corresponds to the antisense strand of an siRNA molecule, *e.g.*, one of the siRNA molecules described 25 herein. In certain embodiments, aiRNAs of the invention may silence ALDH gene expression. In particular embodiments, aiRNAs targeting ALDH mRNA are administered using a carrier system such as a nucleic acid-lipid particle. In a preferred embodiment, the nucleic acid-lipid particle comprises: (a) one or more aiRNA molecules targeting ALDH gene expression; (b) a cationic lipid (*e.g.*, DLinDMA, DLenDMA, DLin-K-C2-DMA, and/or  $\gamma$ -DLenDMA); and (c) a non-cationic lipid 30 (*e.g.*, DPPC, DSPC, DSPE, and/or cholesterol). In certain instances, the nucleic acid-lipid particle may further comprise a conjugated lipid that prevents aggregation of particles (*e.g.*, PEG-DAA and/or POZ-DAA).

**[00184]** Suitable aiRNA sequences can be identified, synthesized, and modified using any means known in the art for designing, synthesizing, and modifying siRNA sequences. Additional

embodiments related to the aiRNA molecules of the invention are described in U.S. Patent Application No. 12/343,342, filed December 23, 2008, and U.S. Patent Application No. 12/424,367, filed April 15, 2009, the disclosures of which are herein incorporated by reference in their entirety for all purposes.

5           E.        miRNA

[00185]    Generally, microRNAs (miRNA) are single-stranded RNA molecules of about 21-23 nucleotides in length which regulate gene expression. miRNAs are encoded by genes from whose DNA they are transcribed, but miRNAs are not translated into protein (non-coding RNA); instead, each primary transcript (a pri-miRNA) is processed into a short stem-loop structure called a pre-miRNA and finally into a functional mature miRNA. Mature miRNA molecules are either partially or completely complementary to one or more messenger RNA (mRNA) molecules, and their main function is to downregulate gene expression. The identification of miRNA molecules is described, e.g., in Lagos-Quintana *et al.*, *Science*, 294:853-858; Lau *et al.*, *Science*, 294:858-862; and Lee *et al.*, *Science*, 294:862-864.

15    [00186]   The genes encoding miRNA are much longer than the processed mature miRNA molecule. miRNA are first transcribed as primary transcripts or pri-miRNA with a cap and poly-A tail and processed to short, ~70-nucleotide stem-loop structures known as pre-miRNA in the cell nucleus. This processing is performed in animals by a protein complex known as the Microprocessor complex, consisting of the nuclease Drosha and the double-stranded RNA binding protein Pasha (Denli *et al.*, *Nature*, 432:231-235 (2004)). These pre-miRNA are then processed to mature miRNA in the cytoplasm by interaction with the endonuclease Dicer, which also initiates the formation of the RNA-induced silencing complex (RISC) (Bernstein *et al.*, *Nature*, 409:363-366 (2001)). Either the sense strand or antisense strand of DNA can function as templates to give rise to miRNA.

25    [00187]   When Dicer cleaves the pre-miRNA stem-loop, two complementary short RNA molecules are formed, but only one is integrated into the RISC complex. This strand is known as the guide strand and is selected by the argonaute protein, the catalytically active RNase in the RISC complex, on the basis of the stability of the 5' end (Preall *et al.*, *Curr. Biol.*, 16:530-535 (2006)). The remaining strand, known as the anti-guide or passenger strand, is degraded as a RISC complex substrate (Gregory *et al.*, *Cell*, 123:631-640 (2005)). After integration into the active RISC complex, 30 miRNAs base pair with their complementary mRNA molecules and induce target mRNA degradation and/or translational silencing.

[00188]    Mammalian miRNA molecules are usually complementary to a site in the 3' UTR of the target mRNA sequence. In certain instances, the annealing of the miRNA to the target mRNA

inhibits protein translation by blocking the protein translation machinery. In certain other instances, the annealing of the miRNA to the target mRNA facilitates the cleavage and degradation of the target mRNA through a process similar to RNA interference (RNAi). miRNA may also target methylation of genomic sites which correspond to targeted mRNA. Generally, miRNA function in association 5 with a complement of proteins collectively termed the miRNP.

[00189] In certain aspects, the miRNA molecules described herein are about 15-100, 15-90, 15-80, 15-75, 15-70, 15-60, 15-50, or 15-40 nucleotides in length, more typically about 15-30, 15-25, or 19-25 nucleotides in length, and are preferably about 20-24, 21-22, or 21-23 nucleotides in length. In certain other aspects, miRNA molecules may comprise one or more modified nucleotides. As a non-limiting example, miRNA sequences may comprise one or more of the modified nucleotides described above for siRNA sequences. In a preferred embodiment, the miRNA molecule comprises 2'OMe nucleotides such as, for example, 2'OMe-guanosine nucleotides, 2'OMe-uridine nucleotides, or mixtures thereof.

[00190] In some embodiments, miRNA molecules may be used to silence ALDH gene 15 expression. In particular embodiments, miRNAs targeting ALDH mRNA are administered using a carrier system such as a nucleic acid-lipid particle. In a preferred embodiment, the nucleic acid-lipid particle comprises: (a) one or more miRNA molecules targeting ALDH gene expression; (b) a cationic lipid (e.g., DLinDMA, DLenDMA, DLin-K-C2-DMA, and/or  $\gamma$ -DLenDMA); and (c) a non-cationic lipid (e.g., DPPC, DSPC, DSPE, and/or cholesterol). In certain instances, the nucleic acid- 20 lipid particle may further comprise a conjugated lipid that prevents aggregation of particles (e.g., PEG-DAA and/or POZ-DAA).

[00191] In other embodiments, one or more agents that block the activity of an miRNA targeting ALDH mRNA are administered using a lipid particle of the invention (e.g., a nucleic acid-lipid particle). Examples of blocking agents include, but are not limited to, steric blocking 25 oligonucleotides, locked nucleic acid oligonucleotides, and Morpholino oligonucleotides. Such blocking agents may bind directly to the miRNA or to the miRNA binding site on the target RNA.

## V. Carrier Systems Containing Therapeutic Nucleic Acids

[00192] In one aspect, the present invention provides carrier systems containing one or more therapeutic nucleic acids (e.g., interfering RNA such as dsRNA). In some embodiments, the carrier 30 system is a lipid-based carrier system such as a lipid particle (e.g., SNALP), a cationic lipid or liposome nucleic acid complex (i.e., lipoplex), a liposome, a micelle, a virosome, or a mixture thereof. In other embodiments, the carrier system is a polymer-based carrier system such as a cationic polymer-nucleic acid complex (i.e., polyplex). In additional embodiments, the carrier system is a

cyclodextrin-based carrier system such as a cyclodextrin polymer-nucleic acid complex. In further embodiments, the carrier system is a protein-based carrier system such as a cationic peptide-nucleic acid complex. Preferably, the carrier system is a lipid particle such as a SNALP. One skilled in the art will appreciate that the therapeutic nucleic acids of the present invention can also be delivered as a 5 naked molecule.

#### A. Lipid Particles

**[00193]** In certain aspects, the present invention provides lipid particles comprising one or more therapeutic nucleic acids (e.g., interfering RNA such as dsRNA) and one or more of cationic (amino) lipids or salts thereof. In some embodiments, the lipid particles of the invention further comprise one 10 or more non-cationic lipids. In other embodiments, the lipid particles further comprise one or more conjugated lipids capable of reducing or inhibiting particle aggregation.

**[00194]** The lipid particles of the invention preferably comprise a therapeutic nucleic acid such as an interfering RNA (e.g., siRNA), a cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of particles. In some embodiments, the therapeutic nucleic acid is fully 15 encapsulated within the lipid portion of the lipid particle such that the therapeutic nucleic acid in the lipid particle is resistant in aqueous solution to nuclease degradation. In other embodiments, the lipid particles described herein are substantially non-toxic to mammals such as humans. The lipid particles of the invention typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from 20 about 70 nm to about 110 nm, or from about 70 to about 90 nm. The lipid particles of the invention also typically have a lipid:therapeutic agent (e.g., lipid:nucleic acid) ratio (mass/mass ratio) of from about 1:1 to about 100:1, from about 1:1 to about 50:1, from about 2:1 to about 25:1, from about 3:1 to about 20:1, from about 5:1 to about 15:1, or from about 5:1 to about 10:1.

**[00195]** In preferred embodiments, the lipid particles of the invention are serum-stable nucleic 25 acid-lipid particles (SNALP) which comprise an interfering RNA (e.g., dsRNA such as siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, and/or miRNA), a cationic lipid (e.g., one or more cationic lipids of Formula I-III or salts thereof as set forth herein), a non-cationic lipid (e.g., mixtures of one or more phospholipids and cholesterol), and a conjugated lipid that inhibits aggregation of the particles (e.g., one or more PEG-lipid conjugates). The SNALP may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 30 more unmodified and/or modified interfering RNA (e.g., siRNA) that target one or more of the genes described herein. Nucleic acid-lipid particles and their method of preparation are described in, e.g., U.S. Patent Nos. 5,753,613; 5,785,992; 5,705,385; 5,976,567; 5,981,501; 6,110,745; and 6,320,017; and PCT Publication No. WO 96/40964, the disclosures of which are each herein incorporated by reference in their entirety for all purposes.

[00196] In the nucleic acid-lipid particles of the invention, the nucleic acid may be fully encapsulated within the lipid portion of the particle, thereby protecting the nucleic acid from nuclease degradation. In preferred embodiments, a SNALP comprising a nucleic acid such as an interfering RNA is fully encapsulated within the lipid portion of the particle, thereby protecting the nucleic acid from nuclease degradation. In certain instances, the nucleic acid in the SNALP is not substantially degraded after exposure of the particle to a nuclease at 37°C for at least about 20, 30, 45, or 60 minutes. In certain other instances, the nucleic acid in the SNALP is not substantially degraded after incubation of the particle in serum at 37°C for at least about 30, 45, or 60 minutes or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36 hours. In other embodiments, the nucleic acid is complexed with the lipid portion of the particle. One of the benefits of the formulations of the present invention is that the nucleic acid-lipid particle compositions are substantially non-toxic to mammals such as humans.

[00197] The term “fully encapsulated” indicates that the nucleic acid in the nucleic acid-lipid particle is not significantly degraded after exposure to serum or a nuclease assay that would significantly degrade free DNA or RNA. In a fully encapsulated system, preferably less than about 25% of the nucleic acid in the particle is degraded in a treatment that would normally degrade 100% of free nucleic acid, more preferably less than about 10%, and most preferably less than about 5% of the nucleic acid in the particle is degraded. “Fully encapsulated” also indicates that the nucleic acid-lipid particles are serum-stable, that is, that they do not rapidly decompose into their component parts upon *in vivo* administration.

[00198] In the context of nucleic acids, full encapsulation may be determined by performing a membrane-impermeable fluorescent dye exclusion assay, which uses a dye that has enhanced fluorescence when associated with nucleic acid. Specific dyes such as OliGreen® and RiboGreen® (Invitrogen Corp.; Carlsbad, CA) are available for the quantitative determination of plasmid DNA, single-stranded deoxyribonucleotides, and/or single- or double-stranded ribonucleotides. Encapsulation is determined by adding the dye to a liposomal formulation, measuring the resulting fluorescence, and comparing it to the fluorescence observed upon addition of a small amount of nonionic detergent. Detergent-mediated disruption of the liposomal bilayer releases the encapsulated nucleic acid, allowing it to interact with the membrane-impermeable dye. Nucleic acid encapsulation may be calculated as  $E = (I_o - I)/I_o$ , where  $I$  and  $I_o$  refer to the fluorescence intensities before and after the addition of detergent (see, Wheeler *et al.*, *Gene Ther.*, 6:271-281 (1999)).

[00199] In other embodiments, the present invention provides a nucleic acid-lipid particle (e.g., SNALP) composition comprising a plurality of nucleic acid-lipid particles.

[00200] In some instances, the SNALP composition comprises nucleic acid that is fully encapsulated within the lipid portion of the particles, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from about 70% to about 100%, from about 80% to about 100%, from about 90% to about 100%, from 5 about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 10 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (or any fraction thereof or range therein) of the particles have the nucleic acid encapsulated therein.


[00201] In other instances, the SNALP composition comprises nucleic acid that is fully encapsulated within the lipid portion of the particles, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from 15 about 70% to about 100%, from about 80% to about 100%, from about 90% to about 100%, from about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 20 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (or any fraction thereof or range therein) of the input nucleic acid is encapsulated in the particles.

[00202] Depending on the intended use of the lipid particles of the invention, the proportions of the components can be varied and the delivery efficiency of a particular formulation can be measured 25 using, *e.g.*, an endosomal release parameter (ERP) assay.

## 1. Cationic Lipids

[00203] Any of a variety of cationic lipids or salts thereof may be used in the lipid particles of the present invention (*e.g.*, SNALP), either alone or in combination with one or more other cationic lipid species or non-cationic lipid species. The cationic lipids include the (R) and/or (S) enantiomers 30 thereof.

[00204] In one aspect, cationic lipids of Formula I having the following structure are useful in the present invention:



5 [00205] or salts thereof, wherein:

[00206]  $\text{R}^1$  and  $\text{R}^2$  are either the same or different and are independently hydrogen (H) or an optionally substituted  $\text{C}_1\text{-}\text{C}_6$  alkyl,  $\text{C}_2\text{-}\text{C}_6$  alkenyl, or  $\text{C}_2\text{-}\text{C}_6$  alkynyl, or  $\text{R}^1$  and  $\text{R}^2$  may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof;

10 [00207]  $\text{R}^3$  is either absent or is hydrogen (H) or a  $\text{C}_1\text{-}\text{C}_6$  alkyl to provide a quaternary amine;

[00208]  $\text{R}^4$  and  $\text{R}^5$  are either the same or different and are independently an optionally substituted  $\text{C}_{10}\text{-}\text{C}_{24}$  alkyl,  $\text{C}_{10}\text{-}\text{C}_{24}$  alkenyl,  $\text{C}_{10}\text{-}\text{C}_{24}$  alkynyl, or  $\text{C}_{10}\text{-}\text{C}_{24}$  acyl, wherein at least one of  $\text{R}^4$  and  $\text{R}^5$  comprises at least two sites of unsaturation; and

[00209]  $n$  is 0, 1, 2, 3, or 4.

15 [00210] In some embodiments,  $\text{R}^1$  and  $\text{R}^2$  are independently an optionally substituted  $\text{C}_1\text{-}\text{C}_4$  alkyl,  $\text{C}_2\text{-}\text{C}_4$  alkenyl, or  $\text{C}_2\text{-}\text{C}_4$  alkynyl. In one preferred embodiment,  $\text{R}^1$  and  $\text{R}^2$  are both methyl groups. In other preferred embodiments,  $n$  is 1 or 2. In other embodiments,  $\text{R}^3$  is absent when the pH is above the  $\text{pK}_a$  of the cationic lipid and  $\text{R}^3$  is hydrogen when the pH is below the  $\text{pK}_a$  of the cationic lipid such that the amino head group is protonated. In an alternative embodiment,  $\text{R}^3$  is an optionally substituted  $\text{C}_1\text{-}\text{C}_4$  alkyl to provide a quaternary amine. In further embodiments,  $\text{R}^4$  and  $\text{R}^5$  are independently an optionally substituted  $\text{C}_{12}\text{-}\text{C}_{20}$  or  $\text{C}_{14}\text{-}\text{C}_{22}$  alkyl,  $\text{C}_{12}\text{-}\text{C}_{20}$  or  $\text{C}_{14}\text{-}\text{C}_{22}$  alkenyl,  $\text{C}_{12}\text{-}\text{C}_{20}$  or  $\text{C}_{14}\text{-}\text{C}_{22}$  alkynyl, or  $\text{C}_{12}\text{-}\text{C}_{20}$  or  $\text{C}_{14}\text{-}\text{C}_{22}$  acyl, wherein at least one of  $\text{R}^4$  and  $\text{R}^5$  comprises at least two sites of unsaturation.


25 [00211] In certain embodiments,  $\text{R}^4$  and  $\text{R}^5$  are independently selected from the group consisting of a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, an icosadienyl moiety, a dodecatrienyl moiety, a tetradectrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, an icosatrienyl moiety, an arachidonyl moiety, and a docosahexaenoyl moiety, as well as acyl derivatives thereof (e.g., linoleoyl, linolenoyl,  $\gamma$ -linolenoyl, etc.). In some instances, one of  $\text{R}^4$  and  $\text{R}^5$  comprises a branched alkyl group (e.g., a phytanyl moiety) or an acyl derivative thereof (e.g., a phytanoyl moiety). In certain instances, the octadecadienyl moiety is a linoleyl moiety. In certain other instances, the octadecatrienyl moiety is a linolenyl moiety or a  $\gamma$ -linolenyl moiety. In certain embodiments,  $\text{R}^4$  and  $\text{R}^5$  are both linoleyl moieties,

linolenyl moieties, or  $\gamma$ -linolenyl moieties. In particular embodiments, the cationic lipid of Formula I is 1,2-dilinoleyl-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenoxy-N,N-dimethylaminopropane (DLenDMA), 1,2-dilinoleyl-N,N-dimethylbutyl-4-amine (C2-DLinDMA), 1,2-dilinoleoyloxy-(N,N-dimethyl)-butyl-4-amine (C2-DLinDAP), or mixtures thereof.

5 [00212] In some embodiments, the cationic lipid of Formula I forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of Formula I is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.

10 [00213] The synthesis of cationic lipids such as DLinDMA and DLenDMA, as well as additional cationic lipids, is described in U.S. Patent Publication No. 20060083780, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as C2-DLinDMA and C2-DLinDAP, as well as additional cationic lipids, is described in international patent application number WO2011/000106 the disclosure of which is herein incorporated by reference in its entirety for all purposes.

15 [00214] In another aspect, cationic lipids of Formula II having the following structure (or salts thereof) are useful in the present invention:



20 [00215] wherein R<sup>1</sup> and R<sup>2</sup> are either the same or different and are independently an optionally substituted C<sub>12</sub>-C<sub>24</sub> alkyl, C<sub>12</sub>-C<sub>24</sub> alkenyl, C<sub>12</sub>-C<sub>24</sub> alkynyl, or C<sub>12</sub>-C<sub>24</sub> acyl; R<sup>3</sup> and R<sup>4</sup> are either the same or different and are independently an optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, or C<sub>2</sub>-C<sub>6</sub> alkynyl, or R<sup>3</sup> and R<sup>4</sup> may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen; R<sup>5</sup> is either absent or is hydrogen (H) or a C<sub>1</sub>-C<sub>6</sub> alkyl to provide a quaternary amine; m, n, and p are either the same or different and are independently either 0, 1, or 2, with the proviso that m, n, and p are not simultaneously 0; q is 0, 1, 2, 3, or 4; and Y and Z are either the same or different and are independently O, S, or NH. In a preferred embodiment, q is 2.


25 [00216] In some embodiments, the cationic lipid of Formula II is 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-K-C2-DMA; “XTC2” or “C2K”), 2,2-dilinoleyl-4-(3-dimethylaminopropyl)-[1,3]-dioxolane (DLin-K-C3-DMA; “C3K”), 2,2-dilinoleyl-4-(4-dimethylaminobutyl)-[1,3]-dioxolane (DLin-K-C4-DMA; “C4K”), 2,2-dilinoleyl-5-dimethylaminomethyl-[1,3]-dioxane (DLin-K6-DMA), 2,2-dilinoleyl-4-N-methylpepiazino-[1,3]-

dioxolane (DLin-K-MPZ), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), 2,2-dioleoyl-4-dimethylaminomethyl-[1,3]-dioxolane (DO-K-DMA), 2,2-distearoyl-4-dimethylaminomethyl-[1,3]-dioxolane (DS-K-DMA), 2,2-dilinoleyl-4-N-morpholino-[1,3]-dioxolane (DLin-K-MA), 2,2-Dilinoleyl-4-trimethylamino-[1,3]-dioxolane chloride (DLin-K-TMA.Cl), 2,2-dilinoleyl-4,5-bis(dimethylaminomethyl)-[1,3]-dioxolane (DLin-K<sup>2</sup>-DMA), 2,2-dilinoleyl-4-methylpiperazine-[1,3]-dioxolane (D-Lin-K-N-methylpiperazine), or mixtures thereof. In preferred embodiments, the cationic lipid of Formula II is DLin-K-C2-DMA.

[00217] In some embodiments, the cationic lipid of Formula II forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of Formula II is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.

[00218] The synthesis of cationic lipids such as DLin-K-DMA, as well as additional cationic lipids, is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as DLin-K-C2-DMA, DLin-K-C3-DMA, DLin-K-C4-DMA, DLin-K6-DMA, DLin-K-MPZ, DO-K-DMA, DS-K-DMA, DLin-K-MA, DLin-K-TMA.Cl, DLin-K<sup>2</sup>-DMA, and D-Lin-K-N-methylpiperazine, as well as additional cationic lipids, is described in PCT Application No. PCT/US2009/060251, entitled "Improved Amino Lipids and Methods for the Delivery of Nucleic Acids," filed October 9, 2009, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[00219] In a further aspect, cationic lipids of Formula III having the following structure are useful in the present invention:




[00220] or salts thereof, wherein: R<sup>1</sup> and R<sup>2</sup> are either the same or different and are independently an optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, or C<sub>2</sub>-C<sub>6</sub> alkynyl, or R<sup>1</sup> and R<sup>2</sup> may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof; R<sup>3</sup> is either absent or is hydrogen (H) or a C<sub>1</sub>-C<sub>6</sub> alkyl to provide a quaternary amine; R<sup>4</sup> and R<sup>5</sup> are either absent or present and when present are either the same or different and are independently an optionally substituted C<sub>1</sub>-C<sub>10</sub> alkyl or C<sub>2</sub>-C<sub>10</sub> alkenyl; and n is 0, 1, 2, 3, or 4.

[00221] In some embodiments, R<sup>1</sup> and R<sup>2</sup> are independently an optionally substituted C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, or C<sub>2</sub>-C<sub>4</sub> alkynyl. In a preferred embodiment, R<sup>1</sup> and R<sup>2</sup> are both methyl groups. In another preferred embodiment, R<sup>4</sup> and R<sup>5</sup> are both butyl groups. In yet another preferred embodiment, n is 1. In other embodiments, R<sup>3</sup> is absent when the pH is above the pK<sub>a</sub> of the cationic lipid and R<sup>3</sup> is hydrogen when the pH is below the pK<sub>a</sub> of the cationic lipid such that the amino head group is protonated. In an alternative embodiment, R<sup>3</sup> is an optionally substituted C<sub>1</sub>-C<sub>4</sub> alkyl to provide a quaternary amine. In further embodiments, R<sup>4</sup> and R<sup>5</sup> are independently an optionally substituted C<sub>2</sub>-C<sub>6</sub> or C<sub>2</sub>-C<sub>4</sub> alkyl or C<sub>2</sub>-C<sub>6</sub> or C<sub>2</sub>-C<sub>4</sub> alkenyl.

[00222] In an alternative embodiment, the cationic lipid of Formula III comprises ester linkages between the amino head group and one or both of the alkyl chains. In some embodiments, the cationic lipid of Formula III forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of Formula III is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.


[00223] Although each of the alkyl chains in Formula III contains *cis* double bonds at positions 6, 9, and 12 (i.e., *cis,cis,cis*-Δ<sup>6</sup>,Δ<sup>9</sup>,Δ<sup>12</sup>), in an alternative embodiment, one, two, or three of these double bonds in one or both alkyl chains may be in the *trans* configuration.

[00224] In a particularly preferred embodiment, the cationic lipid of Formula III has the structure:



[00225] The synthesis of cationic lipids such as  $\gamma$ -DLenDMA, as well as additional cationic lipids, is described in U.S. Provisional Application No. 61/222,462, entitled "Improved Cationic Lipids and Methods for the Delivery of Nucleic Acids," filed July 1, 2009, the disclosure of which is herein incorporated by reference in its entirety for all purposes.

[00226] In particular embodiments, a cationic lipid having the following structure is useful in the present invention:



[00227] The synthesis of cationic lipids such as DLin-M-C3-DMA (“MC3”), as well as additional cationic lipids (e.g., certain analogs of MC3), is described in U.S. Provisional Application No. 61/185,800, entitled “Novel Lipids and Compositions for the Delivery of Therapeutics,” filed June 10, 2009, and U.S. Provisional Application No. 61/287,995, entitled “Methods and Compositions for Delivery of Nucleic Acids,” filed December 18, 2009, the disclosures of which are herein incorporated by reference in their entirety for all purposes.

[00228] Examples of other cationic lipids or salts thereof which may be included in the lipid particles of the present invention include, but are not limited to, cationic lipids such as those described in WO2011/000106, the disclosure of which is herein incorporated by reference in its entirety for all purposes, as well as cationic lipids such as N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), 1,2-distearyloxy-N,N-dimethylaminopropane (DSDMA), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), 3 -(N-(N',N'-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanaminiumtrifluoroacetate (DOSPA), dioctadecylamidoglycyl spermine (DOGS), 3-dimethylamino-2-(cholest-5-en-3-beta-oxybutan-4-oxy)-1-(cis,cis-9,12-octadecadienoxy)propane (CLinDMA), 2-[5'-(cholest-5-en-3-beta-oxy)-3'-oxapentoxy)-3-dimethyl-1-(cis,cis-9',1,2'-octadecadienoxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleyloxybenzylamine (DMOBA), 1,2-N,N'-dioleylcarbamyl-3-dimethylaminopropane (DOcarbDAP), 1,2-N,N'-dilinoleylcarbamyl-3-dimethylaminopropane (DLincarbDAP), 1,2-dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-dilinoleyoxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-dilinoleyoxy-3-morpholinopropane (DLin-MA), 1,2-dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-linoleoyl-2-linoleyoxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-dilinoleyoxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-dilinoleyoxy-3-(N-methylpiperazino)propane (DLin-MPZ), 3-(N,N-dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-dioleylamino)-1,2-propanedio (DOAP), 1,2-dilinoleyoxy-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1,2-dioeylcarbamoyloxy-3-dimethylaminopropane (DO-C-DAP), 1,2-dimyristoleoyl-3-dimethylaminopropane (DMDAP), 1,2-dioleoyl-3-trimethylaminopropane chloride (DOTAP.Cl), dilinoleylmethyl-3-dimethylaminopropionate (DLin-M-C2-DMA; also known as DLin-M-K-DMA or DLin-M-DMA), and mixtures thereof. Additional cationic lipids or salts thereof which may be included in the lipid particles of the present invention are described in U.S. Patent Publication No. 20090023673, the disclosure of which is herein incorporated by reference in its entirety for all purposes.

[00229] The synthesis of cationic lipids such as CLinDMA, as well as additional cationic lipids, is described in U.S. Patent Publication No. 20060240554, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as DLin-C-DAP, DLinDAC, DLinMA, DLinDAP, DLin-S-DMA, DLin-2-DMAP, DLinTMA.Cl, 5 DLinTAP.Cl, DLinMPZ, DLinAP, DOAP, and DLin-EG-DMA, as well as additional cationic lipids, is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as DO-C-DAP, DMDAP, DOTAP.Cl, DLin-M-C2-DMA, as well as additional cationic lipids, is described in PCT Application No. PCT/US2009/060251, entitled "Improved Amino Lipids and Methods for the 10 Delivery of Nucleic Acids," filed October 9, 2009, the disclosure of which is incorporated herein by reference in its entirety for all purposes. The synthesis of a number of other cationic lipids and related analogs has been described in U.S. Patent Nos. 5,208,036; 5,264,618; 5,279,833; 5,283,185; 15 5,753,613; and 5,785,992; and PCT Publication No. WO 96/10390, the disclosures of which are each herein incorporated by reference in their entirety for all purposes. Additionally, a number of commercial preparations of cationic lipids can be used, such as, *e.g.*, LIPOFECTIN® (including DOTMA and DOPE, available from Invitrogen); LIPOFECTAMINE® (including DOSPA and DOPE, available from Invitrogen); and TRANSFECTAM® (including DOGS, available from Promega Corp.).

[00230] In some embodiments, the cationic lipid comprises from about 50 mol % to about 90 mol 20 %, from about 50 mol % to about 85 mol %, from about 50 mol % to about 80 mol %, from about 50 mol % to about 75 mol %, from about 50 mol % to about 70 mol %, from about 50 mol % to about 65 mol %, from about 50 mol % to about 60 mol %, from about 55 mol % to about 65 mol %, or from 25 about 55 mol % to about 70 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. In particular embodiments, the cationic lipid comprises about 50 mol %, 51 mol %, 52 mol %, 53 mol %, 54 mol %, 55 mol %, 56 mol %, 57 mol %, 58 mol %, 59 mol %, 60 mol %, 61 mol %, 62 mol %, 63 mol %, 64 mol %, or 65 mol % (or any fraction thereof) of the total lipid present 30 in the particle.

[00231] In other embodiments, the cationic lipid comprises from about 2 mol % to about 60 mol %, from about 5 mol % to about 50 mol %, from about 10 mol % to about 50 mol %, from about 20 mol % to about 50 mol %, from about 20 mol % to about 40 mol %, from about 30 mol % to about 40 mol %, or about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the 35 particle.

[00232] Additional percentages and ranges of cationic lipids suitable for use in the lipid particles of the present invention are described in PCT Publication No. WO 09/127060, U.S. Published 35 Application No. US 2011/0071208, PCT Publication No. WO2011/000106, and U.S. Published

Application No. US 2011/0076335, the disclosures of which are herein incorporated by reference in their entirety for all purposes.

[00233] It should be understood that the percentage of cationic lipid present in the lipid particles of the invention is a target amount, and that the actual amount of cationic lipid present in the formulation may vary, for example, by  $\pm 5$  mol %. For example, in the 1:57 lipid particle (e.g., SNALP) formulation, the target amount of cationic lipid is 57.1 mol %, but the actual amount of cationic lipid may be  $\pm 5$  mol %,  $\pm 4$  mol %,  $\pm 3$  mol %,  $\pm 2$  mol %,  $\pm 1$  mol %,  $\pm 0.75$  mol %,  $\pm 0.5$  mol %,  $\pm 0.25$  mol %, or  $\pm 0.1$  mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).

## 10 2. Non-cationic Lipids

[00234] The non-cationic lipids used in the lipid particles of the invention (e.g., SNALP) can be any of a variety of neutral uncharged, zwitterionic, or anionic lipids capable of producing a stable complex.

[00235] Non-limiting examples of non-cationic lipids include phospholipids such as lecithin, 15 phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), 20 dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoyl-phosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), palmitoyloleyol-phosphatidylglycerol (POPG), dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), monomethyl-phosphatidylethanolamine, dimethyl- 25 phosphatidylethanolamine, dielaidoyl-phosphatidylethanolamine (DEPE), stearoyloleoyl-phosphatidylethanolamine (SOPE), lysophosphatidylcholine, dilinoleoylphosphatidylcholine, and mixtures thereof. Other diacylphosphatidylcholine and diacylphosphatidylethanolamine phospholipids can also be used. The acyl groups in these lipids are preferably acyl groups derived from fatty acids having C<sub>10</sub>-C<sub>24</sub> carbon chains, e.g., lauroyl, myristoyl, palmitoyl, stearoyl, or oleoyl.

[00236] Additional examples of non-cationic lipids include sterols such as cholesterol and derivatives thereof. Non-limiting examples of cholesterol derivatives include polar analogues such as  $5\alpha$ -cholestanol,  $5\beta$ -coprostanol, cholesteryl-(2'-hydroxy)-ethyl ether, cholesteryl-(4'-hydroxy)-butyl ether, and 6-ketocholestanol; non-polar analogues such as  $5\alpha$ -cholestane, cholestenone,  $5\alpha$ -

cholestanone,  $5\beta$ -cholestanone, and cholesteryl decanoate; and mixtures thereof. In preferred embodiments, the cholesterol derivative is a polar analogue such as cholesteryl-(4'-hydroxy)-butyl ether. The synthesis of cholesteryl-(2'-hydroxy)-ethyl ether is described in PCT Publication No. WO 09/127060, the disclosure of which is herein incorporated by reference in its entirety for all purposes.

5 [00237] In some embodiments, the non-cationic lipid present in the lipid particles (e.g., SNALP) comprises or consists of a mixture of one or more phospholipids and cholesterol or a derivative thereof. In other embodiments, the non-cationic lipid present in the lipid particles (e.g., SNALP) comprises or consists of one or more phospholipids, e.g., a cholesterol-free lipid particle formulation. In yet other embodiments, the non-cationic lipid present in the lipid particles (e.g., SNALP) comprises 10 or consists of cholesterol or a derivative thereof, e.g., a phospholipid-free lipid particle formulation.

15 [00238] Other examples of non-cationic lipids suitable for use in the present invention include nonphosphorous containing lipids such as, e.g., stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl stearate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethoxylated fatty acid amides, dioctadecyldimethyl ammonium bromide, ceramide, sphingomyelin, and the like.

20 [00239] In some embodiments, the non-cationic lipid comprises from about 10 mol % to about 60 mol %, from about 20 mol % to about 55 mol %, from about 20 mol % to about 45 mol %, from about 20 mol % to about 40 mol %, from about 25 mol % to about 50 mol %, from about 25 mol % to about 45 mol %, from about 30 mol % to about 50 mol %, from about 30 mol % to about 45 mol %, from 25 about 30 mol % to about 40 mol %, from about 35 mol % to about 45 mol %, from about 37 mol % to about 42 mol %, or about 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, 40 mol %, 41 mol %, 42 mol %, 43 mol %, 44 mol %, or 45 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.

25 [00240] In embodiments where the lipid particles contain a mixture of phospholipid and cholesterol or a cholesterol derivative, the mixture may comprise up to about 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle.

30 [00241] In some embodiments, the phospholipid component in the mixture may comprise from about 2 mol % to about 20 mol %, from about 2 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 4 mol % to about 15 mol %, or from about 4 mol % to about 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. In certain preferred embodiments, the phospholipid component in the mixture comprises from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol % to about 8 mol %, or about 5 mol %, 6 mol %, 7 mol %,

8 mol %, 9 mol %, or 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. As a non-limiting example, a 1:57 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), *e.g.*, in a mixture with cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof) of the total lipid present in the particle. As another non-limiting example, a 7:54 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), *e.g.*, in a mixture with cholesterol or a cholesterol derivative at about 32 mol % (or any fraction thereof) of the total lipid present in the particle.

10 [00242] In other embodiments, the cholesterol component in the mixture may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 27 mol % to about 37 mol %, from about 25 mol % to about 30 mol %, or from about 35 mol % to about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. In certain preferred embodiments, 15 the cholesterol component in the mixture comprises from about 25 mol % to about 35 mol %, from about 27 mol % to about 35 mol %, from about 29 mol % to about 35 mol %, from about 30 mol % to about 35 mol %, from about 30 mol % to about 34 mol %, from about 31 mol % to about 33 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, or 35 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. Typically, a 1:57 lipid particle formulation 20 comprising a mixture of phospholipid and cholesterol may comprise cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof), *e.g.*, in a mixture with a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof) of the total lipid present in the particle. Typically, a 7:54 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise cholesterol or a cholesterol derivative at about 32 mol % (or any fraction thereof), *e.g.*, in a 25 mixture with a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof) of the total lipid present in the particle.

[00243] In embodiments where the lipid particles are phospholipid-free, the cholesterol or derivative thereof may comprise up to about 25 mol %, 30 mol %, 35 mol %, 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle.

30 [00244] In some embodiments, the cholesterol or derivative thereof in the phospholipid-free lipid particle formulation may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 31 mol % to about 39 mol %, from about 32 mol % to about 38 mol %, from about 33 mol % to about 37 mol %, from about 35 mol % to about 45 mol %, from about 30 mol % to about 35 mol %, from about 35 mol % to about 40 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34

mol %, 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, or 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. As a non-limiting example, a 1:62 lipid particle formulation may comprise cholesterol at about 37 mol % (or any fraction thereof) of the total lipid present in the particle. As another non-limiting example, a 7:58 lipid particle formulation may 5 comprise cholesterol at about 35 mol % (or any fraction thereof) of the total lipid present in the particle.

[00245] In other embodiments, the non-cationic lipid comprises from about 5 mol % to about 90 mol %, from about 10 mol % to about 85 mol %, from about 20 mol % to about 80 mol %, about 10 mol % (e.g., phospholipid only), or about 60 mol % (e.g., phospholipid and cholesterol or derivative 10 thereof) (or any fraction thereof or range therein) of the total lipid present in the particle.

[00246] Additional percentages and ranges of non-cationic lipids suitable for use in the lipid particles of the present invention are described in PCT Publication No. WO 09/127060, U.S. Published Application No. US 2011/0071208, PCT Publication No. WO2011/000106, and U.S. Published Application No. US 2011/0076335, the disclosures of which are herein incorporated by 15 reference in their entirety for all purposes.

[00247] It should be understood that the percentage of non-cationic lipid present in the lipid particles of the invention is a target amount, and that the actual amount of non-cationic lipid present in the formulation may vary, for example, by  $\pm$  5 mol %. For example, in the 1:57 lipid particle (e.g., SNALP) formulation, the target amount of phospholipid is 7.1 mol % and the target amount of 20 cholesterol is 34.3 mol %, but the actual amount of phospholipid may be  $\pm$  2 mol %,  $\pm$  1.5 mol %,  $\pm$  1 mol %,  $\pm$  0.75 mol %,  $\pm$  0.5 mol %,  $\pm$  0.25 mol %, or  $\pm$  0.1 mol % of that target amount, and the actual amount of cholesterol may be  $\pm$  3 mol %,  $\pm$  2 mol %,  $\pm$  1 mol %,  $\pm$  0.75 mol %,  $\pm$  0.5 mol %,  $\pm$  0.25 mol %, or  $\pm$  0.1 mol % of that target amount, with the balance of the formulation being made up 25 of other lipid components (adding up to 100 mol % of total lipids present in the particle). Similarly, in the 7:54 lipid particle (e.g., SNALP) formulation, the target amount of phospholipid is 6.75 mol % and the target amount of cholesterol is 32.43 mol %, but the actual amount of phospholipid may be  $\pm$  2 mol %,  $\pm$  1.5 mol %,  $\pm$  1 mol %,  $\pm$  0.75 mol %,  $\pm$  0.5 mol %,  $\pm$  0.25 mol %, or  $\pm$  0.1 mol % of that target amount, and the actual amount of cholesterol may be  $\pm$  3 mol %,  $\pm$  2 mol %,  $\pm$  1 mol %,  $\pm$  0.75 mol %,  $\pm$  0.5 mol %,  $\pm$  0.25 mol %, or  $\pm$  0.1 mol % of that target amount, with the balance of the 30 formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).

### 3. Lipid Conjugates

[00248] In addition to cationic and non-cationic lipids, the lipid particles of the invention (e.g., SNALP) may further comprise a lipid conjugate. The conjugated lipid is useful in that it prevents the aggregation of particles. Suitable conjugated lipids include, but are not limited to, PEG-lipid conjugates, POZ-lipid conjugates, ATTA-lipid conjugates, cationic-polymer-lipid conjugates (CPLs), and mixtures thereof. In certain embodiments, the particles comprise either a PEG-lipid conjugate or an ATTA-lipid conjugate together with a CPL.

[00249] In a preferred embodiment, the lipid conjugate is a PEG-lipid. Examples of PEG-lipids include, but are not limited to, PEG coupled to dialkyloxypropyls (PEG-DAA) as described in, e.g., PCT Publication No. WO 05/026372, PEG coupled to diacylglycerol (PEG-DAG) as described in, e.g., U.S. Patent Publication Nos. 20030077829 and 2005008689, PEG coupled to phospholipids such as phosphatidylethanolamine (PEG-PE), PEG conjugated to ceramides as described in, e.g., U.S. Patent No. 5,885,613, PEG conjugated to cholesterol or a derivative thereof, and mixtures thereof. The disclosures of these patent documents are herein incorporated by reference in their entirety for all purposes. [0001] Additional PEG-lipids suitable for use in the invention include, without limitation, mPEG2000-1,2-di-O-alkyl-*sn*3-carbomoylglyceride (PEG-C-DOMG). The synthesis of PEG-C-DOMG is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes. Yet additional suitable PEG-lipid conjugates include, without limitation, 1-[8'-(1,2-dimyristoyl-3-propanoxy)-carboxamido-3',6'-dioxaoctanyl]carbamoyl- $\omega$ -methyl-poly(ethylene glycol) (2KPEG-DMG). The synthesis of 2KPEG-DMG is described in U.S. Patent No. 7,404,969, the disclosure of which is herein incorporated by reference in its entirety for all purposes.

[00250] PEG is a linear, water-soluble polymer of ethylene PEG repeating units with two terminal hydroxyl groups. PEGs are classified by their molecular weights; for example, PEG 2000 has an average molecular weight of about 2,000 daltons, and PEG 5000 has an average molecular weight of about 5,000 daltons. PEGs are commercially available from Sigma Chemical Co. and other companies and include, but are not limited to, the following: monomethoxypolyethylene glycol (MePEG-OH), monomethoxypolyethylene glycol-succinate (MePEG-S), monomethoxypolyethylene glycol-succinimidyl succinate (MePEG-S-NHS), monomethoxypolyethylene glycol-amine (MePEG-NH<sub>2</sub>), monomethoxypolyethylene glycol-tresylate (MePEG-TRES), monomethoxypolyethylene glycol-imidazolyl-carbonyl (MePEG-IM), as well as such compounds containing a terminal hydroxyl group instead of a terminal methoxy group (e.g., HO-PEG-S, HO-PEG-S-NHS, HO-PEG-NH<sub>2</sub>, etc.). Other PEGs such as those described in U.S. Patent Nos. 6,774,180 and 7,053,150 (e.g., mPEG (20 KDa) amine) are also useful for preparing the PEG-lipid conjugates of the present invention. The disclosures of these patents are herein incorporated by reference in their entirety for all purposes. In

addition, monomethoxypolyethyleneglycol-acetic acid (MePEG-CH<sub>2</sub>COOH) is particularly useful for preparing PEG-lipid conjugates including, *e.g.*, PEG-DAA conjugates.

**[00251]** The PEG moiety of the PEG-lipid conjugates described herein may comprise an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In certain instances, the

5 PEG moiety has an average molecular weight of from about 750 daltons to about 5,000 daltons (*e.g.*, from about 1,000 daltons to about 5,000 daltons, from about 1,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, *etc.*). In preferred embodiments, the PEG moiety has an average molecular weight of about 2,000 daltons or about 750 daltons.

10 **[00252]** In certain instances, the PEG can be optionally substituted by an alkyl, alkoxy, acyl, or aryl group. The PEG can be conjugated directly to the lipid or may be linked to the lipid via a linker

moiety. Any linker moiety suitable for coupling the PEG to a lipid can be used including, *e.g.*, non-ester containing linker moieties and ester-containing linker moieties. In a preferred embodiment, the linker moiety is a non-ester containing linker moiety. As used herein, the term “non-ester containing

15 linker moiety” refers to a linker moiety that does not contain a carboxylic ester bond (-OC(O)-). Suitable non-ester containing linker moieties include, but are not limited to, amido (-C(O)NH-),

amino (-NR-), carbonyl (-C(O)-), carbamate (-NHC(O)O-), urea (-NHC(O)NH-), disulphide (-S-S-), ether (-O-), succinyl (-(O)CCH<sub>2</sub>CH<sub>2</sub>C(O)-), succinimidyl (-NHC(O)CH<sub>2</sub>CH<sub>2</sub>C(O)NH-), ether, disulphide, as well as combinations thereof (such as a linker containing both a carbamate linker

20 moiety and an amido linker moiety). In a preferred embodiment, a carbamate linker is used to couple the PEG to the lipid.


**[00253]** In other embodiments, an ester containing linker moiety is used to couple the PEG to the lipid. Suitable ester containing linker moieties include, *e.g.*, carbonate (-OC(O)O-), succinyl, phosphate esters (-O-(O)POH-O-), sulfonate esters, and combinations thereof.

25 **[00254]** Phosphatidylethanolamines having a variety of acyl chain groups of varying chain lengths and degrees of saturation can be conjugated to PEG to form the lipid conjugate. Such phosphatidylethanolamines are commercially available, or can be isolated or synthesized using conventional techniques known to those of skilled in the art. Phosphatidyl-ethanolamines containing saturated or unsaturated fatty acids with carbon chain lengths in the range of C<sub>10</sub> to C<sub>20</sub> are preferred.

30 Phosphatidylethanolamines with mono- or diunsaturated fatty acids and mixtures of saturated and unsaturated fatty acids can also be used. Suitable phosphatidylethanolamines include, but are not limited to, dimyristoyl-phosphatidylethanolamine (DMPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE), and distearoyl-phosphatidylethanolamine (DSPE).

**[00255]** The term “ATTA” or “polyamide” includes, without limitation, compounds described in U.S. Patent Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes. These compounds include a compound having the formula:


5



**[00256]** wherein R is a member selected from the group consisting of hydrogen, alkyl and acyl; R<sup>1</sup> is a member selected from the group consisting of hydrogen and alkyl; or optionally, R and R<sup>1</sup> and the nitrogen to which they are bound form an azido moiety; R<sup>2</sup> is a member of the group selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and a side chain of an amino acid; R<sup>3</sup> is a member selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, mercapto, hydrazino, amino and NR<sup>4</sup>R<sup>5</sup>, wherein R<sup>4</sup> and R<sup>5</sup> are independently hydrogen or alkyl; n is 4 to 80; m is 2 to 6; p is 1 to 4; and q is 0 or 1. It will be apparent to those of skill in the art that other polyamides can be used in the compounds of the present invention.


**[00257]** The term “diacylglycerol” or “DAG” includes a compound having 2 fatty acyl chains, R<sup>1</sup> and R<sup>2</sup>, both of which have independently between 2 and 30 carbons bonded to the 1- and 2-position of glycerol by ester linkages. The acyl groups can be saturated or have varying degrees of unsaturation. Suitable acyl groups include, but are not limited to, lauroyl (C<sub>12</sub>), myristoyl (C<sub>14</sub>), palmitoyl (C<sub>16</sub>), stearoyl (C<sub>18</sub>), and icosoyl (C<sub>20</sub>). In preferred embodiments, R<sup>1</sup> and R<sup>2</sup> are the same, *i.e.*, R<sup>1</sup> and R<sup>2</sup> are both myristoyl (*i.e.*, dimyristoyl), R<sup>1</sup> and R<sup>2</sup> are both stearoyl (*i.e.*, distearoyl), *etc.*

20 Diacylglycerols have the following general formula:




**[00258]** The term “dialkyloxypropyl” or “DAA” includes a compound having 2 alkyl chains, R<sup>1</sup> and R<sup>2</sup>, both of which have independently between 2 and 30 carbons. The alkyl groups can be

saturated or have varying degrees of unsaturation. Dialkyloxypropyls have the following general formula:



[00259] In a preferred embodiment, the PEG-lipid is a PEG-DAA conjugate having the following 5 formula:




[00260] wherein R<sup>1</sup> and R<sup>2</sup> are independently selected and are long-chain alkyl groups having from about 10 to about 22 carbon atoms; PEG is a polyethyleneglycol; and L is a non-ester containing linker moiety or an ester containing linker moiety as described above. The long-chain alkyl groups 10 can be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, decyl (C<sub>10</sub>), lauryl (C<sub>12</sub>), myristyl (C<sub>14</sub>), palmityl (C<sub>16</sub>), stearyl (C<sub>18</sub>), and icosyl (C<sub>20</sub>). In preferred embodiments, R<sup>1</sup> and R<sup>2</sup> are the same, *i.e.*, R<sup>1</sup> and R<sup>2</sup> are both myristyl (*i.e.*, dimyristyl), R<sup>1</sup> and R<sup>2</sup> are both stearyl (*i.e.*, distearyl), *etc.*

[00261] In Formula VII above, the PEG has an average molecular weight ranging from about 550 15 daltons to about 10,000 daltons. In certain instances, the PEG has an average molecular weight of from about 750 daltons to about 5,000 daltons (*e.g.*, from about 1,000 daltons to about 5,000 daltons, from about 1,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, *etc.*). In preferred embodiments, the PEG has an average molecular weight of about 2,000 daltons or about 750 daltons. The PEG can be optionally substituted 20 with alkyl, alkoxy, acyl, or aryl groups. In certain embodiments, the terminal hydroxyl group is substituted with a methoxy or methyl group.

[00262] In a preferred embodiment, “L” is a non-ester containing linker moiety. Suitable non-ester containing linkers include, but are not limited to, an amido linker moiety, an amino linker 25 moiety, a carbonyl linker moiety, a carbamate linker moiety, a urea linker moiety, an ether linker moiety, a disulphide linker moiety, a succinamidyl linker moiety, and combinations thereof. In a

preferred embodiment, the non-ester containing linker moiety is a carbamate linker moiety (*i.e.*, a PEG-C-DAA conjugate). In another preferred embodiment, the non-ester containing linker moiety is an amido linker moiety (*i.e.*, a PEG-A-DAA conjugate). In yet another preferred embodiment, the non-ester containing linker moiety is a succinimidyl linker moiety (*i.e.*, a PEG-S-DAA conjugate).

5 [00263] In particular embodiments, the PEG-lipid conjugate is selected from:



[00264] The PEG-DAA conjugates are synthesized using standard techniques and reagents known to those of skill in the art. It will be recognized that the PEG-DAA conjugates will contain 10 various amide, amine, ether, thio, carbamate, and urea linkages. Those of skill in the art will recognize that methods and reagents for forming these bonds are well known and readily available. *See, e.g.*, March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992); Larock, COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss, VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY, 5th ed. (Longman 1989). It will also be 15 appreciated that any functional groups present may require protection and deprotection at different points in the synthesis of the PEG-DAA conjugates. Those of skill in the art will recognize that such techniques are well known. *See, e.g.*, Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (Wiley 1991).

[00265] Preferably, the PEG-DAA conjugate is a PEG-didecyloxypropyl (C<sub>10</sub>) conjugate, a PEG-20 dilauryloxypropyl (C<sub>12</sub>) conjugate, a PEG-dimyristyloxypropyl (C<sub>14</sub>) conjugate, a PEG-dipalmityloxypropyl (C<sub>16</sub>) conjugate, or a PEG-distearyoxypropyl (C<sub>18</sub>) conjugate. In these embodiments, the PEG preferably has an average molecular weight of about 750 or about 2,000 daltons. In one particularly preferred embodiment, the PEG-lipid conjugate comprises PEG2000-C-DMA, wherein the “2000” denotes the average molecular weight of the PEG, the “C” denotes a 25 carbamate linker moiety, and the “DMA” denotes dimyristyloxypropyl. In another particularly preferred embodiment, the PEG-lipid conjugate comprises PEG750-C-DMA, wherein the “750” denotes the average molecular weight of the PEG, the “C” denotes a carbamate linker moiety, and the “DMA” denotes dimyristyloxypropyl. In particular embodiments, the terminal hydroxyl group of the

PEG is substituted with a methyl group. Those of skill in the art will readily appreciate that other dialkyloxypropyls can be used in the PEG-DAA conjugates of the present invention.

**[00266]** In addition to the foregoing, it will be readily apparent to those of skill in the art that other hydrophilic polymers can be used in place of PEG. Examples of suitable polymers that can be 5 used in place of PEG include, but are not limited to, polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide and polydimethylacrylamide, polylactic acid, polyglycolic acid, and derivatized celluloses such as hydroxymethylcellulose or hydroxyethylcellulose.

**[00267]** In addition to the foregoing components, the lipid particles (e.g., SNALP) of the present 10 invention can further comprise cationic poly(ethylene glycol) (PEG) lipids or CPLs (see, e.g., Chen *et al.*, *Bioconj. Chem.*, 11:433-437 (2000); U.S. Patent No. 6,852,334; PCT Publication No. WO 00/62813, the disclosures of which are herein incorporated by reference in their entirety for all purposes).

**[00268]** Suitable CPLs include compounds of Formula VIII:

15 A-W-Y (VIII),

**[00269]** wherein A, W, and Y are as described below.

**[00270]** With reference to Formula VIII, "A" is a lipid moiety such as an amphipathic lipid, a 20 neutral lipid, or a hydrophobic lipid that acts as a lipid anchor. Suitable lipid examples include, but are not limited to, diacylglycerolyls, dialkylglycerolyls, N-N-dialkylaminos, 1,2-diacyloxy-3-aminopropanes, and 1,2-dialkyl-3-aminopropanes.

**[00271]** "W" is a polymer or an oligomer such as a hydrophilic polymer or oligomer. Preferably, 25 the hydrophilic polymer is a biocompatible polymer that is nonimmunogenic or possesses low inherent immunogenicity. Alternatively, the hydrophilic polymer can be weakly antigenic if used with appropriate adjuvants. Suitable nonimmunogenic polymers include, but are not limited to, PEG, polyamides, polylactic acid, polyglycolic acid, polylactic acid/polyglycolic acid copolymers, and combinations thereof. In a preferred embodiment, the polymer has a molecular weight of from about 250 to about 7,000 daltons.

**[00272]** "Y" is a polycationic moiety. The term polycationic moiety refers to a compound, derivative, or functional group having a positive charge, preferably at least 2 positive charges at a 30 selected pH, preferably physiological pH. Suitable polycationic moieties include basic amino acids and their derivatives such as arginine, asparagine, glutamine, lysine, and histidine; spermine; spermidine; cationic dendrimers; polyamines; polyamine sugars; and amino polysaccharides. The

polycationic moieties can be linear, such as linear tetrалysine, branched or dendrimeric in structure. Polycationic moieties have between about 2 to about 15 positive charges, preferably between about 2 to about 12 positive charges, and more preferably between about 2 to about 8 positive charges at selected pH values. The selection of which polycationic moiety to employ may be determined by the 5 type of particle application which is desired.

[00273] The charges on the polycationic moieties can be either distributed around the entire particle moiety, or alternatively, they can be a discrete concentration of charge density in one particular area of the particle moiety *e.g.*, a charge spike. If the charge density is distributed on the particle, the charge density can be equally distributed or unequally distributed. All variations of 10 charge distribution of the polycationic moiety are encompassed by the present invention.

[00274] The lipid “A” and the nonimmunogenic polymer “W” can be attached by various methods and preferably by covalent attachment. Methods known to those of skill in the art can be used for the covalent attachment of “A” and “W.” Suitable linkages include, but are not limited to, amide, amine, carboxyl, carbonate, carbamate, ester, and hydrazone linkages. It will be apparent to 15 those skilled in the art that “A” and “W” must have complementary functional groups to effectuate the linkage. The reaction of these two groups, one on the lipid and the other on the polymer, will provide the desired linkage. For example, when the lipid is a diacylglycerol and the terminal hydroxyl is activated, for instance with NHS and DCC, to form an active ester, and is then reacted with a polymer which contains an amino group, such as with a polyamide (*see, e.g.*, U.S. Patent Nos. 6,320,017 and 20 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes), an amide bond will form between the two groups.

[00275] In certain instances, the polycationic moiety can have a ligand attached, such as a targeting ligand or a chelating moiety for complexing calcium. Preferably, after the ligand is attached, the cationic moiety maintains a positive charge. In certain instances, the ligand that is 25 attached has a positive charge. Suitable ligands include, but are not limited to, a compound or device with a reactive functional group and include lipids, amphipathic lipids, carrier compounds, bioaffinity compounds, biomaterials, biopolymers, biomedical devices, analytically detectable compounds, therapeutically active compounds, enzymes, peptides, proteins, antibodies, immune stimulators, radiolabels, fluorogens, biotin, drugs, haptens, DNA, RNA, polysaccharides, liposomes, virosomes, 30 micelles, immunoglobulins, functional groups, other targeting moieties, or toxins.

[00276] In some embodiments, the lipid conjugate (*e.g.*, PEG-lipid) comprises from about 0.1 mol % to about 2 mol %, from about 0.5 mol % to about 2 mol %, from about 1 mol % to about 2 mol %, from about 0.6 mol % to about 1.9 mol %, from about 0.7 mol % to about 1.8 mol %, from about 0.8 mol % to about 1.7 mol %, from about 0.9 mol % to about 1.6 mol %, from about 0.9 mol % to

about 1.8 mol %, from about 1 mol % to about 1.8 mol %, from about 1 mol % to about 1.7 mol %, from about 1.2 mol % to about 1.8 mol %, from about 1.2 mol % to about 1.7 mol %, from about 1.3 mol % to about 1.6 mol %, or from about 1.4 mol % to about 1.5 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.

5 [00277] In other embodiments, the lipid conjugate (e.g., PEG-lipid) comprises from about 0 mol % to about 20 mol %, from about 0.5 mol % to about 20 mol %, from about 2 mol % to about 20 mol %, from about 1.5 mol % to about 18 mol %, from about 2 mol % to about 15 mol %, from about 4 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 5 mol % to about 12 mol %, or about 2 mol % (or any fraction thereof or range therein) of the total lipid present in the  
10 particle.

15 [00278] In further embodiments, the lipid conjugate (e.g., PEG-lipid) comprises from about 4 mol % to about 10 mol %, from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol % to about 8 mol %, or about 5 mol %, 6 mol %, 7 mol %, 8 mol %, 9 mol %, or 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.

20 [00279] Additional percentages and ranges of lipid conjugates suitable for use in the lipid particles of the present invention are described in PCT Publication No. WO 09/127060, U.S. Published Application No. US 2011/0071208, PCT Publication No. WO2011/000106, and U.S. Published Application No. US 2011/0076335, the disclosures of which are herein incorporated by reference in their entirety for all purposes.

25 [00280] It should be understood that the percentage of lipid conjugate (e.g., PEG-lipid) present in the lipid particles of the invention is a target amount, and that the actual amount of lipid conjugate present in the formulation may vary, for example, by  $\pm$  2 mol %. For example, in the 1:57 lipid particle (e.g., SNALP) formulation, the target amount of lipid conjugate is 1.4 mol %, but the actual amount of lipid conjugate may be  $\pm$  0.5 mol %,  $\pm$  0.4 mol %,  $\pm$  0.3 mol %,  $\pm$  0.2 mol %,  $\pm$  0.1 mol %, or  $\pm$  0.05 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle). Similarly, in the 7:54 lipid particle (e.g., SNALP) formulation, the target amount of lipid conjugate is 6.76 mol %, but the actual amount of lipid conjugate may be  $\pm$  2 mol %,  $\pm$  1.5 mol %,  $\pm$  1 mol %,  $\pm$  0.75 mol %,  $\pm$  0.5 mol %,  $\pm$  0.25 mol %, or  $\pm$  0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).

[00281] One of ordinary skill in the art will appreciate that the concentration of the lipid conjugate can be varied depending on the lipid conjugate employed and the rate at which the lipid particle is to become fusogenic.

[00282] By controlling the composition and concentration of the lipid conjugate, one can control 5 the rate at which the lipid conjugate exchanges out of the lipid particle and, in turn, the rate at which the lipid particle becomes fusogenic. For instance, when a PEG-DAA conjugate is used as the lipid conjugate, the rate at which the lipid particle becomes fusogenic can be varied, for example, by varying the concentration of the lipid conjugate, by varying the molecular weight of the PEG, or by varying the chain length and degree of saturation of the alkyl groups on the PEG-DAA conjugate. In 10 addition, other variables including, for example, pH, temperature, ionic strength, *etc.* can be used to vary and/or control the rate at which the lipid particle becomes fusogenic. Other methods which can be used to control the rate at which the lipid particle becomes fusogenic will become apparent to those of skill in the art upon reading this disclosure. Also, by controlling the composition and concentration of the lipid conjugate, one can control the lipid particle (*e.g.*, SNALP) size.

15            **B.        Additional Carrier Systems**

[00283] Non-limiting examples of additional lipid-based carrier systems suitable for use in the present invention include lipoplexes (*see, e.g.*, U.S. Patent Publication No. 20030203865; and Zhang *et al.*, *J. Control Release*, 100:165-180 (2004)), pH-sensitive lipoplexes (*see, e.g.*, U.S. Patent Publication No. 20020192275), reversibly masked lipoplexes (*see, e.g.*, U.S. Patent Publication Nos. 20 20030180950), cationic lipid-based compositions (*see, e.g.*, U.S. Patent No. 6,756,054; and U.S. Patent Publication No. 20050234232), cationic liposomes (*see, e.g.*, U.S. Patent Publication Nos. 20030229040, 20020160038, and 20020012998; U.S. Patent No. 5,908,635; and PCT Publication No. WO 01/72283), anionic liposomes (*see, e.g.*, U.S. Patent Publication No. 20030026831), pH-sensitive liposomes (*see, e.g.*, U.S. Patent Publication No. 20020192274; and AU 2003210303), antibody-coated liposomes (*see, e.g.*, U.S. Patent Publication No. 20030108597; and PCT Publication No. WO 00/50008), cell-type specific liposomes (*see, e.g.*, U.S. Patent Publication No. 20030198664), liposomes containing nucleic acid and peptides (*see, e.g.*, U.S. Patent No. 6,207,456), liposomes containing lipids derivatized with releasable hydrophilic polymers (*see, e.g.*, U.S. Patent Publication No. 20030031704), lipid-entrapped nucleic acid (*see, e.g.*, PCT Publication Nos. WO 03/057190 and 25 WO 03/059322), lipid-encapsulated nucleic acid (*see, e.g.*, U.S. Patent Publication No. 20030129221; and U.S. Patent No. 5,756,122), other liposomal compositions (*see, e.g.*, U.S. Patent Publication Nos. 20030035829 and 20030072794; and U.S. Patent No. 6,200,599), stabilized mixtures of liposomes and emulsions (*see, e.g.*, EP1304160), emulsion compositions (*see, e.g.*, U.S. Patent No. 6,747,014), 30 and nucleic acid micro-emulsions (*see, e.g.*, U.S. Patent Publication No. 20050037086).

**[00284]** Examples of polymer-based carrier systems suitable for use in the present invention include, but are not limited to, cationic polymer-nucleic acid complexes (*i.e.*, polyplexes). To form a polyplex, a nucleic acid (*e.g.*, interfering RNA) is typically complexed with a cationic polymer having a linear, branched, star, or dendritic polymeric structure that condenses the nucleic acid into positively charged particles capable of interacting with anionic proteoglycans at the cell surface and entering cells by endocytosis. In some embodiments, the polyplex comprises nucleic acid (*e.g.*, interfering RNA) complexed with a cationic polymer such as polyethylenimine (PEI) (*see, e.g.*, U.S. Patent No. 6,013,240; commercially available from Qbiogene, Inc. (Carlsbad, CA) as *In vivo* jetPEI™, a linear form of PEI), polypropylenimine (PPI), polyvinylpyrrolidone (PVP), poly-L-lysine (PLL), diethylaminoethyl (DEAE)-dextran, poly( $\beta$ -amino ester) (PAE) polymers (*see, e.g.*, Lynn *et al.*, *J. Am. Chem. Soc.*, 123:8155-8156 (2001)), chitosan, polyamidoamine (PAMAM) dendrimers (*see, e.g.*, Kukowska-Latallo *et al.*, *Proc. Natl. Acad. Sci. USA*, 93:4897-4902 (1996)), porphyrin (*see, e.g.*, U.S. Patent No. 6,620,805), polyvinylether (*see, e.g.*, U.S. Patent Publication No. 20040156909), polycyclic amidinium (*see, e.g.*, U.S. Patent Publication No. 20030220289), other polymers comprising primary amine, imine, guanidine, and/or imidazole groups (*see, e.g.*, U.S. Patent No. 6,013,240; PCT Publication No. WO/9602655; PCT Publication No. WO95/21931; Zhang *et al.*, *J. Control Release*, 100:165-180 (2004); and Tiera *et al.*, *Curr. Gene Ther.*, 6:59-71 (2006)), and a mixture thereof. In other embodiments, the polyplex comprises cationic polymer-nucleic acid complexes as described in U.S. Patent Publication Nos. 20060211643, 20050222064, 20030125281, and 20030185890, and PCT Publication No. WO 03/066069; biodegradable poly( $\beta$ -amino ester) polymer-nucleic acid complexes as described in U.S. Patent Publication No. 20040071654; microparticles containing polymeric matrices as described in U.S. Patent Publication No. 20040142475; other microparticle compositions as described in U.S. Patent Publication No. 20030157030; condensed nucleic acid complexes as described in U.S. Patent Publication No. 20050123600; and nanocapsule and microcapsule compositions as described in AU 2002358514 and PCT Publication No. WO 02/096551.

**[00285]** In certain instances, the interfering RNA may be complexed with cyclodextrin or a polymer thereof. Non-limiting examples of cyclodextrin-based carrier systems include the cyclodextrin-modified polymer-nucleic acid complexes described in U.S. Patent Publication No. 20040087024; the linear cyclodextrin copolymer-nucleic acid complexes described in U.S. Patent Nos. 6,509,323, 6,884,789, and 7,091,192; and the cyclodextrin polymer-complexing agent-nucleic acid complexes described in U.S. Patent No. 7,018,609. In certain other instances, the interfering RNA may be complexed with a peptide or polypeptide. An example of a protein-based carrier system includes, but is not limited to, the cationic oligopeptide-nucleic acid complex described in PCT Publication No. WO95/21931.

## VI. Preparation of Lipid Particles

[00286] The lipid particles of the present invention, *e.g.*, SNALP, in which a nucleic acid such as an interfering RNA (*e.g.*, siRNA) is entrapped within the lipid portion of the particle and is protected from degradation, can be formed by any method known in the art including, but not limited to, a 5 continuous mixing method, a direct dilution process, and an in-line dilution process.

[00287] In particular embodiments, the cationic lipids may comprise lipids of Formula I-III or salts thereof, alone or in combination with other cationic lipids. In other embodiments, the non-cationic lipids are egg sphingomyelin (ESM), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), 10 dipalmitoyl-phosphatidylcholine (DPPC), monomethyl-phosphatidylethanolamine, dimethyl-phosphatidylethanolamine, 14:0 PE (1,2-dimyristoyl-phosphatidylethanolamine (DMPE)), 16:0 PE (1,2-dipalmitoyl-phosphatidylethanolamine (DPPE)), 18:0 PE (1,2-distearoyl-phosphatidylethanolamine (DSPE)), 18:1 PE (1,2-dioleoyl-phosphatidylethanolamine (DOPE)), 18:1 trans PE (1,2-dielaidoyl-phosphatidylethanolamine (DEPE)), 18:0-18:1 PE (1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE)), 16:0-18:1 PE (1-palmitoyl-2-oleoyl-phosphatidylethanolamine (POPE)), polyethylene glycol-based polymers (*e.g.*, PEG 2000, PEG 5000, PEG-modified diacylglycerols, or PEG-modified dialkyloxypropyls), cholesterol, derivatives thereof, or combinations thereof.

[00288] In certain embodiments, the present invention provides nucleic acid-lipid particles (*e.g.*, SNALP) produced via a continuous mixing method, *e.g.*, a process that includes providing an aqueous solution comprising a nucleic acid (*e.g.*, interfering RNA) in a first reservoir, providing an organic lipid solution in a second reservoir (wherein the lipids present in the organic lipid solution are solubilized in an organic solvent, *e.g.*, a lower alkanol such as ethanol), and mixing the aqueous solution with the organic lipid solution such that the organic lipid solution mixes with the aqueous solution so as to substantially instantaneously produce a lipid vesicle (*e.g.*, liposome) encapsulating the nucleic acid within the lipid vesicle. This process and the apparatus for carrying out this process are described in detail in U.S. Patent Publication No. 20040142025, the disclosure of which is herein incorporated by reference in its entirety for all purposes.

[00289] The action of continuously introducing lipid and buffer solutions into a mixing 30 environment, such as in a mixing chamber, causes a continuous dilution of the lipid solution with the buffer solution, thereby producing a lipid vesicle substantially instantaneously upon mixing. As used herein, the phrase “continuously diluting a lipid solution with a buffer solution” (and variations) generally means that the lipid solution is diluted sufficiently rapidly in a hydration process with sufficient force to effectuate vesicle generation. By mixing the aqueous solution comprising a nucleic

acid with the organic lipid solution, the organic lipid solution undergoes a continuous stepwise dilution in the presence of the buffer solution (*i.e.*, aqueous solution) to produce a nucleic acid-lipid particle.

[00290] The nucleic acid-lipid particles formed using the continuous mixing method typically 5 have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 110 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 10 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm (or any fraction thereof or 15 range therein). The particles thus formed do not aggregate and are optionally sized to achieve a uniform particle size.

[00291] In another embodiment, the present invention provides nucleic acid-lipid particles (*e.g.*, 15 SNALP) produced via a direct dilution process that includes forming a lipid vesicle (*e.g.*, liposome) solution and immediately and directly introducing the lipid vesicle solution into a collection vessel containing a controlled amount of dilution buffer. In preferred aspects, the collection vessel includes one or more elements configured to stir the contents of the collection vessel to facilitate dilution. In 20 one aspect, the amount of dilution buffer present in the collection vessel is substantially equal to the volume of lipid vesicle solution introduced thereto. As a non-limiting example, a lipid vesicle solution in 45% ethanol when introduced into the collection vessel containing an equal volume of dilution buffer will advantageously yield smaller particles.

[00292] In yet another embodiment, the present invention provides nucleic acid-lipid particles 25 (*e.g.*, SNALP) produced via an in-line dilution process in which a third reservoir containing dilution buffer is fluidly coupled to a second mixing region. In this embodiment, the lipid vesicle (*e.g.*, liposome) solution formed in a first mixing region is immediately and directly mixed with dilution buffer in the second mixing region. In preferred aspects, the second mixing region includes a T- connector arranged so that the lipid vesicle solution and the dilution buffer flows meet as opposing 30 180° flows; however, connectors providing shallower angles can be used, *e.g.*, from about 27° to about 180° (*e.g.*, about 90°). A pump mechanism delivers a controllable flow of buffer to the second mixing region. In one aspect, the flow rate of dilution buffer provided to the second mixing region is controlled to be substantially equal to the flow rate of lipid vesicle solution introduced thereto from the first mixing region. This embodiment advantageously allows for more control of the flow of dilution buffer mixing with the lipid vesicle solution in the second mixing region, and therefore also 35 the concentration of lipid vesicle solution in buffer throughout the second mixing process. Such

control of the dilution buffer flow rate advantageously allows for small particle size formation at reduced concentrations.

5 [00293] These processes and the apparatuses for carrying out these direct dilution and in-line dilution processes are described in detail in U.S. Patent Publication No. 20070042031, the disclosure of which is herein incorporated by reference in its entirety for all purposes.

10 [00294] The nucleic acid-lipid particles formed using the direct dilution and in-line dilution processes typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 110 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm (or any fraction thereof or range therein). The particles thus formed do not aggregate and are optionally sized 15 to achieve a uniform particle size.

[00295] If needed, the lipid particles of the invention (e.g., SNALP) can be sized by any of the methods available for sizing liposomes. The sizing may be conducted in order to achieve a desired size range and relatively narrow distribution of particle sizes.

20 [00296] Several techniques are available for sizing the particles to a desired size. One sizing method, used for liposomes and equally applicable to the present particles, is described in U.S. Patent No. 4,737,323, the disclosure of which is herein incorporated by reference in its entirety for all purposes. Sonicating a particle suspension either by bath or probe sonication produces a progressive size reduction down to particles of less than about 50 nm in size. Homogenization is another method which relies on shearing energy to fragment larger particles into smaller ones. In a typical 25 homogenization procedure, particles are recirculated through a standard emulsion homogenizer until selected particle sizes, typically between about 60 and about 80 nm, are observed. In both methods, the particle size distribution can be monitored by conventional laser-beam particle size discrimination, or QELS.

30 [00297] Extrusion of the particles through a small-pore polycarbonate membrane or an asymmetric ceramic membrane is also an effective method for reducing particle sizes to a relatively well-defined size distribution. Typically, the suspension is cycled through the membrane one or more times until the desired particle size distribution is achieved. The particles may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in size.

**[00298]** In some embodiments, the nucleic acids present in the particles are precondensed as described in, *e.g.*, U.S. Patent Application No. 09/744,103, the disclosure of which is herein incorporated by reference in its entirety for all purposes.

**[00299]** In other embodiments, the methods may further comprise adding non-lipid polycations which are useful to effect the lipofection of cells using the present compositions. Examples of suitable non-lipid polycations include, hexadimethrine bromide (sold under the brand name POLYBRENE<sup>®</sup>, from Aldrich Chemical Co., Milwaukee, Wisconsin, USA) or other salts of hexadimethrine. Other suitable polycations include, for example, salts of poly-L-ornithine, poly-L-arginine, poly-L-lysine, poly-D-lysine, polyallylamine, and polyethyleneimine. Addition of these salts is preferably after the particles have been formed.

**[00300]** In some embodiments, the nucleic acid to lipid ratios (mass/mass ratios) in a formed nucleic acid-lipid particle (*e.g.*, SNALP) will range from about 0.01 to about 0.2, from about 0.05 to about 0.2, from about 0.02 to about 0.1, from about 0.03 to about 0.1, or from about 0.01 to about 0.08. The ratio of the starting materials (input) also falls within this range. In other embodiments, the particle preparation uses about 400  $\mu$ g nucleic acid per 10 mg total lipid or a nucleic acid to lipid mass ratio of about 0.01 to about 0.08 and, more preferably, about 0.04, which corresponds to 1.25 mg of total lipid per 50  $\mu$ g of nucleic acid. In other preferred embodiments, the particle has a nucleic acid:lipid mass ratio of about 0.08.

**[00301]** In other embodiments, the lipid to nucleic acid ratios (mass/mass ratios) in a formed nucleic acid-lipid particle (*e.g.*, SNALP) will range from about 1 (1:1) to about 100 (100:1), from about 5 (5:1) to about 100 (100:1), from about 1 (1:1) to about 50 (50:1), from about 2 (2:1) to about 50 (50:1), from about 3 (3:1) to about 50 (50:1), from about 4 (4:1) to about 50 (50:1), from about 5 (5:1) to about 50 (50:1), from about 1 (1:1) to about 25 (25:1), from about 2 (2:1) to about 25 (25:1), from about 3 (3:1) to about 25 (25:1), from about 4 (4:1) to about 25 (25:1), from about 5 (5:1) to about 25 (25:1), from about 5 (5:1) to about 20 (20:1), from about 5 (5:1) to about 15 (15:1), from about 5 (5:1) to about 10 (10:1), or about 5 (5:1), 6 (6:1), 7 (7:1), 8 (8:1), 9 (9:1), 10 (10:1), 11 (11:1), 12 (12:1), 13 (13:1), 14 (14:1), 15 (15:1), 16 (16:1), 17 (17:1), 18 (18:1), 19 (19:1), 20 (20:1), 21 (21:1), 22 (22:1), 23 (23:1), 24 (24:1), or 25 (25:1), or any fraction thereof or range therein. The ratio of the starting materials (input) also falls within this range.

**[00302]** As previously discussed, the conjugated lipid may further include a CPL. A variety of general methods for making SNALP-CPLs (CPL-containing SNALP) are discussed herein. Two general techniques include the “post-insertion” technique, that is, insertion of a CPL into, for example, a pre-formed SNALP, and the “standard” technique, wherein the CPL is included in the lipid mixture during, for example, the SNALP formation steps. The post-insertion technique results in

SNALP having CPLs mainly in the external face of the SNALP bilayer membrane, whereas standard techniques provide SNALP having CPLs on both internal and external faces. The method is especially useful for vesicles made from phospholipids (which can contain cholesterol) and also for vesicles containing PEG-lipids (such as PEG-DAs and PEG-DAGs). Methods of making SNALP-  
5 CPLs are taught, for example, in U.S. Patent Nos. 5,705,385; 6,586,410; 5,981,501; 6,534,484; and 6,852,334; U.S. Patent Publication No. 20020072121; and PCT Publication No. WO 00/62813, the disclosures of which are herein incorporated by reference in their entirety for all purposes.

## VII. Kits

[00303] The present invention also provides lipid particles (*e.g.*, SNALP) in kit form. In some  
10 embodiments, the kit comprises a container which is compartmentalized for holding the various elements of the lipid particles (*e.g.*, the active agents or therapeutic agents such as nucleic acids and the individual lipid components of the particles). Preferably, the kit comprises a container (*e.g.*, a vial or ampoule) which holds the lipid particles of the invention (*e.g.*, SNALP), wherein the particles are produced by one of the processes set forth herein. In certain embodiments, the kit may further  
15 comprise an endosomal membrane destabilizer (*e.g.*, calcium ions). The kit typically contains the particle compositions of the invention, either as a suspension in a pharmaceutically acceptable carrier or in dehydrated form, with instructions for their rehydration (if lyophilized) and administration.

[00304] The SNALP formulations of the present invention can be tailored to preferentially target particular cells, tissues, or organs of interest. Preferential targeting of SNALP may be carried out by  
20 controlling the composition of the SNALP itself. In particular embodiments, the kits of the invention comprise these lipid particles, wherein the particles are present in a container as a suspension or in dehydrated form.

[00305] In certain instances, it may be desirable to have a targeting moiety attached to the surface of the lipid particle to further enhance the targeting of the particle. Methods of attaching targeting  
25 moieties (*e.g.*, antibodies, proteins, *etc.*) to lipids (such as those used in the present particles) are known to those of skill in the art.

## VIII. Administration of Lipid Particles

[00306] Once formed, the lipid particles of the invention (*e.g.*, SNALP) are particularly useful for the introduction of nucleic acids (*e.g.*, interfering RNA such as dsRNA) into cells. Accordingly, the  
30 present invention also provides methods for introducing a nucleic acid (*e.g.*, interfering RNA) into a cell. In particular embodiments, the nucleic acid (*e.g.*, interfering RNA) is introduced into an infected cell such as reticuloendothelial cells (*e.g.*, macrophages, monocytes, *etc.*) as well as other cell types, including fibroblasts, endothelial cells (such as those lining the interior surface of blood vessels),

and/or platelet cells. The methods may be carried out *in vitro* or *in vivo* by first forming the particles as described above and then contacting the particles with the cells for a period of time sufficient for delivery of the interfering RNA to the cells to occur.

[00307] The lipid particles of the invention (*e.g.*, SNALP) can be adsorbed to almost any cell type with which they are mixed or contacted. Once adsorbed, the particles can either be endocytosed by a portion of the cells, exchange lipids with cell membranes, or fuse with the cells. Transfer or incorporation of the nucleic acid (*e.g.*, interfering RNA) portion of the particle can take place via any one of these pathways. In particular, when fusion takes place, the particle membrane is integrated into the cell membrane and the contents of the particle combine with the intracellular fluid.

[00308] The lipid particles of the invention (*e.g.*, SNALP) can be administered either alone or in a mixture with a pharmaceutically acceptable carrier (*e.g.*, physiological saline or phosphate buffer) selected in accordance with the route of administration and standard pharmaceutical practice.

Generally, normal buffered saline (*e.g.*, 135-150 mM NaCl) will be employed as the pharmaceutically acceptable carrier. Other suitable carriers include, *e.g.*, water, buffered water, 0.4% saline, 0.3%

glycine, and the like, including glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, *etc.* Additional suitable carriers are described in, *e.g.*, REMINGTON'S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985). As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.

[00309] The pharmaceutically acceptable carrier is generally added following lipid particle formation. Thus, after the lipid particle (*e.g.*, SNALP) is formed, the particle can be diluted into

pharmaceutically acceptable carriers such as normal buffered saline.

[00310] The concentration of particles in the pharmaceutical formulations can vary widely, *i.e.*, from less than about 0.05%, usually at or at least about 2 to 5%, to as much as about 10 to 90% by weight, and will be selected primarily by fluid volumes, viscosities, *etc.*, in accordance with the particular mode of administration selected. For example, the concentration may be increased to lower

the fluid load associated with treatment. This may be particularly desirable in patients having atherosclerosis-associated congestive heart failure or severe hypertension. Alternatively, particles composed of irritating lipids may be diluted to low concentrations to lessen inflammation at the site of administration.

[00311] The pharmaceutical compositions of the present invention may be sterilized by conventional, well-known sterilization techniques. Aqueous solutions can be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration. The compositions can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, and calcium chloride. Additionally, the particle suspension may include lipid-protective agents which protect lipids against free-radical and lipid-peroxidative damages on storage. Lipophilic free-radical quenchers, such as alphatocopherol, and water-soluble iron-specific chelators, such as ferrioxamine, are suitable.

[00312] In some embodiments, the lipid particles of the invention (e.g., SNALP) are particularly useful in methods for the therapeutic delivery of one or more nucleic acids comprising an interfering RNA sequence (e.g., siRNA). In particular, it is an object of this invention to provide *in vivo* methods for treatment of alcoholism in humans by downregulating or silencing the transcription and/or translation of one or more ALDH isozymes.

#### A. *In vivo* Administration

[00313] Systemic delivery for *in vivo* therapy, e.g., delivery of a therapeutic nucleic acid to a distal target cell via body systems such as the circulation, has been achieved using nucleic acid-lipid particles such as those described in PCT Publication Nos. WO 05/007196, WO 05/121348, WO 20 05/120152, and WO 04/002453, the disclosures of which are herein incorporated by reference in their entirety for all purposes. The present invention also provides fully encapsulated lipid particles that protect the nucleic acid from nuclease degradation in serum, are non-immunogenic, are small in size, and are suitable for repeat dosing.

[00314] For *in vivo* administration, administration can be in any manner known in the art, e.g., by injection, oral administration, inhalation (e.g., intranasal or intratracheal), transdermal application, or rectal administration. Administration can be accomplished via single or divided doses. The pharmaceutical compositions can be administered parenterally, i.e., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly. In some embodiments, the pharmaceutical compositions are administered intravenously or intraperitoneally by a bolus injection (see, e.g., U.S. Patent No. 5,286,634). Intracellular nucleic acid delivery has also been discussed in Straubinger *et al.*, *Methods Enzymol.*, 101:512 (1983); Mannino *et al.*, *Biotechniques*, 6:682 (1988); Nicolau *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.*, 6:239 (1989); and Behr, *Acc. Chem. Res.*, 26:274 (1993). Still other methods of administering lipid-based therapeutics are described in, for example, U.S. Patent Nos. 3,993,754; 4,145,410; 4,235,871; 4,224,179; 4,522,803; and 4,588,578. The lipid particles can

be administered by direct injection at the site of disease or by injection at a site distal from the site of disease (see, e.g., Culver, HUMAN GENE THERAPY, MaryAnn Liebert, Inc., Publishers, New York. pp.70-71(1994)). The disclosures of the above-described references are herein incorporated by reference in their entirety for all purposes.

5 [00315] In embodiments where the lipid particles of the present invention (e.g., SNALP) are administered intravenously, at least about 5%, 10%, 15%, 20%, or 25% of the total injected dose of the particles is present in plasma about 8, 12, 24, 36, or 48 hours after injection. In other embodiments, more than about 20%, 30%, 40% and as much as about 60%, 70% or 80% of the total injected dose of the lipid particles is present in plasma about 8, 12, 24, 36, or 48 hours after injection.

10 In certain instances, more than about 10% of a plurality of the particles is present in the plasma of a mammal about 1 hour after administration. In certain other instances, the presence of the lipid particles is detectable at least about 1 hour after administration of the particle. In some embodiments, the presence of a therapeutic nucleic acid such as an interfering RNA molecule is detectable in cells at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration. In other embodiments, 15 downregulation of expression of a target sequence, such as a viral or host sequence, by an interfering RNA (e.g., siRNA) is detectable at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration. In yet other embodiments, downregulation of expression of a target sequence, such as a viral or host sequence, by an interfering RNA (e.g., siRNA) occurs preferentially in infected cells and/or cells capable of being infected. In further embodiments, the presence or effect of an interfering RNA (e.g., 20 siRNA) in cells at a site proximal or distal to the site of administration is detectable at about 12, 24, 48, 72, or 96 hours, or at about 6, 8, 10, 12, 14, 16, 18, 19, 20, 22, 24, 26, or 28 days after administration. In additional embodiments, the lipid particles (e.g., SNALP) of the invention are administered parenterally or intraperitoneally.

25 [00316] The compositions of the present invention, either alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be “nebulized”) to be administered via inhalation (e.g., intranasally or intratracheally) (see, Brigham *et al.*, *Am. J. Sci.*, 298:278 (1989)). Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

30 [00317] In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering nucleic acid compositions directly to the lungs via nasal aerosol sprays have been described, e.g., in U.S. Patent Nos. 5,756,353 and 5,804,212. Likewise, the delivery of drugs using intranasal microparticle resins and lysophosphatidyl-glycerol compounds (U.S. Patent 5,725,871) are also well-known in the pharmaceutical arts. Similarly, transmucosal drug delivery in the form of a polytetrafluoroethylene

support matrix is described in U.S. Patent No. 5,780,045. The disclosures of the above-described patents are herein incorporated by reference in their entirety for all purposes.

[00318] Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions are preferably administered, for example, by intravenous infusion, orally, topically, 10 intraperitoneally, intravesically, or intrathecally.

[00319] Generally, when administered intravenously, the lipid particle formulations are formulated with a suitable pharmaceutical carrier. Many pharmaceutically acceptable carriers may be employed in the compositions and methods of the present invention. Suitable formulations for use in the present invention are found, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES, 15 Mack Publishing Company, Philadelphia, PA, 17th ed. (1985). A variety of aqueous carriers may be used, for example, water, buffered water, 0.4% saline, 0.3% glycine, and the like, and may include glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, *etc.* Generally, normal buffered saline (135-150 mM NaCl) will be employed as the pharmaceutically acceptable carrier, but other suitable carriers will suffice. These compositions can be sterilized by conventional liposomal 20 sterilization techniques, such as filtration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, *etc.* These compositions can be sterilized using the techniques referred to above or, alternatively, they can be produced under sterile conditions. The resulting 25 aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.

[00320] In certain applications, the lipid particles disclosed herein may be delivered via oral administration to the individual. The particles may be incorporated with excipients and used in the 30 form of ingestible tablets, buccal tablets, troches, capsules, pills, lozenges, elixirs, mouthwash, suspensions, oral sprays, syrups, wafers, and the like (*see, e.g.*, U.S. Patent Nos. 5,641,515, 5,580,579, and 5,792,451, the disclosures of which are herein incorporated by reference in their entirety for all purposes). These oral dosage forms may also contain the following: binders, gelatin; excipients, lubricants, and/or flavoring agents. When the unit dosage form is a capsule, it may contain, in 35 addition to the materials described above, a liquid carrier. Various other materials may be present as

coatings or to otherwise modify the physical form of the dosage unit. Of course, any material used in preparing any unit dosage form should be pharmaceutically pure and substantially non-toxic in the amounts employed.

[00321] Typically, these oral formulations may contain at least about 0.1% of the lipid particles or more, although the percentage of the particles may, of course, be varied and may conveniently be between about 1% or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of particles in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

[00322] Formulations suitable for oral administration can consist of: (a) liquid solutions, such as an effective amount of a packaged therapeutic nucleic acid (e.g., interfering RNA) suspended in diluents such as water, saline, or PEG 400; (b) capsules, sachets, or tablets, each containing a predetermined amount of a therapeutic nucleic acid (e.g., interfering RNA), as liquids, solids, granules, or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise a therapeutic nucleic acid (e.g., interfering RNA) in a flavor, e.g., sucrose, as well as pastilles comprising the therapeutic nucleic acid in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the therapeutic nucleic acid, carriers known in the art.

[00323] In another example of their use, lipid particles can be incorporated into a broad range of topical dosage forms. For instance, a suspension containing nucleic acid-lipid particles such as SNALP can be formulated and administered as gels, oils, emulsions, topical creams, pastes, ointments, lotions, foams, mousses, and the like.

[00324] When preparing pharmaceutical preparations of the lipid particles of the invention, it is preferable to use quantities of the particles which have been purified to reduce or eliminate empty particles or particles with therapeutic agents such as nucleic acid associated with the external surface.

[00325] The methods of the present invention may be practiced in a variety of hosts. Preferred hosts include mammalian species, such as primates (e.g., humans and chimpanzees as well as other nonhuman primates), canines, felines, equines, bovines, ovines, caprines, rodents (e.g., rats and mice), lagomorphs, and swine.

5 [00326] The amount of particles administered will depend upon the ratio of therapeutic nucleic acid (e.g., interfering RNA) to lipid, the particular therapeutic nucleic acid used, the disease or disorder being treated, the age, weight, and condition of the patient, and the judgment of the clinician, but will generally be between about 0.01 and about 50 mg per kilogram of body weight, preferably between about 0.1 and about 5 mg/kg of body weight, or about  $10^8$ - $10^{10}$  particles per administration  
10 (e.g., injection).

#### B. *In vitro* Administration

15 [00327] For *in vitro* applications, the delivery of therapeutic nucleic acids (e.g., interfering RNA) can be to any cell grown in culture, whether of plant or animal origin, vertebrate or invertebrate, and of any tissue or type. In preferred embodiments, the cells are animal cells, more preferably mammalian cells, and most preferably human cells.

20 [00328] Contact between the cells and the lipid particles, when carried out *in vitro*, takes place in a biologically compatible medium. The concentration of particles varies widely depending on the particular application, but is generally between about 1  $\mu$ mol and about 10 mmol. Treatment of the cells with the lipid particles is generally carried out at physiological temperatures (about 37°C) for periods of time of from about 1 to 48 hours, preferably of from about 2 to 4 hours.

25 [00329] In one group of preferred embodiments, a lipid particle suspension is added to 60-80% confluent plated cells having a cell density of from about  $10^3$  to about  $10^5$  cells/ml, more preferably about  $2 \times 10^4$  cells/ml. The concentration of the suspension added to the cells is preferably of from about 0.01 to 0.2  $\mu$ g/ml, more preferably about 0.1  $\mu$ g/ml.

30 [00330] To the extent that tissue culture of cells may be required, it is well-known in the art. For example, Freshney, Culture of Animal Cells, a Manual of Basic Technique, 3rd Ed., Wiley-Liss, New York (1994), Kuchler *et al.*, Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc. (1977), and the references cited therein provide a general guide to the culture of cells. Cultured cell systems often will be in the form of monolayers of cells, although cell suspensions are also used.

[00331] Using an Endosomal Release Parameter (ERP) assay, the delivery efficiency of the SNALP or other lipid particle of the invention can be optimized. An ERP assay is described in detail

in U.S. Patent Publication No. 20030077829, the disclosure of which is herein incorporated by reference in its entirety for all purposes. More particularly, the purpose of an ERP assay is to distinguish the effect of various cationic lipids and helper lipid components of SNALP or other lipid particle based on their relative effect on binding/uptake or fusion with/destabilization of the 5 endosomal membrane. This assay allows one to determine quantitatively how each component of the SNALP or other lipid particle affects delivery efficiency, thereby optimizing the SNALP or other lipid particle. Usually, an ERP assay measures expression of a reporter protein (e.g., luciferase,  $\beta$ -galactosidase, green fluorescent protein (GFP), etc.), and in some instances, a SNALP formulation optimized for an expression plasmid will also be appropriate for encapsulating an interfering RNA. In 10 other instances, an ERP assay can be adapted to measure downregulation of transcription or translation of a target sequence in the presence or absence of an interfering RNA (e.g., siRNA). By comparing the ERPs for each of the various SNALP or other lipid particles, one can readily determine the optimized system, e.g., the SNALP or other lipid particle that has the greatest uptake in the cell.

### C. Cells for Delivery of Lipid Particles

15 [00332] The compositions and methods of the present invention are particularly well suited for treating alcoholism by targeting ALDH gene expression *in vivo*. The present invention can be practiced on a wide variety of cell types from any vertebrate species, including mammals, such as, e.g., canines, felines, equines, bovines, ovines, caprines, rodents (e.g., mice, rats, and guinea pigs), lagomorphs, swine, and primates (e.g. monkeys, chimpanzees, and humans).

### 20 D. Detection of Lipid Particles

25 [00333] In some embodiments, the lipid particles of the present invention (e.g., SNALP) are detectable in the subject at about 1, 2, 3, 4, 5, 6, 7, 8 or more hours. In other embodiments, the lipid particles of the present invention (e.g., SNALP) are detectable in the subject at about 8, 12, 24, 48, 60, 72, or 96 hours, or about 6, 8, 10, 12, 14, 16, 18, 19, 22, 24, 25, or 28 days after administration of the particles. The presence of the particles can be detected in the cells, tissues, or other biological samples from the subject. The particles may be detected, e.g., by direct detection of the particles, detection of a therapeutic nucleic acid such as an interfering RNA (e.g., siRNA) sequence, detection of the target sequence of interest (i.e., by detecting expression or reduced expression of the sequence of interest), detection of a compound modulated by an EBOV protein (e.g., interferon), detection of 30 viral load in the subject, or a combination thereof.

#### 1. Detection of Particles

[00334] Lipid particles of the invention such as SNALP can be detected using any method known in the art. For example, a label can be coupled directly or indirectly to a component of the lipid

particle using methods well-known in the art. A wide variety of labels can be used, with the choice of label depending on sensitivity required, ease of conjugation with the lipid particle component, stability requirements, and available instrumentation and disposal provisions. Suitable labels include, but are not limited to, spectral labels such as fluorescent dyes (e.g., fluorescein and derivatives, such as fluorescein isothiocyanate (FITC) and Oregon Green™; rhodamine and derivatives such Texas red, tetrarhodamine isothiocyanate (TRITC), etc., digoxigenin, biotin, phycoerythrin, AMCA, CyDyes™, and the like; radiolabels such as <sup>3</sup>H, <sup>125</sup>I, <sup>35</sup>S, <sup>14</sup>C, <sup>32</sup>P, <sup>33</sup>P, etc.; enzymes such as horse radish peroxidase, alkaline phosphatase, etc.; spectral colorimetric labels such as colloidal gold or colored glass or plastic beads such as polystyrene, polypropylene, latex, etc. The label can be detected using any means known in the art.

## 2. Detection of Nucleic Acids

[00335] Nucleic acids (e.g., interfering RNA) are detected and quantified herein by any of a number of means well-known to those of skill in the art. The detection of nucleic acids may proceed by well-known methods such as Southern analysis, Northern analysis, gel electrophoresis, PCR, radiolabeling, scintillation counting, and affinity chromatography. Additional analytic biochemical methods such as spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography may also be employed.

[00336] The selection of a nucleic acid hybridization format is not critical. A variety of nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assays and competition or displacement assays. Hybridization techniques are generally described in, e.g., "Nucleic Acid Hybridization, A Practical Approach," Eds. Hames and Higgins, IRL Press (1985).

[00337] The sensitivity of the hybridization assays may be enhanced through the use of a nucleic acid amplification system which multiplies the target nucleic acid being detected. *In vitro* amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning are known. Examples of techniques sufficient to direct persons of skill through such *in vitro* amplification methods, including the polymerase chain reaction (PCR), the ligase chain reaction (LCR), Q $\beta$ -replicase amplification, and other RNA polymerase mediated techniques (e.g., NASBA™) are found in Sambrook *et al.*, *In Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (2000); and Ausubel *et al.*, *SHORT PROTOCOLS IN MOLECULAR BIOLOGY*, eds., Current Protocols, Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (2002); as well as U.S. Patent No. 4,683,202; PCR Protocols, A Guide to Methods and Applications (Innis *et al.* eds.) Academic Press Inc. San Diego,

CA (1990); Arnheim & Levinson (October 1, 1990), *C&EN* 36; *The Journal Of NIH Research*, 3:81 (1991); Kwok *et al.*, *Proc. Natl. Acad. Sci. USA*, 86:1173 (1989); Guatelli *et al.*, *Proc. Natl. Acad. Sci. USA*, 87:1874 (1990); Lomell *et al.*, *J. Clin. Chem.*, 35:1826 (1989); Landegren *et al.*, *Science*, 241:1077 (1988); Van Brunt, *Biotechnology*, 8:291 (1990); Wu and Wallace, *Gene*, 4:560 (1989); 5 Barringer *et al.*, *Gene*, 89:117 (1990); and Sooknanan and Malek, *Biotechnology*, 13:563 (1995). Improved methods of cloning *in vitro* amplified nucleic acids are described in U.S. Pat. No. 5,426,039. Other methods described in the art are the nucleic acid sequence based amplification (NASBA™, Cangene, Mississauga, Ontario) and Qβ-replicase systems. These systems can be used to directly identify mutants where the PCR or LCR primers are designed to be extended or ligated only 10 when a select sequence is present. Alternatively, the select sequences can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation. The disclosures of the above-described references are herein incorporated by reference in their entirety for all purposes.

[00338] Nucleic acids for use as probes, *e.g.*, in *in vitro* amplification methods, for use as gene 15 probes, or as inhibitor components are typically synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage *et al.*, *Tetrahedron Letts.*, 22:1859 1862 (1981), *e.g.*, using an automated synthesizer, as described in Needham VanDevanter *et al.*, *Nucleic Acids Res.*, 12:6159 (1984). Purification of polynucleotides, where necessary, is typically performed by either native acrylamide gel electrophoresis or by anion exchange HPLC as described in Pearson *et 20 al.*, *J. Chrom.*, 255:137 149 (1983). The sequence of the synthetic polynucleotides can be verified using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, *Methods in Enzymology*, 65:499.

[00339] An alternative means for determining the level of transcription is *in situ* hybridization. *In situ* hybridization assays are well-known and are generally described in Angerer *et al.*, *Methods Enzymol.*, 152:649 (1987). In an *in situ* hybridization assay, cells are fixed to a solid support, 25 typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of specific probes that are labeled. The probes are preferably labeled with radioisotopes or fluorescent reporters.

## 30 IX. Examples

[00340] The present invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results.

**Example 1.**

[00341] This examples demonstrates that serum stable nucleic acid-lipid particles (SNALP) containing an siRNA that targets ALDH2 reduces aldehyde dehydrogenase 2 gene expression in a murine hepatocyte cell line *in vitro*.

5 **Materials:**

[00342] All siRNA molecules used in these studies were chemically synthesized and annealed using standard procedures.

[00343] Aldehyde dehydrogenase 2 (ALDH2)-targeting siRNA sequences used in this study:

siRNA Identifier	Sense Strand (5' to 3')	Antisense Strand (5' to 3')
1	rArArCrArAmGrArUrArUrArCmUrGrAmGrArATT (SEQ ID NO:3)	rUrUrUrCrUrCrAmGrUrArUrArUrCmUrUrGrUmUrGrG (SEQ ID NO:4)
2	mGrCrAmGrCrArArUrUrGrAmGrCrArAmUrArArATT (SEQ ID NO:5)	rUrUrUrArUrUrUmGrCrUrCrArUrUmUrGrCrUmGrCrUrU (SEQ ID NO:6)
3	rGmGrArGrArAmUrGrUrGrUrAmUrGrArCmGrArATT (SEQ ID NO:7)	rUrUrCrGrUrCrAmUrArCrArCrArUmUrCrUrCrCmUrG (SEQ ID NO:8)
4	rCmGrArCmGrCrCrGrUrCrAmGrCrArGmGrArArATT (SEQ ID NO:9)	rUrUrUrCrCmUrGrCrUrGrArCrGmGrCrGrUrCmGrUrG (SEQ ID NO:10)

[00344] Where 'r' indicates a ribonucleotide, 'm' indicates a 2'-O-methylated ribonucleotide, and 10 lack of either prefix indicates a deoxynucleotide.

[00345] Additionally, a non-targeting siRNA was included in the study as a control. This siRNA targets firefly luciferase gene and is not intended to have any specific gene silencing activity in mammalian cells.

**Methods:**

15 [00346] The nucleic acid-lipid particles were composed of the following "1:57" formulation: 1.4% PEG2000-C-DMA; 57.1% DLinDMA; 7.1% DPPC; and 34.3% cholesterol. Typically, in the 1:57 formulation, the amount of DLinDMA was 57.1 mol %  $\pm$  5 mol %, and the amount of lipid conjugate was 1.4 mol %  $\pm$  0.5 mol %, with the balance of the 1:57 formulation being made up of non-cationic lipid (e.g., phospholipid, cholesterol, or a 20 mixture of the two) with final siRNA/lipid ratio of approximately 0.11 to 0.15 (wt/wt). Upon formation of the siRNA-loaded particles, mean particle sizes were 85 – 100 nm in diameter.

**Mammalian Cell Treatments and mRNA Analysis:**

[00347] Primary hepatocytes were isolated from a mouse and maintained as adherent cultures in 96-well plates. ALDH-2 targeting or non-targeting control SNALP were added to the culture medium

at siRNA concentrations of 0.03125 to 0.5  $\mu$ g/mL; each treatment condition was performed in triplicate wells. After approximately 24 h incubation in the presence of SNALP, cells were harvested and lysed for mRNA analysis. Mouse ALDH2 mRNA in cell lysate was measured using a branched DNA assay (QuantiGene®, Affymetrix) with normalization against mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

**Results:**

[00348] Table A shows the gene silencing activity of lipid-nucleic acid treatments (mean of triplicate wells,  $\pm$  standard deviation) relative to the amount of GAPDH-normalized ALDH2 mRNA measured in untreated culture wells arbitrarily set at “100.0%” (mean of nine replicate wells,  $\pm$  6.9% standard deviation).

**Table A**

siRNA	0.03125 $\mu$ g/mL	0.125 $\mu$ g/mL	0.5 $\mu$ g/mL
1	(14.7 $\pm$ 0.7)%	(5.0 $\pm$ 0.3)%	(3.1 $\pm$ 0.2)%
2	(32.9 $\pm$ 2.9)%	(9.9 $\pm$ 1.2)%	(5.5 $\pm$ 0.5)%
3	(20.9 $\pm$ 1.6)%	(6.3 $\pm$ 0.4)%	(3.5 $\pm$ 0.3)%
4	(91.3 $\pm$ 0.5)%	(71.5 $\pm$ 7.0)%	(47.7 $\pm$ 3.1)%
Non-targeting control	(87.9 $\pm$ 10.9)%	(85.5 $\pm$ 10.2)%	(79.6 $\pm$ 6.4)%

**Conclusion:**

[00349] All four siRNA formulations that target mouse ALDH2 demonstrated gene silencing activity in isolated primary mouse hepatocytes, in a dose-responsive manner. Of the four tested, duplex 1 was the most active and duplex 4 was the least active.

**Example 2**

[00350] This example shows that SNALP that include an siRNA that targets ALDH2 reduce aldehyde dehydrogenase 2 gene expression in a whole-animal system via an intravenous route of administration.

**Materials:**

[00351] Mouse ALDH-2 siRNA duplex 1 and non-targeting control siRNA used in this study are described in Example 1.

**Methods:**

[00352] SNALP formulations were prepared as described in Example 1.

**Animal Treatments:**

[00353] Female BALB/c mice were obtained from Harlan Labs. Animals were administered a single dose of SNALP-formulated siRNA, or phosphate-buffered saline, via 10 mL/kg intravenous injection in the lateral tail vein. The administered siRNA dosage was either 0.025, 0.050 or 0.25 mg per kg body weight. Approximately 48 h after SNALP injection, animals were euthanized and liver tissue was collected into RNAlater® RNA stabilizing solution.

**Tissue Analysis:**

[00354] Liver tissues were analyzed for mouse ALDH2 mRNA levels normalized against GAPDH mRNA levels using the QuantiGene® branched DNA assay (Panomics, Freemont, CA; now part of Affymetrix) essentially as described in Judge *et al.*, 2006, Molecular Therapy 13:494.

**Results:**

[00355] Table B shows the gene silencing activity of SNALP treatments (mean of 3 animals,  $\pm$  standard deviation) relative to the amount of GAPDH-normalized liver ALDH2 mRNA measured in control PBS-treated animals arbitrarily set at “100.0%” (mean of six animals,  $\pm$  6.3% standard deviation).

**Table B**

Treatment	Liver ALDH2:GAPD mRNA Ratio Relative to PBS Control Group Mean
Formulated siRNA 1, 0.025 mg/kg	(70.2 $\pm$ 18.4)%
Formulated siRNA 1, 0.050 mg/kg	(35.9 $\pm$ 3.7)%
Formulated siRNA 1, 0.25 mg/kg	(10.8 $\pm$ 0.9)%
Non-targeting control siRNA, 0.25 mg/kg	(86.8 $\pm$ 6.3)%

**Conclusion:**

[00356] A single intravenous administration of SNALP-formulated siRNA 1 targeting mouse ALDH2 resulted in ALDH2 gene silencing activity in mice, in a dose-responsive manner.

**Example 3.**

[00357] This Example describes a method for making serum-stable nucleic acid-lipid particles of the present invention.

[00358] siRNA molecules are chemically synthesized and annealed using standard procedures.

[00359] In some embodiments, siRNA molecules are encapsulated into serum-stable nucleic acid-lipid particles composed of the following lipids: (1) the lipid conjugate PEG2000-C-DMA (3-N-[-methoxypoly(ethylene glycol)2000]carbamoyl]-1,2-dimyristyloxypropylamine); (2) a cationic lipid, e.g. DLinDMA; (3) the phospholipid DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) (Avanti 5 Polar Lipids; Alabaster, AL); and (4) synthetic cholesterol (Sigma-Aldrich Corp.; St. Louis, MO) in the molar ratio 1.4:57.1:7.1:34.3, respectively. In other words, siRNA molecules are encapsulated into nucleic acid-lipid particles of the following “1:57” formulation: 1.4% PEG2000-C-DMA; 57.1% cationic lipid; 7.1% DPPC; and 34.3% cholesterol. It should be understood that the 1:57 formulation is a target formulation, and that the amount of lipid (both cationic and non-cationic) present and the 10 amount of lipid conjugate present in the formulation may vary. Typically, in the 1:57 formulation, the amount of cationic lipid is 57.1 mol %  $\pm$  5 mol %, and the amount of lipid conjugate is 1.4 mol %  $\pm$  0.5 mol %, with the balance of the 1:57 formulation being made up of non-cationic lipid (e.g., phospholipid, cholesterol, or a mixture of the two). Formulations are made using the process described in United States Patent Application US2007/0042031, which is incorporated herein by 15 reference in its entirety. Upon formation the nucleic acid-lipid particles are dialyzed against PBS and filter sterilized through a 0.2  $\mu$ m filter before use. Mean particle sizes can be in the range of 75 – 90 nm, with final siRNA/lipid ratio of 0.15 (wt/wt).

#### Example 4.

[00360] This Example describes siRNA-mediated reduction of ALDH2 gene expression 20 in human cells *in vitro*.

#### Materials:

[00361] All siRNA molecules used in these studies were chemically synthesized and annealed using standard procedures.

[00362] Table A in this Example shows the aldehyde dehydrogenase 2 (ALDH2)-targeting siRNA sequences used in the experiments described in this Example: 25

**Table A**

siRNA Identifier	Sense Strand (5' to 3')	Antisense Strand (5' to 3')
1	rGmUrG rGrAmU rGrArA rArCmU rCrArG mUrUrU rArArG (SEQ ID NO:11)	rUrArA rArCrU mGrAmG rUrUrU rCrAmU rCrCrA rCrCrU (SEQ ID NO:12)
2	mGrUmG rGrArU mGrArA rArCrU rCrAmG rUrUrU rArArG (SEQ ID NO:13)	rUrArA rArCrU mGrAmG rUrUrU rCrAmU rCrCrA rCrCrU (SEQ ID NO:12)
3	rGmGrA rUmGrA rArArC rUrCrA mGrUmU rUrArA rGrArA (SEQ ID NO:14)	rCrUrU rArArA rCmUrG rArGrU mUrUrC rAmUrC rCrArC (SEQ ID NO:15)
4	mGrGrA rUmGrA rArArC rUrCrA rGmUrU mUrArA rGrArA (SEQ ID NO:16)	rCrUrU rArArA rCmUrG rArGrU mUrUrC rAmUrC rCrArC (SEQ ID NO:15)
5	rCmUrG rUrCmU rUrCrA rCrArA rAmGrG rAmUrU rUrGrG (SEQ ID NO:17)	rArArA rUrCrC rUmUrU rGrUmG rArAmG rArCrA mGrCrU (SEQ ID NO:18)
6	rCmUrG mUrCrU mUrCrA rCrArA rArGmG rArUrU rUrGrG (SEQ ID NO:19)	rArArA rUrCrC rUmUrU rGrUmG rArAmG rArCrA mGrCrU (SEQ ID NO:18)

Where 'r' indicates a ribonucleotide and 'm' indicates a 2'-O-methylated ribonucleotide

## 5 Methods:

[00363] The nucleic acid-lipid particles were composed of the following "1:57" formulation: 1.4% PEG2000-C-DMA; 57.1% DLinDMA; 7.1% DPPC; and 34.3% cholesterol. Typically, in the 1:57 formulation, the amount of DLinDMA was 57.1 mol %  $\pm$  5 mol %, and the amount of lipid conjugate was 1.4 mol %  $\pm$  0.5 mol %, with the balance of the 10 1:57 formulation being made up of non-cationic lipid (e.g., phospholipid, cholesterol, or a mixture of the two) with final siRNA/lipid ratio of approximately 0.11 to 0.15 (wt/wt). Upon formation of the siRNA-loaded particles, mean particle sizes were 85 – 100 nm in diameter.

[00364] **Mammalian Cell Treatment and mRNA Analysis:** HepG2 (human hepatocellular carcinoma) cells were maintained as adherent cultures in 96-well plates. 15 ALDH2-targeting or non-targeting control nucleic acid-lipid particles were added to the culture medium at siRNA concentrations of 3.91 and 15.63 ng/mL; each treatment condition was performed in duplicate wells. After approximately 48 hours nucleic acid-lipid particle incubation, cells were harvested and lysed for mRNA analysis. Human ALDH2 mRNA in cell lysate was measured using a branched DNA assay (Panomics, Freemont, CA; now part of 20 Affymetrix) with normalization against human glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

## Results:

[00365] Table B in this Example shows the gene silencing activity of nucleic acid-lipid particle treatments (mean of duplicate wells,  $\pm$  standard deviation) are described as 25 percentage GAPDH-normalized ALDH2 mRNA relative to the amount of GAPDH-

normalized ALDH2 mRNA measured in untreated culture wells arbitrarily set at “100.0%” (mean of 2 replicate wells,  $\pm$  7.4% standard deviation).

**Table B**

siRNA	3.9 ng/mL	15.63 ng/mL
1	(19.8 $\pm$ 3.4)%	(7.5 $\pm$ 0.6)%
2	(18.9 $\pm$ 0.8)%	(6.6 $\pm$ 0.6)%
3	(34.2 $\pm$ 0.0)%	(11.2 $\pm$ 1.4)%
4	(22.6 $\pm$ 0.5)%	(7.6 $\pm$ 0.9)%
5	(21.9 $\pm$ 3.2)%	(6.8 $\pm$ 0.7)%
6	(24.1 $\pm$ 2.2)%	(7.7 $\pm$ 0.6)%
Non-targeting control	(85.5 $\pm$ 7.1)%	(90.2 $\pm$ 3.8)%

5 **Conclusions:**

[00366] All six siRNAs, formulated within lipid particles, silenced ALDH2 activity in human HepG2 cells, in a dose-responsive manner. Of the six siRNA that were tested, siRNA 2 was the most active and siRNA 3 was the least active.

10 [00367] All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification are incorporated herein by reference, in their entirety to the extent not inconsistent with the present description.

15 [00368] From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

**WHAT IS CLAIMED IS:**

1. A composition comprising an interfering RNA that silences aldehyde dehydrogenase (ALDH) gene expression, wherein the interfering RNA comprises a sense strand and a complementary antisense strand, and wherein the interfering RNA comprises a double-stranded region of about 15 to about 60 nucleotides in length.

5 2. The composition of claim 1, wherein the interfering RNA is a double-stranded RNA (dsRNA) selected from the group consisting of an siRNA, a Dicer-substrate dsRNA, an shRNA, an aiRNA, a pre-miRNA, and combinations thereof.

10 3. The composition of claim 1, wherein the interfering RNA comprises a double-stranded region of about 19 to about 25 nucleotides in length.

4. The composition of claim 1, wherein the interfering RNA is chemically synthesized.

5. The composition of claim 1, wherein the interfering RNA comprises a 3' overhang in one or both strands of the interfering RNA.

15 6. The composition of claim 1, wherein the interfering RNA comprises at least one modified nucleotide in the double-stranded region.

7. The composition of claim 6, wherein less than about 30% of the nucleotides in the double-stranded region comprise modified nucleotides.

8. The composition of claim 6, wherein the modified nucleotide is a 2'-O-methyl (2'OMe) nucleotide.

20 9. The composition of claim 8, wherein the 2'OMe nucleotide comprises a 2'OMe-guanosine nucleotide, a 2'OMe-uridine nucleotide, or mixtures thereof.

10. The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

25 11. The composition of any one of claims 1-10 wherein the interfering RNA silences aldehyde dehydrogenase2 (ALDH2) gene expression.

12. A nucleic acid-lipid particle comprising:

(a) an interfering RNA of claim 1;

(b) a cationic lipid; and

(c) a non-cationic lipid.

13. The nucleic acid-lipid particle of claim 11, wherein the cationic lipid comprises 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-di- $\gamma$ -linolenyloxy-N,N-dimethylaminopropane ( $\gamma$ -DLenDMA), a salt thereof, or a mixture thereof.

14. The nucleic acid-lipid particle of claim 12, wherein the cationic lipid comprises 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-K-C2-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), a salt thereof, or a mixture thereof.

15. The nucleic acid-lipid particle of claim 12, wherein the cationic lipid comprises (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate (DLin-M-C3-DMA), dilinoleylmethyl-3-dimethylaminopropionate (DLin-M-C2-DMA), a salt thereof, or a mixture thereof.

16. The nucleic acid-lipid particle of claim 12, wherein the non-cationic lipid is a phospholipid.

15 17. The nucleic acid-lipid particle of claim 12, wherein the non-cationic lipid is cholesterol or a derivative thereof.

18. The nucleic acid-lipid particle of claim 12, wherein the non-cationic lipid is a mixture of a phospholipid and cholesterol or a derivative thereof.

19. The nucleic acid-lipid particle of claim 16 or claim 18, wherein the phospholipid 20 comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.

20. The nucleic acid-lipid particle of claim 12, wherein the non-cationic lipid is a mixture of DPPC and cholesterol.

21. The nucleic acid-lipid particle of claim 12, further comprising a conjugated lipid that 25 inhibits aggregation of particles.

22. The nucleic acid-lipid particle of claim 21, wherein the conjugated lipid that inhibits aggregation of particles is a polyethyleneglycol (PEG)-lipid conjugate.

23. The nucleic acid-lipid particle of claim 22, wherein the PEG-lipid conjugate is selected from the group consisting of a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-

dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof.

24. The nucleic acid-lipid particle of claim 22, wherein the PEG-lipid conjugate is a PEG-DAA conjugate.

5 25. The nucleic acid-lipid particle of claim 24, wherein the PEG-DAA conjugate is selected from the group consisting of a PEG-didecyloxypropyl ( $C_{10}$ ) conjugate, a PEG-dilauryloxypropyl ( $C_{12}$ ) conjugate, a PEG-dimyristyloxypropyl ( $C_{14}$ ) conjugate, a PEG-dipalmityloxypropyl ( $C_{16}$ ) conjugate, a PEG-distearyloxypropyl ( $C_{18}$ ) conjugate, and a mixture thereof.

10 26. The nucleic acid-lipid particle of claim 21, wherein the conjugated lipid that inhibits aggregation of particles is a polyoxazoline (POZ)-lipid conjugate.

27. The nucleic acid-lipid particle of claim 26, wherein the POZ-lipid conjugate is a POZ-DAA conjugate.

15 28. The nucleic acid-lipid particle of claim 12, wherein the interfering RNA is fully encapsulated in the particle.

29. The nucleic acid-lipid particle of claim 12, wherein the particle has a lipid:interfering RNA mass ratio of from about 5:1 to about 15:1.

30. The nucleic acid-lipid particle of claim 12, wherein the particle has a median diameter of from about 30 nm to about 150 nm.

20 31. The nucleic acid-lipid particle of claim 12, wherein the cationic lipid comprises from about 50 mol % to about 65 mol % of the total lipid present in the particle.

25 32. The nucleic acid-lipid particle of claim 12, wherein the non-cationic lipid comprises a mixture of a phospholipid and cholesterol or a derivative thereof, wherein the phospholipid comprises from about 4 mol % to about 10 mol % of the total lipid present in the particle and the cholesterol or derivative thereof comprises from about 30 mol % to about 40 mol % of the total lipid present in the particle.

30 33. The nucleic acid-lipid particle of claim 32, wherein the phospholipid comprises from about 5 mol % to about 9 mol % of the total lipid present in the particle and the cholesterol or derivative thereof comprises from about 32 mol % to about 37 mol % of the total lipid present in the particle.

34. The nucleic acid-lipid particle of claim 21, wherein the conjugated lipid that inhibits aggregation of particles comprises from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.

35. A pharmaceutical composition comprising a nucleic acid-lipid particle of claim 12  
5 and a pharmaceutically acceptable carrier.

36. A method for introducing an interfering RNA that silences ALDH gene expression into a cell, the method comprising contacting the cell with a nucleic acid-lipid particle of claim 12.

37. The method of claim 36, wherein the cell is in a mammal.

38. The method of claim 36, wherein the cell is contacted by administering the particle to  
10 the mammal via a systemic route.

39. The method of claim 36, wherein the mammal is a human.

40. The method of claim 36, wherein the mammal has been diagnosed with alcoholism.

41. The method of claim 36, wherein the interfering RNA silences ALDH2 gene expression in the cell.

15 42. A method for silencing ALDH gene expression in a mammal in need thereof, the method comprising administering to the mammal a nucleic acid-lipid particle of claim 12.

43. The method of claim 42, wherein the particle is administered via a systemic route.

44. The method of claim 42, wherein the mammal is a human.

45. The method of claim 44, wherein the human is suffering from alcoholism.

20 46. The method of claim 42, wherein administration of the particle reduces ALDH RNA levels in the mammal by at least about 50% relative to ALDH RNA levels in the absence of the particle.

47. The method of claim 42, wherein the nucleic acid-lipid particle silences ALDH2 gene expression.

25 48. A method for treating and/or ameliorating one or more symptoms associated with alcoholism in a human, the method comprising administering to the human a therapeutically effective amount of a nucleic acid-lipid particle of claim 12.

49. The method of claim 48, wherein the particle is administered via a systemic route.

50. The method of claim 48, wherein the human has alcoholism.

51. The method of claim 48, wherein the interfering RNA of the nucleic acid-lipid particle inhibits expression of an ALDH2 gene in the human.

52. A method for inhibiting the expression of ALDH in a mammal in need thereof, the  
5 method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-  
lipid particle of claim 12.

53. The method of claim 52, wherein the particle is administered via a systemic route.

54. The method of claim 52, wherein the mammal is a human.

55. The method of claim 54, wherein the human has alcoholism.

10 56. The method of claim 52, wherein administration of the particle reduces ALDH gene  
expression in the mammal by at least about 50% relative to the ALDH gene expression in the absence  
of the particle.

57. The method of claim 52 wherein the expression of ALDH2 is inhibited in the  
mammal.

15 58. A method for preventing and/or treating alcoholism in a human, the method  
comprising administering to the human a therapeutically effective amount of a nucleic acid-lipid  
particle of claim 12.

59. The method of claim 58, wherein the particle is administered via a systemic route.

60. The method of claim 58, wherein the human is suffering from alcoholism.

20 61. The method of claim 58, wherein the interfering RNA of the nucleic acid-lipid  
particle inhibits expression of an ALDH2 gene in the human.

62. A double-stranded siRNA molecule selected from the group consisting of Identifier 1,  
Identifier 2, Identifier 3, Identifier 4, Identifier 5 and Identifier 6 as set forth in Table A of Example 4  
herein.

25 63. A single-stranded RNA molecule selected from the single-stranded sense strand  
molecules set forth in Table A of Example 4 herein.

64. A single-stranded RNA molecule selected from the single-stranded antisense strand  
molecules set forth in Table A of Example 4 herein.

65. Use of an siRNA molecule of the present invention for inhibiting ALDH gene expression in a living cell.

66. Use of a pharmaceutical composition of the present invention for inhibiting ALDH gene expression in a living cell.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/58770

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07H 21/02, C12N 15/11 (2012.01)

USPC - 514/44A, 536/24.5; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): C07H 21/02, C12N 15/11 (2012.01)

USPC: 514/44A, 536/24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
USPC: 536/23.1Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
PatBase, PubWEST, Google Scholar; interfering RNA, iRNA, RNAi, siRNA, dsRNA, shRNA, aiRNA, pre-mRNA, aldehyde dehydrogenase, ALDH, ALDH2, synthesize, overhang, modify, 2'-O-methyl, 2'OMe, 2'OMeguanosine, 2'OMe-uridine, cationic, POZ-DAA, POZ, PEG-DAA, cholesterol, DPPC, alcohol, alcoholism

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	CORTINEZ et al., RNA interference against aldehyde dehydrogenase-2: development of tools for alcohol research. Alcohol, March 2009, Vol. 43, No 2, pages 97-104. Especially abstract, page 98, col 1, para 4- col 2, para 1	1-4, 11/(1-4), 65 5-10, 11/(5-10), 12-64, 66
Y	US 2011/0201667 A1 (GEISBERT et al.) 18 August 2011 (18.08.2011); abstract, para [0019], [0020], [0068], [0161], [0217], [0435], [0459], [0504], [0510]	5-10, 11/(5-10), 12-61, 66
Y	HSU et al., Genomic Structure of the Human Mitochondrial Aldehyde Dehydrogenase Gene, Genomics, January 1988, Vol 2, No 1, pages 57-65. Especially page 62	62-64

Further documents are listed in the continuation of Box C.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"E" earlier application or patent but published on or after the international filing date

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"O" document referring to an oral disclosure, use, exhibition or other means

"&amp;" document member of the same patent family

"P" document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search

29 November 2012 (29.11.2012)

Date of mailing of the international search report

26 DEC 2012

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774

## 摘要

本发明提供包含以醛脱氢酶 (ALDH) 基因表达为靶标的治疗性核酸如干扰 RNA (例如, dsRNA 如 siRNA) 的组合物、包含治疗性核酸的一种或多种 (例如, 混合物) 的脂质颗粒、制造脂质颗粒的方法、以及递送和/或施用脂质颗粒的方法 (例如, 用于治疗人中的酒精中毒)。